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Peroxisomes are crucial for cell survival but do not possess a genome, so protein 
import is essential for correct functioning of the organelle. The PTS1 (peroxisomal 
targeting signal 1) pathway is the major, and in some organisms the only, transport 
pathway for proteins to enter the peroxisome. PTS1 is a recognition sequence at the 
C-terminus of peroxisomal cargo proteins, which allows their binding to the receptor 
protein PEX5 (peroxin 5). PEX5 then acts as the vehicle for transporting PTS1-cargo 
proteins into peroxisomes. 
This work concerned the disruption of the natural PEX5:PTS1 interaction and the 
generation of an interaction between a mutated form of PEX5 (PEX5*) and a peptide 
representing a non-natural PTS1 (PTS1*). An in vitro protein-peptide binding screen 
was developed to test Arabidopsis thaliana PEX5-C (AtPEX5-C), and variants, with a 
library of peptides to identify corresponding binding peptides. For wild-type AtPEX5-C, 
peptides identified were consistent with bioinformatics predictions for plant PTS1 
sequences, confirming the validity of the screen. Fluorescence anisotropy was then 
used to validate binding peptides, revealing that two variants of AtPEX5-C, D505H and 
N601A, exhibited reduced affinity to a representative native PTS1 (YQSKL-CO2H), yet 
increased affinity to a non-PTS1 sequence (YQSYY-CO2H). When these two 
mutations were combined, the affinity for YQSKL was further reduced and the affinity 
for YQSYY was further enhanced. This effect was amplified when an additional 
mutation, D507T, was incorporated into the AtPEX5-C double variant. The resulting 
triple variant was termed PEX5*. Various 9-amino acid sequences were added 
upstream of YQSYY, and the optimal resulting 14-amino acid sequence was termed 
PTS1*. 
The in vitro-validated binding of PEX5* to PTS1* was tested in vivo (in the moss 
Physcomitrella patens; by R. Paudyal) to investigate whether expression of PEX5* 





Table of Contents 
 
Acknowledgements .............................................................................................. iii 
Abstract ..................................................................................................................v 
Abbreviations ....................................................................................................... xv 
Amino acids .................................................................................................. xv 
Organisms .................................................................................................... xv 
Units  ............................................................................................................ xvi 
General ........................................................................................................ xvi 
Chapter 1 ................................................................................................................1 
1.1 Plant peroxisomes; adaptable cellular organelles ...................................1 
1.1.1 Adaptability of peroxisomal function ...............................................3 
1.2 Formation and maintenance of peroxisomes ..........................................4 
1.3 The peroxisomal matrix protein import pathway ......................................6 
1.3.1 Cargo recognition by the PTS receptors ........................................8 
1.3.2 The peroxisomal membrane docking complex ............................. 10 
1.3.3 The mechanism for ubiquitination of the PTS receptors ............... 12 
1.3.4 The receptor recycling complex ................................................... 14 
1.3.5 Export-driven import .................................................................... 16 
1.3.6 A focus on the PTS1-mediated import pathway ........................... 18 
1.4 PEX5 structure and function ................................................................. 18 
1.4.1 The N-terminal domain of PEX5 .................................................. 19 
1.4.2 The C-terminal domain of PEX5, and PTS1 binding .................... 20 
1.5 What makes a PTS1 sequence? .......................................................... 26 
1.5.1 Variation to the PTS1 by mutation, and the effect on 
peroxisomal import and on PEX5 binding .................................... 28 
1.5.2 Extension of the PTS1 consensus through in silico predictions .... 30 
1.6 Peroxisomes and synthetic biology ....................................................... 31 
1.7 Directed evolution and orthogonality ..................................................... 32 
1.8 Objectives of this study ......................................................................... 33 
Chapter 2 .............................................................................................................. 34 
2.1 Introduction .......................................................................................... 34 




2.3 Synthesis of a ‘native’ PTS1 peptide and a subsequent binding study 
with AtPEX5-C ...................................................................................... 38 
2.4 Potential PTS1* peptide sequences ..................................................... 43 
2.5 Variants of AtPEX5-C designed for altered peptide-binding specificity . 47 
2.6 Screen development for the study of PEX5:PTS1 binding by colony 
blotting ................................................................................................. 55 
2.7 Summary .............................................................................................. 66 
Chapter 3 .............................................................................................................. 67 
3.1 Introduction .......................................................................................... 67 
3.2 Synthesis of a library of N-terminally labelled peptides ......................... 68 
3.2.1 Assembly of a peptide library ....................................................... 68 
3.2.2 Determination of a suitable N-terminal label for peptides ............. 70 
3.3 Peptide library characterisation ............................................................ 74 
3.3.1 Extraction of ion chromatograms based on exact masses of 
peptides ....................................................................................... 75 
3.3.2 The use of tandem mass spectrometry for further 
characterisation ........................................................................... 78 
3.3.3 Sorting of peptides into sub-libraries based on mass ................... 82 
3.3.4 Data processing after an LC-MS run ............................................ 83 
3.3.5 An LC-MS run and processing of the full peptide library ............... 85 
3.4 Development and optimisation of a peptide pull-down screen .............. 86 
3.5 Further optimisation of the pull-down screen and validation .................. 87 
3.6 Summary .............................................................................................. 93 
Chapter 4 .............................................................................................................. 94 
4.1 Introduction .......................................................................................... 94 
4.2 Screening of a small library of AtPEX5-C variants using pull-down 
coupled with LC-MS ............................................................................. 95 
4.3 Quantitative binding analysis using fluorescence anisotropy to assess 
the reliability of results obtained by pull-down-LC-MS screening ........ 102 
4.4 Further mutation of the preliminary AtPEX5-C* and subsequent 
analysis of peptide binding ................................................................. 105 
4.5 The addition of upstream residues to the preliminary PTS1* with the 
aim of altering binding affinity ............................................................. 112 
4.6 In vivo testing of PhypaPEX5-N–AtPEX5-C and PhypaPEX5-N–
AtPEX5-C* with PTS1 and PTS1* ...................................................... 118 
4.7 Summary ............................................................................................ 124 
Chapter 5 ............................................................................................................ 126 




5.2 Future perspectives ............................................................................ 129 
Chapter 6 ............................................................................................................ 135 
6.1 Bacterial strains and plasmids ............................................................ 135 
6.2 Kanamycin stock solution ................................................................... 135 
6.3 Bacterial media ................................................................................... 135 
6.4 Restriction enzymes ........................................................................... 136 
6.5 Site-directed mutagenesis .................................................................. 136 
6.6 Ligation-independent cloning (for the production of AtPEX5         
(444-728)) .......................................................................................... 136 
6.7 Transformations ................................................................................. 137 
6.8 Plasmid DNA extractions .................................................................... 137 
6.9 Protease inhibition .............................................................................. 137 
6.10 Expression and purification of His6-AtPEX5(340-728) and variants .... 138 
6.10.1 Solutions ........................................................................... 138 
6.10.2 Autoinduction of His6-AtPEX5(340-728) and variants ........ 138 
6.10.3 Cell disruption of BL21-Gold (DE3) E .coli cells ................. 139 
6.10.4 Purification of His6-AtPEX5(340-728) and variants ............ 139 
6.10.5 Gel filtration of His6-AtPEX5(340-728) ............................... 139 
6.10.6 Concentration and buffer exchange of  His6-AtPEX5    
(340-728) ................................................................................... 140 
6.10.7 Protein concentration determination .................................. 140 
6.11 SDS-PAGE ......................................................................................... 140 
6.12 Blotting ............................................................................................... 141 
6.12.1 Antibodies ......................................................................... 141 
6.12.2 Western blotting ................................................................ 142 
6.12.3 Dot blotting ........................................................................ 143 
6.12.4 Colony blotting .................................................................. 143 
6.13 Peptide synthesis ............................................................................... 144 
6.13.1 General procedure for Fmoc-protected amino acid 
coupling (manual SPPS) ............................................................ 145 
6.13.2 Procedure for Fmoc-protected amino acid coupling 
(automated SPPS) ..................................................................... 145 
6.13.3 Split-and-pool amino acid coupling .................................... 146 
6.13.4 N-terminal lissamine coupling ........................................... 146 
6.13.5 N-terminal coumarin coupling ............................................ 146 
6.13.6 N-terminal dansyl coupling ................................................ 147 




6.13.8 N-terminal biotin-(PEG)2 coupling ...................................... 147 
6.13.9 Cleavage of peptides from the solid resin support ............. 148 
6.14 Fluorescence anisotropy .................................................................... 148 
6.14.1 Solutions ........................................................................... 148 
6.14.2 Fluorescently labelled peptide solutions ............................ 148 
6.14.3 Protein solutions ............................................................... 148 
6.14.4 General assay information ................................................ 149 
6.14.5 Protein titration .................................................................. 149 
6.14.6 Peptide competition assay ................................................ 149 
6.14.7 Reading of fluorescence anisotropy plates ........................ 150 
6.15 Pull-down-LC-MS screening ............................................................... 150 
6.15.1 Pull-down of binding peptides by Co-NTA purification of 
AtPEX5-C protein ...................................................................... 150 
6.15.2 Mass spectrometry for identification of binding peptides ... 151 
6.15.3 Data processing ................................................................ 151 
6.16 Circular dichroism ............................................................................... 152 
6.16.1 Buffer exchange of His6-AtPEX5(340-728) ........................ 152 
6.16.2 Measurement of circular dichroism .................................... 152 
6.17 Crystallisation screens ........................................................................ 153 
6.17.1 Gel filtration, concentration and buffer exchange of His6-
AtPEX5(340-728) ....................................................................... 153 
6.17.2 Setting up of crystal screens ............................................. 153 
6.18 Synthetic peptide analytical data ........................................................ 154 
6.18.1 H2N-YQSKL-CO2H ............................................................ 154 
6.18.2 Lissamine-YQSKL-CO2H .................................................. 155 
6.18.3 Lissamine-YQSEL-CO2H .................................................. 156 
6.18.4 Lissamine-YQSKV-CO2H .................................................. 157 
6.18.5 Lissamine-YQSEV-CO2H .................................................. 158 
6.18.6 H2N-CGGGYQSKL-CO2H ................................................. 159 
6.18.7 H2N-CGGGYQSEL-CO2H ................................................. 160 
6.18.8 H2N-CGGGYQSKV-CO2H ................................................. 161 
6.18.9 H2N-CGGGYQSEV-CO2H ................................................. 162 
6.18.10 Coumarin-YQSKL-CO2H ................................................... 163 
6.18.11 Dansyl-YQSKL-CO2H ........................................................ 164 
6.18.12 Lissamine-YQSFY-CO2H .................................................. 165 




6.18.14 Lissamine-SHIQTEAERLYSKL-CO2H ............................... 167 
6.18.15 Lissamine-IIAAVDASYNSSTL-CO2H ................................ 168 
6.18.16 Lissamine-WIAGDNSQHYQSYY-CO2H ............................ 169 
6.18.17 Lissamine-WWRDPYSPMYQSYY-CO2H .......................... 170 
6.18.18 Biotin-GGGYQSKL-CO2H ................................................. 171 
6.18.19 Biotin-(PEG)2-YQSKL-CO2H ............................................. 172 
6.18.20 Biotin-(PEG)2-YQSEV-CO2H ............................................. 173 
6.18.21 Biotin-(PEG)2-YQSYY-CO2H ............................................. 174 
References ......................................................................................................... 175 
Appendix A ......................................................................................................... 186 
A.1 His6-AtPEX5(340-728) ........................................................................ 186 
A.1.1 His6-AtPEX5(340-728) plasmid map .......................................... 186 
A.1.2 His6-AtPEX5(340-728) DNA sequence ...................................... 187 
A.1.3 His6-AtPEX5(340-728) protein sequence ................................... 187 
A.2 His6-AtPEX5(444-728) ........................................................................ 188 
A.2.1 His6-AtPEX5(444-728) plasmid map .......................................... 188 
A.2.2 His6-AtPEX5(444-728) DNA sequence ...................................... 188 
A.2.3 His6-AtPEX5(444-728) protein sequence ................................... 189 
Appendix B ......................................................................................................... 190 
B.1 AtPEX5(340-728) D505A primers ....................................................... 190 
B.2 AtPEX5(340-728) D505H and AtPEX5(340-728) D505H(-N601A) 
primers ............................................................................................... 190 
B.3 AtPEX5(340-728) D505K primers ....................................................... 190 
B.4 AtPEX5(340-728) D507A primers ....................................................... 190 
B.5 AtPEX5(340-728) D507K primers ....................................................... 190 
B.6 AtPEX5(340-728) V533A primers ....................................................... 191 
B.7 AtPEX5(340-728) V533W primers ...................................................... 191 
B.8 AtPEX5(340-728) T536A primers ....................................................... 191 
B.9 AtPEX5(340-728) T536N primers ....................................................... 191 
B.10 AtPEX5(340-728) T536W primers ...................................................... 191 
B.11 AtPEX5(340-728) N537A primers ....................................................... 191 
B.12 AtPEX5(340-728) N537Q primers ...................................................... 191 
B.13 AtPEX5(340-728) N537T primers ....................................................... 192 
B.14 AtPEX5(340-728) E538A primers ....................................................... 192 
B.15 AtPEX5(340-728) N601A primers ....................................................... 192 




B.17 AtPEX5(340-728) F613A primers ....................................................... 192 
B.18 AtPEX5(340-728) N628A primers ....................................................... 192 
B.19 AtPEX5(340-728) A632G primers ....................................................... 192 
B.20 AtPEX5(340-728) N636A primers ....................................................... 193 
B.21 AtPEX5(340-728) Y647F primers ....................................................... 193 
B.22 AtPEX5(340-728) R659A primers ....................................................... 193 
B.23 AtPEX5(340-728) N663A primers ....................................................... 193 
B.24 AtPEX5(340-728) S667A primers ....................................................... 193 
B.25 AtPEX5(340-728) D505K-D507K primers ........................................... 193 
B.26 AtPEX5(340-728) D505F(-N601A) primers ......................................... 193 
B.27 AtPEX5(340-728) D505F-D507F(-N601A) primers ............................. 194 
B.28 AtPEX5(340-728) D505H/D507H(-N601A) primers ............................ 194 
B.29 AtPEX5(340-728) D505H-D507T(-N601A) primers............................. 194 
B.30 AtPEX5(340-728) D505H-D507V(-N601A) primers ............................ 194 
B.31 AtPEX5(340-728) D505x/D507x primers ............................................ 194 
B.32 AtPEX5(340-728) V533x/T536x primers ............................................. 194 
B.33 AtPEX5(340-728) N601x primers ....................................................... 194 
B.34 AtPEX5(444-728) primers .................................................................. 195 
Appendix C ......................................................................................................... 196 
C.1 Wild-type AtPEX5(340-728): MS trace ............................................... 196 
C.2 AtPEX5(340-728) D505A: MS trace ................................................... 197 
C.3 AtPEX5(340-728) D505H: MS trace ................................................... 197 
C.4 AtPEX5(340-728) D505K: MS trace ................................................... 198 
C.5 AtPEX5(340-728) D507A: MS trace ................................................... 198 
C.6 AtPEX5(340-728) D507K: MS trace ................................................... 199 
C.7 AtPEX5(340-728) V533A: MS trace .................................................... 199 
C.8 AtPEX5(340-728) V533W: MS trace ................................................... 200 
C.9 AtPEX5(340-728) T536A: MS trace .................................................... 200 
C.10 AtPEX5(340-728) T536N: MS trace .................................................... 201 
C.11 AtPEX5(340-728) T536W: MS trace ................................................... 201 
C.12 AtPEX5(340-728) N537A: MS trace ................................................... 202 
C.13 AtPEX5(340-728) N537Q: MS trace ................................................... 202 
C.14 AtPEX5(340-728) N537T: MS trace .................................................... 203 
C.15 AtPEX5(340-728) E538A: MS trace .................................................... 203 




C.17 AtPEX5(340-728) N601Q: MS trace ................................................... 204 
C.18 AtPEX5(340-728) F613A: MS trace .................................................... 205 
C.19 AtPEX5(340-728) N628A: MS trace ................................................... 205 
C.20 AtPEX5(340-728) A632G: MS trace ................................................... 206 
C.21 AtPEX5(340-728) N636A: MS trace ................................................... 206 
C.22 AtPEX5(340-728) Y647F: MS trace .................................................... 207 
C.23 AtPEX5(340-728) R659A: MS trace ................................................... 207 
C.24 AtPEX5(340-728) N663A: MS trace ................................................... 208 
C.25 AtPEX5(340-728) S667A: MS trace .................................................... 208 
C.26 AtPEX5(340-728) D505K-D507K: MS trace ....................................... 209 
C.27 AtPEX5(340-728) D505H-T536W: MS trace ....................................... 209 
C.28 AtPEX5(340-728) D505F-N601A: MS trace ........................................ 210 
C.29 AtPEX5(340-728) D505H-N601A: MS trace ....................................... 210 
C.30 AtPEX5(340-728) D505F-D507F-N601A: MS trace ............................ 211 
C.31 AtPEX5(340-728) D505H-D507H-N601A: MS trace ........................... 211 
C.32 AtPEX5(340-728) D505H-D507T-N601A: MS trace ........................... 212 
C.33 AtPEX5(340-728) D505H-D507V-N601A: MS trace ........................... 212 
C.34 AtPEX5(340-728) D505H-N601A-N636A: MS trace ........................... 213 
C.35 AtPEX5(340-728) D505H-D507T-E538A-N601A: MS trace ................ 213 
C.36 Wild-type AtPEX5(444-728): MS trace ............................................... 214 
Appendix D ......................................................................................................... 215 
D.1 Peptide characterisation tables – example data and processing ......... 215 
D.1.1  Retention time-sequence list .................................................... 215 
D.1.2  Peptides with identical exact mass and retention times to 45 
peptides in the retention time-sequence list ............................... 221 
D.1.3  Example data processing ......................................................... 222 
D.2 Code for adding EICs for each peptide sequence after mass 
spectrometry, and exporting data ....................................................... 225 
D.3 Code for data-processing macros ....................................................... 230 
D.3.1  Generation of ‘drifted’ retention times and matching of these to 
the retention times of peptides in the ‘seq-RT’ master list .......... 230 
D.3.2  Average and count of peptide sequences found when each 
‘drift’ time was applied to retention times ................................... 232 
D.3.3  Sorting of peptides by hydrophobicity ....................................... 234 
D.3.4  Adding EIC areas for pair set 2 (of the 45 pairs of peptides 
without unique RT-mass identifiers) when a peptide of pair set 1 




D.3.5  Blank correcting of data ........................................................... 238 
D.3.6  Splitting -1 and -2 amino acids into separate columns .............. 239 
D.3.7  Converting amino acids to numbers ......................................... 240 
D.3.8  Reset of worksheet for processing of the next dataset ............. 243 
Appendix E ......................................................................................................... 244 
E.1 Wild-type AtPEX5(340-728): pull-down-LC-MS heat map ................... 244 
E.2 AtPEX5(340-728) D505A: pull-down-LC-MS heat map ....................... 245 
E.3 AtPEX5(340-728) D505H: pull-down-LC-MS heat map ...................... 245 
E.4 AtPEX5(340-728) D505K: pull-down-LC-MS heat map ....................... 246 
E.5 AtPEX5(340-728) D507A: pull-down-LC-MS heat map ....................... 246 
E.6 AtPEX5(340-728) D507K: pull-down-LC-MS heat map ....................... 247 
E.7 AtPEX5(340-728) V533A: pull-down-LC-MS heat map ....................... 247 
E.8 AtPEX5(340-728) V533W: pull-down-LC-MS heat map ...................... 248 
E.9 AtPEX5(340-728) T536A: pull-down-LC-MS heat map ....................... 248 
E.10 AtPEX5(340-728) T536N: pull-down-LC-MS heat map ....................... 249 
E.11 AtPEX5(340-728) T536W: pull-down-LC-MS heat map ...................... 249 
E.12 AtPEX5(340-728) N537A: pull-down-LC-MS heat map ....................... 250 
E.13 AtPEX5(340-728) N537Q: pull-down-LC-MS heat map ...................... 250 
E.14 AtPEX5(340-728) N537T: pull-down-LC-MS heat map ....................... 251 
E.15 AtPEX5(340-728) E538A: pull-down-LC-MS heat map ....................... 251 
E.16 AtPEX5(340-728) N601A: pull-down-LC-MS heat map ....................... 252 
E.17 AtPEX5(340-728) N601Q: pull-down-LC-MS heat map ...................... 252 
E.18 AtPEX5(340-728) F613A: pull-down-LC-MS heat map ....................... 253 
E.19 AtPEX5(340-728) N628A: pull-down-LC-MS heat map ....................... 253 
E.20 AtPEX5(340-728) A632G: pull-down-LC-MS heat map ...................... 254 
E.21 AtPEX5(340-728) N636A: pull-down-LC-MS heat map ....................... 254 
E.22 AtPEX5(340-728) Y647F: pull-down-LC-MS heat map ....................... 255 
E.23 AtPEX5(340-728) R659A: pull-down-LC-MS heat map ....................... 255 
E.24 AtPEX5(340-728) N663A: pull-down-LC-MS heat map ....................... 256 
E.25 AtPEX5(340-728) S667A: pull-down-LC-MS heat map ....................... 256 
E.26 AtPEX5(340-728) D505K-D507K: pull-down-LC-MS heat map ........... 257 
E.27 AtPEX5(340-728) D505H-T536W: pull-down-LC-MS heat map .......... 257 
E.28 AtPEX5(340-728) D505F-N601A: pull-down-LC-MS heat map ........... 258 
E.29 AtPEX5(340-728) D505H-N601A: pull-down-LC-MS heat map .......... 258 
E.30 AtPEX5(340-728) D505F-D507F-N601A: pull-down-LC-MS           




E.31 AtPEX5(340-728) D505H-D507H-N601A: pull-down-LC-MS           
heat map ............................................................................................ 259 
E.32 AtPEX5(340-728) D505H-D507T-N601A: pull-down-LC-MS           
heat map ............................................................................................ 260 
E.33 AtPEX5(340-728) D505H-D507V-N601A: pull-down-LC-MS           
heat map ............................................................................................ 260 
E.34 AtPEX5(340-728) D505H-N601A-N636A: pull-down-LC-MS           
heat map ............................................................................................ 261 
E.35 AtPEX5(340-728) D505H-D507T-E538A-N601A: pull-down-LC-MS 
heat map ............................................................................................ 261 
E.36 Wild-type AtPEX5(444-728) : pull-down-LC-MS heat map .................. 262 
Appendix F ......................................................................................................... 263 
F.1 H. Ebeed P. patens PTS1 homologues, based on A. thaliana PTS1 
sequences .......................................................................................... 263 
F.2 L. Cross additional data, testing binding of AtPEX5-C with            







Amino acid Three-letter code One-letter code 
Alanine Ala A 
Arginine Arg R 
Asparagine Asn N 
Aspartic acid Asp D 
Cysteine Cys C 
Glutamic acid Glu E 
Glutamine Gln Q 
Glycine Gly G 
Histidine His H 
Isoleucine Ile I 
Leucine Leu L 
Lysine Lys K 
Methionine Met M 
Phenylalanine Phe F 
Proline Pro P 
Serine Ser S 
Threonine Thr T 
Tryptophan Trp W 
Tyrosine Tyr Y 
Valine Val V 
 
Organisms 
At  Arabidopsis thaliana 
Hs  Homo sapiens 
Mm  Mus musculus 
Phypa  Physcomitrella patens 
Sc  Saccharomyces cerevisiae 





Å  angstroms 
bp  base pairs 
°C  degrees Celsius 
cm  centimetres 
Da  daltons 
g  gram 
x g  times gravity (relative centrifugal force) 
h  hour(s) 
kDa  kilodaltons 
L  litre 
M  moles per L (molar) 
mg  milligram 
min  minute(s) 
mL  millilitre 
mM  millimolar 
mol  mole 
μg  microgram 
μL  microlitre 
μM  micromolar 
μm  micrometres 
ng  nanogram 
nM  nanomolar 
nm  nanometres 
s  seconds 
v/v  volume per volume 
w/v  weight per volume 
General 
aa  Amino acid(s) 
AAA  ATPases associated with various cellular activities 
AI  Autoinduction 
ATP  Adenosine triphosphate 
Boc  tert-Butoxycarbamate 




C18  Octadecyl carbon chain 
CD  Circular dichroism 
CFP  Cyan fluorescent protein 
DCM  Dichloromethane 
DIPEA  N,N-Diisopropylethylamine 
DMF  N,N-Dimethylformamide 
DMSO  Dimethylsulfoxide 
DNA  Deoxyribonucleic Acid 
dNTPs  Deoxynucleotides 
EDC  1-(3-Dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride 
EDTA  Ethylenediaminetetraacetic acid 
EIC  Extracted ion chromatogram 
ER  Endoplasmic reticulum 
ESI(+)  Positive electrospray ionisation 
Et2O  Diethyl ether 
FA  Fluorescence anisotropy 
Fmoc  Fluorenylmethoxycarbonyl 
GFP  Green fluorescent protein 
HCTU 2-(6-Chloro-1H-benzotriazole-1-yl)-1,1,3,3-tetramethylaminium 
hexafluorophosphate 
HPLC  High-performance liquid chromatography 
HRP  Horseradish peroxidase 
IC50  Half-maximal inhibitory concentration 
IPTG  Isopropyl-β-D-thiogalactoside 
Kd  Dissociation constant 
Ki  Inhibition constant 
LB  Lysogeny broth 
LC  Liquid chromatography 
LC-MS  Liquid chromatography-mass spectrometry 
LC-MS/MS Liquid chromatography-tandem mass spectrometry 
LoxP  Locus of X(cross)-over in P1 
M + H  Mass + a proton 
m/z  Mass-to-charge ratio 
OD  Optical density 
Pbf  2,2,4,6,7-pentamethyldihydrobenzofuran-5-sulfonyl 
PBS  Phosphate-buffered saline 




PDB  Protein Data Bank 
PEG  Polyethylene glycol 
PEX  Peroxin 
pKa  Logarithmic acid dissociation constant 
PMP  Peroxisomal membrane protein 
PTS  Peroxisomal targeting signal 
PWM  Positional weight matrix 
Q-TOF  Quadrupole time-of-flight 
ReT  Retention time 
RFP  Red fluorescent protein 
RING  Really interesting new gene 
RT  Room temperature 
SDS  Sodium dodecyl sulfate 
SDS-PAGE Sodium dodecyl sulfate-polyacrylamide gel electrophoresis 
SH3  Src homology 3 
SPPS  Solid phase peptide synthesis 
SPR  Surface plasmon resonance 
tBu  Tertiary butyl 
TCEP  Tris(2-carboxyethyl)phosphine 
TFA  Trifluoroacetic acid 
TPR  Tetratricopeptide repeat 
Trt  Trityl 
VBA  Visual Basic for Applications 
WT  Wild-type 
YFP  Yellow fluorescent protein 
 
1 
Chapter 1  
Introduction: A Way to Re-Purpose Peroxisomes? 
 
The overall aim of this research is to manipulate protein import into peroxisomes, ‘re-
engineering’ the peroxisome as a synthetic organelle. The peroxisome is ideally suited 
to this purpose, as it acquires all constituent proteins from the cytosol through 
conserved protein import pathways (Smith and Aitchison, 2013). This means that the 
function of the peroxisome is determined by the proteins imported, so it could be 
possible to manipulate the peroxisome’s function by targeting these conserved import 
pathways. This method could allow non-peroxisomal proteins to be directed to the 
peroxisome, whilst discriminating against natural peroxisomal cargo. 
1.1 Plant peroxisomes; adaptable cellular organelles 
Peroxisomes are cellular membrane-bound organelles involved in pathways critical to 
the function of the cell. They are present in almost all eukaryotic cells and, among 
other functions, play a role in β-oxidation (for the breakdown of fatty acids to produce 
energy, and the production of plant hormones for effective growth, development, and 
function of the plant), and the metabolism of reactive oxygen species (ROS) (reviewed 
in Hu et al., 2012). Based on the requirements of the cell, peroxisomes can have 
different additional functions so adaptability is an important feature of these organelles 
(Mast et al., 2015; Goto-Yamada et al., 2015). 
Peroxisomes were first observed as “Microbodies” in 1954 by electron microscopy 
(Rhodin, 1954; Bernhard and Rouiller, 1956), within mouse kidney cells, and the 
successful isolation of microbodies from rat liver cells was first published in 1965 
(Baudhuin et al., 1965). These microbodies were subsequently named peroxisomes 
because of their involvement in the metabolism of the reactive oxygen species 
hydrogen peroxide (de Duve and Baudhuin, 1966). The first observation of 
peroxisomes in plant cells, termed “phragmosomes” at the time, was published in 1958 




published in 1966, remarking on the morphological similarity between these 
phragmosomes in plants (then re-named “plant microbodies”) and the animal 
microbodies being reported at the time (Mollenhauer et al., 1966). 
There are different types of peroxisomes in plants, including glyoxysomes, leaf 
peroxisomes, and unspecialised peroxisomes (Olsen, 1998; Hayashi et al., 2000a; 
Kamada et al., 2003). These have different functions and so each requires a different 
overall protein content; peroxisomes are able to handle a high protein concentration in 
order to carry out their range of functions (Heupel et al., 1991). The different 
specialised peroxisomes are still collectively referred to as peroxisomes, as they share 
many of the same enzymes involved in β-oxidation (Pracharoenwattana and Smith, 
2008). In Figure 1, the right-hand panel (insert) shows a section of a plant cell treated 
with the stain DAB (3,3’-diaminobenzidine). This is a cytochemical stain for catalase, a 
protein that is found abundantly within the peroxisome. 
 
Figure 1| The peroxisome in the context of a cartoon plant cell. Right-hand panel (insert) 
image courtesy of Alison Baker. A DAB (3,3’-diaminobenzidine) stain for catalase has been 
used for this section of the plant cell, highlighting the peroxisome. ER, endoplasmic reticulum. 
The peroxisome does not possess its own genome and instead acquires proteins from 
the cytosol, through an import pathway which allows fully folded proteins to enter the 
matrix of the peroxisome (reviewed in Lanyon-Hogg et al., 2010). Here, proteins can 
function within the peroxisome as needed for the requirements of the cell. 
Peroxisomes have evolved to change their protein content quickly in response to their 
environment, through protein import and degradation pathways within the organelle. 
Peroxisome turnover and synthesis also contribute to the change in peroxisomal 




1.1.1 Adaptability of peroxisomal function 
Various pathways are in place within the peroxisome for the turnover of proteins, in 
order to facilitate substantial changes in their protein content for a change in overall 
function. For example, in plants, during the early stages of post-germinative growth 
(before seedlings begin to photosynthesise) cells contain specialised peroxisomes 
known as glyoxysomes which contain enzymes involved in the glyoxylate cycle. After 
β-oxidation for the metabolism of storage oils (an energy source within the plant), the 
glyoxylate cycle is responsible for the subsequent production of carbohydrate to gain 
energy in order to form a shoot during germination. When the plant greens and begins 
to photosynthesise, it requires peroxisomes to take part in a new process within leaf 
cells: photorespiration. Photorespiration takes place to carry out the recycling of 2-
phosphoglycolate, a by-product formed when the enzyme rubisco catalyses the 
addition of O2 to ribulose-1,5-biphopshate, rather than the addition of CO2, as is the 
case during photosynthesis (Zhu et al., 2010). In the peroxisomes of a 
photosynthesising plant, the glyoxylate pathway is redundant so plants are able to 
convert glyoxysomes to leaf peroxisomes able to take part in photorespiration. This 
process is known as the ‘functional transition’ of plant peroxisomes (Goto-Yamada et 
al., 2015). 
There were two hypotheses in place for how peroxisomes undergo the functional 
transition: the ‘one-population’ hypothesis, that peroxisomes retain their structure and 
membrane barrier to the cytosol but their entire protein content is replaced; and the 
‘two-population’ hypothesis, that peroxisomes containing newly redundant proteins are 
gradually turned over to allow the population of the cell by new peroxisomes with the 
required function (Beevers, 1979). Recent research suggests that the one-population 
hypothesis is the predominant mode of functional transition: the way in which 
peroxisomes are able to adapt to the change is through dedicated protein import 
pathways, introducing new proteins from the cytosol, and the degradation of existing 
redundant proteins within the peroxisome (reviewed in Goto-Yamada et al., 2015). 
Redundant proteins in the peroxisome are degraded by proteases (Goto-Yamada et 
al., 2014). 
It appears that any remaining peroxisomes that have not undergone the functional 
transition are degraded in an autophagy process specific to peroxisomes. This process 




2014; Yoshimoto et al., 2014). After a number of peroxisomes have undergone 
pexophagy (if damaged or redundant), new peroxisomes are needed. 
1.2 Formation and maintenance of peroxisomes 
The latest research suggests that new peroxisomes arise from a combination of de 
novo formation from the endoplasmic reticulum (ER), and growth and division of, and 
protein import to, pre-existing peroxisomes (reviewed in Agrawal and Subramani, 
2016). Proteins that are required to function within or at the membrane of the 
peroxisome reach their destination through either direct peroxisomal targeting or 
trafficking in vesicles from the ER (reviewed in Kim and Hettema, 2015, and 
Mayerhofer, 2016). In plant peroxisomes, some peroxisomal membrane proteins have 
been found to traffic to peroxisomes via the ER prior to their differentiation into 
specialised peroxisomes (reviewed in Baker and Paudyal, 2014) (Figure 2). 
 
Figure 2|  A schematic of the formation and differentiation of plant peroxisomes. 
Vesicles containing some peroxisomal membrane proteins (PMPs) bud from the ER, 
joining pre-existing peroxisomes. Following establishment of PMPs in the membrane of 
the peroxisome, targeting of peroxisomal matrix proteins can begin. Import of specific 
peroxisomal matrix proteins allows efficient differentiation of the peroxisome, and 
differentiation of one type of peroxisome to another occurs through a combination of 
matrix protein import and degradation (Cross et al., 2016). Copyright clearance license 
obtained from Elsevier; license number 3881361447160. © Elsevier. 
Proteins that function in the formation and/or maintenance of peroxisomes are called 




peroxisomes in the plant cell, and these can be categorised by their functions (Table 
1). 
Function Name First cloned from plants 
Membrane protein targeting 
PEX3 Hunt and Trelease, 2004 
PEX16 Lin et al., 1999 
PEX19 Hadden et al., 2006 
Division and proliferation  
of peroxisomes 
PEX11 Lingard and Trelease, 2006 
Matrix protein import: PTS1-
protein receptor 
PEX5 
Brickner et al., 1998; 
Kragler et al., 1998; 
Wimmer et al., 1998 
Matrix protein import: PTS2-
protein receptor 
PEX7 Li et al., 2003 
Matrix protein import: 
PTS1-/PTS2-protein receptor 
docking at the peroxisomal 
membrane 
PEX13 Mano et al., 2006 
PEX14 
Lopez-Huertas et al., 1999; 
Hayashi et al., 2000b 
Matrix protein import: 
RING-finger (E3 ligase) complex 
PEX2 Hu et al., 2002 
PEX10 
Baker et al., 2000; 
Schumann et al., 2003 
PEX12 Fan et al., 2005 
Matrix protein import: 
E2 ligase 
PEX4 Zolman et al., 2005 
Matrix protein import: 
Membrane anchoring of E2 ligase 
PEX22 Zolman et al., 2005 
Matrix protein import: 
AAA ATPase complex 
PEX1 Lopez-Huertas et al., 2000 
PEX6 Kaplan et al., 2001 
Matrix protein import: 
Membrane anchoring of AAA 
ATPase complex 
APEM9 Goto et al., 2011 
Table 1|  Roles of peroxins in plants. Peroxins are required for both the formation and 
maintenance of peroxisomes. PTS, peroxisomal targeting signal; RING, really interesting 
new gene; AAA, ATPases associated with various cellular activities; PEX, peroxin; 
APEM, aberrant peroxisome morphology. 
Peroxin (PEX) proteins are involved in various stages of peroxisome formation and 
maintenance. These stages are shown in Figure 2. One of these stages, protein 
import into the matrix of the peroxisome, is controlled by PEX5 and PEX7 and this 




peroxisome membrane is a crucial process as this establishes the composition and, 
therefore, role of the peroxisome membrane. When peroxisomal membrane proteins 
are in place, the peroxisome can carry out the import of matrix proteins (the 
peroxisomal matrix protein import pathway depends on peroxisomal membrane 
proteins for its function). 
The following sections will cover peroxisomal matrix protein import, as this is the 
pathway which controls the protein composition and, therefore, function of the 
peroxisome. In order to work towards producing a synthetic organelle from the 
peroxisome, matrix protein import seems the obvious pathway to target and 
manipulate. 
1.3 The peroxisomal matrix protein import pathway 
Import of cargo proteins to the matrix of the peroxisome from the cytosol is dependent 
on two pathways, the peroxisomal targeting signal 1 (PTS1)-mediated pathway and 
the PTS2-mediated pathway. Although these two pathways begin with distinct 
receptor-targeting signal binding events, there is co-dependence between the 
pathways and the separation between the pathways becomes more ambiguous at all 
processes downstream from, and including, docking at the peroxisomal membrane 
(Nito et al., 2002; Woodward and Bartel, 2005; Ramón and Bartel, 2010). PTSs are 
recognition sequences at the C- (PTS1) or N- (PTS2) terminus of cargo proteins, and 






Figure 3|  Scheme for the import of proteins into the matrix of the plant 
peroxisome. Peroxisomal cargo proteins contain either a PTS1 (C-terminal) or a PTS2 
(N-terminal) sequence. These are bound by PEX5 or PEX7, respectively, which allows 
the targeting of cargo proteins to the peroxisomal membrane for import. PTS2 is cleaved 
from PTS2-cargo proteins within the peroxisomal matrix. After cargo protein import, 
PEX5 and possibly PEX7 are recycled to the cytosol for another round of import. Lysine 
polyubiquitination of PEX5 occurs when there is accumulation of PEX5 at the 
peroxisome membrane. This results in the proteasomal degradation of PEX5 in a 
pathway that could involve DSK2a and DSK2b (PEX2/PEX12-binding proteins). PTS, 
peroxisomal targeting signal; PEX, peroxin; Ub, ubiquitin; APEM, aberrant peroxisome 
morphology; DSK, ubiquitin domain-containing protein. (Cross et al., 2016). Copyright 
clearance license obtained from Elsevier; license number 3881361447160. © Elsevier. 
The peroxisomal matrix protein import cycle begins with the PTS1/PTS2-cargo protein 
binding its cognate receptor, followed by docking of this complex at peroxisomal matrix 
proteins (PMPs). Translocation of folded cargo is achieved though interaction of 
peroxin 5 (PEX5)/peroxin 7 (PEX7) with peroxisomal membrane proteins. Cargo is 
released once in the peroxisomal matrix and PEX5/PEX7 is recycled to the cytosol for 




1.3.1 Cargo recognition by the PTS receptors 
PEX5 and PEX7 are responsible for the recognition of PTSs on proteins destined for 
the peroxisome (Figure 4). PEX5 binds to the PTS1 sequence on PTS1-cargo 
proteins, and PEX7 binds to the PTS2 sequence on PTS2-cargo proteins. In the plant 
and mammalian systems, the co-receptor for PEX7 is PEX5 (Nito et al., 2002; 
Woodward and Bartel, 2005; Braverman et al., 1998); however, in S. cerevisiae the 
co-receptors are PEX18 and PEX21 (Purdue et al., 1998), and in other yeasts the co-
receptor is PEX20 (Titorenko et al., 1998). 
 
Figure 4|  Cargo recognition in the plant peroxisomal matrix protein import 
pathway. (Cross et al., 2016). Copyright clearance license obtained from Elsevier; 
license number 3881361447160. © Elsevier. 
The PTS1-mediated import pathway is the most common pathway for cargo proteins 
to enter the plant peroxisome. PEX5 is also a co-receptor for PEX7 in the PTS2 import 
pathway: this has been found through genetic studies, showing that mutation of a site 
within PEX5 of Chinese hamster ovary cells (Ser214Phe) disrupted PTS2 import but 
had no apparent effect on PTS1 import (Matsumura et al., 2000). Mutation of the 
equivalent residue in Arabidopsis PEX5 (Ser318Leu) also had the same effect of 
disrupting only PTS2 import (Zolman et al., 2000; Woodward and Bartel, 2005). PTS2 
import with this A. thaliana protein variant was recovered by the simultaneous 
expression of a truncated PEX5 variant comprising the N-terminal domain, PEX5454, 
which implies that PEX7 relies on the N-terminal domain of PEX5 for PTS2 import. In 
rice and humans, there are two splice variants of PEX5 which result in two possible 
isoforms of the protein: PEX5S and PEX5L (Lee et al., 2006; Braverman et al., 1998). 
PEX5L contains the PEX7 binding site, so can act as a co-receptor in the PTS2 




role in the PTS1 import pathway. In Arabidopsis thaliana, only the equivalent of the 
longer splice variant of PEX5 is expressed (Hayashi et al., 2005; Woodward and 
Bartel, 2005). 
1.3.1.1 PTS1-cargo recognition 
The most abundant PTS1 sequences display the properties [small]-[basic]-
[hydrophobic]-C terminus. These have been generally accepted as the requirements 
for PTS1-mediated peroxisomal targeting; however, it is becoming clear that this C-
terminal sequence can be quite varied, and can rely heavily on its upstream sequence 
to change the targeting abilities of the PTS1-cargo protein (Mullen et al., 1997; 
Maynard et al., 2004; Brocard and Hartig, 2006; Reumann, 2011; Chowdhary et al., 
2012). A PTS1 prediction algorithm (PTS1 Predictor) was created by Neuberger and 
colleagues for the prediction of PTS1-containing proteins in largely metazoan and 
fungal species (Neuberger et al., 2003a; Neuberger et al., 2003b). The bioinformatics 
tool PredPlantPTS1 allows prediction of the probability of specifically a plant C-
terminal sequence allowing PTS1-mediated targeting to peroxisomes (Lingner et al., 
2011; Reumann et al., 2012). This has been validated by in vitro binding studies and in 
vivo import experiments (Skoulding et al., 2015). 
The C-terminal domain of PEX5 is responsible for PTS1 binding. This has been shown 
by the expression of only the C-terminal domain of Arabidopsis PEX5. An in vitro 
binding study with this N-terminally truncated variant of PEX5 has demonstrated that 
binding of a PTS1 peptide is effectively unchanged when comparing the full-length 
protein to the TPR domain alone (Skoulding, 2011). 
1.3.1.2 PTS2-cargo recognition 
The consensus for a PTS2 sequence is [R/K]-[L/V/I/Q]-X2-[L/V/I/H/Q]-[L/S/G/A/K]-X-
[H/Q]-[L/A/F] and this sequence is found near the N-terminus of PTS2-cargo proteins 
(Petriv et al., 2004). To date, no PTS2 prediction tool has been published. 
Genetic studies of PEX7 have shown that reduced PTS2 import is observed when 
expression of PEX7 is knocked down (Hayashi et al., 2005; Woodward and Bartel, 
2005; Ramón and Bartel, 2010). Interestingly, a missense mutation in PEX7 




also rely on PEX7 for import, possibly suggesting some co-dependence (Ramón and 
Bartel, 2010). 
1.3.1.3 PTS-mediated import of folded proteins 
Peroxisomes are unusual in that they facilitate the import of fully folded proteins 
(Walton et al., 1995). The PTS1 pathway in yeast has been shown to accommodate 
large complexes through the membrane by forming a pore that can reach up to 
9.25 nm in diameter (Meinecke et al., 2010). A phenomenon known as ‘piggyback 
import’ also occurs in the PTS1 and PTS2 import pathways. This is where a protein 
without a PTS can associate with a PTS-cargo protein in order for both proteins to gain 
access to the peroxisomal matrix (McNew and Goodman, 1994; Glover et al., 1994; 
Kato et al., 1999). Some of the subunits of the enzyme protein phosphatase 2A 
(PP2A), which seems to be involved in β-oxidation in peroxisomes, have been found to 
target to the peroxisome by piggyback import. In this case, only one of the subunits of 
PP2A possesses a PTS1, [S]-[S]-[L]-C terminus, and this sequence targets all 
associated subunits of PP2A to the peroxisome (Kataya et al., 2015). 
1.3.2 The peroxisomal membrane docking complex 
Cargo-loaded peroxisomal targeting receptors dock to proteins at the membrane of the 
peroxisome for delivery of the cargo to the matrix of the peroxisome. PEX14 and 
PEX13 are the major known docking proteins (Figure 5). 
 
Figure 5|  Peroxisome membrane docking in the plant peroxisomal matrix protein 
import pathway. (Cross et al., 2016). Copyright clearance license obtained from 
Elsevier; license number 3881361447160. © Elsevier. 
It has come to light that PEX14, although playing a major role in facilitating 




Arabidopsis (Hayashi et al., 2000b; Monroe-Augustus et al., 2011; Burkhart et al., 
2013) or the yeast Hansenula polymorpha (Salomons et al., 2000). Arabidopsis 
PEX14 mutants, which reduced PEX14 protein expression levels, resulted in reduced 
PTS1 and PTS2 import (Monroe-Augustus et al., 2011; Burkhart et al., 2013). This 
suggests that PEX14 is still important for Arabidopsis matrix protein import into the 
peroxisome, even if it is not essential for this process. A dynamic transient pore 
between PEX5 and PEX14 has been demonstrated to form in the Saccharomyces 
cerevisiae system, which is presumed to allow cargo to enter the matrix of the 
peroxisome (Meinecke et al., 2010). This was initially suspected when size exclusion 
chromatography and immunoblot analysis revealed a complex the size of 
PEX5:PEX14 but lacking cargo protein. When this complex was reconstituted into 
liposomes and incubated with purified PEX5-cargo, a dynamic pore could be 
measured by monitoring ion channel activity (Meinecke et al., 2010). Recent work by 
Meinecke and colleagues suggests that this is a water-filled pore, which expands 
depending on the size and oligomeric state of cargo (Meinecke et al., 2016). In the 
absence of PEX14, it could be postulated that PEX5 can form PEX5-only pores by 
self-oligomerisation as low levels of PTS1-cargo import are still observed in the 
absence of PEX14 in both Arabidopsis and yeast (Monroe-Augustus et al., 2011; 
Salomons et al., 2000). Also, Kerssen and colleagues showed that Saccharomyces 
cerevisiae PEX5 containing two point mutations, which prevented its association with 
PEX13 and PEX14, still associated with the peroxisome membrane (Kerssen et al., 
2006). 
PEX13 is also part of the docking complex for cargo-loaded receptors, and an 
interaction between PEX13 and PEX14 has been reported in yeast and mammals 
(Albertini et al., 1997; Fransen et al., 1998). In Arabidopsis, a point mutation within 
PEX13 (Glu243Lys) results in reduced PTS1 and PTS2 import (Woodward et al., 
2014), and the site of this mutation sits within the putative Src homology 3 (SH3) 
domain of PEX13, which has been determined as the binding site for PEX14 in yeast 
and mammals (Albertini et al., 1997; Fransen et al., 1998). Other genetic studies in 
Arabidopsis, in which PEX13 is truncated or its expression is knocked down, have also 
resulted in reduced PTS1 and PTS2 import (Mano et al., 2006; Nito et al., 2007). 
Studies of PEX13 have also given insight into the overall import process. For example, 
knockdown of PEX13 expression levels exacerbates the effects of mutation in ‘early 
acting’ peroxins PEX5 and PEX14, resulting in further impaired peroxisomal protein 
import, yet restores the detrimental effects of mutation in ‘late acting’ peroxins PEX1 




import (Ratzel et al., 2011). This suggests that the ‘early acting’ peroxins and the ‘late 
acting’ peroxins are linked in overall function but not in mechanism (Ratzel et al., 
2011). 
Interactions between the Arabidopsis import receptors and the docking peroxins have 
been studied in vitro using yeast-two-hybrid studies, filter binding and pull-down 
analysis (Nito et al., 2002; Mano et al., 2006; Lanyon-Hogg et al., 2014). In an 
Arabidopsis study by Nito and colleagues, no binding of PEX14 to PEX7 was 
observed, unlike the mammalian and yeast import systems (Nito et al., 2002). Yeast-
two-hybrid was also used to investigate binding of Arabidopsis PEX13 to PEX5 and 
PEX7, and it was shown that PEX13 interacts with PEX7 but not PEX5 (Mano et al., 
2006). In the mammalian import system, binding of PEX5 to PEX14 caused the 
release of the PTS1 cargo catalase (Freitas et al., 2011); however, recent work in 
Arabidopsis has shown that the interaction between PEX5 and a PTS1-representative 
peptide is unchanged when increasing concentrations of PEX14 are titrated into the 
mixture (Lanyon-Hogg et al., 2014). It has also been demonstrated by Lanyon-Hogg 
and colleagues that PTS1-PEX5-PEX7-PTS2 interact by pull-down from the cytosolic 
fraction of Arabidopsis, but with AtPEX14 only PTS1-PEX5-PEX7 are pulled down, 
which suggests a potential role for PEX14 in PTS2 cargo unloading (Lanyon-Hogg et 
al., 2014). 
The PTS receptor(s) must be recycled to the cytosol for subsequent rounds of cargo 
import. Ubiquitin is an important part of the recycling process of the PTS receptor(s), 
as ubiquitin must be transferred onto PEX5, and possibly PEX7, to allow for receptor 
recycling (Platta et al., 2016). 
1.3.3 The mechanism for ubiquitination of the PTS receptors 
In order for multiple rounds of cargo import into peroxisomes to be carried out, the 
PEX5 receptor must be recycled to the cytosol. This process is governed by 
monoubiquitination of a cysteine residue (in yeast (Williams et al., 2007) and mammals 
(Carvalho et al., 2007a)) which also appears to be conserved in plant PEX5. There is 
also the option for PEX5 degradation by polyubiquitination of one or more lysine 
residues of PEX5, which directs PEX5 through the RADAR (Receptor Accumulation 
and Degradation in the Absence of Recycling) pathway if there is inefficient export of 
PEX5, and therefore a build-up of PEX5 at the peroxisome membrane (Léon et al., 




transfers ubiquitin to an E2 ubiquitin-conjugating enzyme. This allows the transfer of 
ubiquitin to the target protein in the presence of an E3 ligase (Deshaies and Joazeiro, 
2009). 
 
Figure 6|  Ubiquitination of the PTS1 receptor in the plant peroxisomal matrix 
protein import pathway. (Cross et al., 2016). Copyright clearance license obtained from 
Elsevier; license number 3881361447160. © Elsevier. 
PEX4 has been identified in yeast as the E2 ubiquitin-conjugating enzyme which 
comes into close proximity to PEX12 of the PEX2/10/12 RING-finger (E3 ligase) 
complex to allow the catalysis of ubiquitin transfer from PEX4 to PEX5 (Platta et al., 
2007; Platta et al., 2009) (Figure 6). PEX4 is anchored to the membrane by PEX22 
(Koller et al., 1999; Zolman et al., 2005). Mammals do not possess PEX4, so rely on 
cytosolic E2 enzymes (reviewed in Francisco et al., 2014). The ubiquitination 
machinery for receptor recycling in plants has not been extensively studied; however, 
it has been found that the Arabidopsis PEX4-PEX22 complex can restore function of 
yeast peroxisomes in which PEX4 and PEX22 are deficient (Zolman et al., 2005). In 
yeasts, the function of PEX4 is enhanced by the cytosolic domain of PEX22 (Platta et 
al., 2007; Williams et al., 2007; El Magraoui et al., 2014). Knockdown of PEX22 
expression in Arabidopsis by T-DNA insertion enhances effects caused by PEX4 
knockdown (Zolman et al., 2005), suggesting that the two proteins are connected in 
mechanism. As Arabidopsis and yeast PEX4-PEX22 seem to be interchangeable, and 
Arabidopsis PEX22 has also been found to be an enhancer of PEX4 (Zolman et al., 
2005), it seems likely that that the plant ubiquitin machinery for recycling or 




PEX2, PEX10 and PEX12 form the RING complex, so named because each of these 
peroxins contains at least a partial RING-finger domain. PEX2 and PEX10 contain full 
RING-finger domains, whereas PEX12 contains a partial RING-finger domain. The 
RING-finger domains of the three proteins from Arabidopsis have been isolated and 
studied to elucidate function, and it has been found that all three possess E3 ligase 
activity (Kaur et al., 2013). The RING complex is vital for peroxisome function and 
therefore cell survival, which has been shown through genetic studies. Mutants of the 
three proteins (pex2-T-DNA; pex10-1; pex12-T-DNA), in which T-DNA insertion results 
in frameshift, are all lethal to the plant (Hu et al., 2002; Schumann et al., 2003; 
Sparkes et al., 2003; Fan et al., 2005; Nito et al., 2007). Truncation of PEX10 (pex10-
W313*) also results in a lethal phenotype (Prestele et al., 2010). Knockdown of 
expression of the three RING peroxins by RNA interference (pex2i, pex10i and pex12i) 
all result in reduced PTS1 and PTS2 import (Nito et al., 2007), potentially due to the 
reduced presence of PEX5 in the cytosol as less PEX5 is ubiquitinated and available 
for export to the cytosol. 
In yeast, PEX12 is the E3 ligase involved in PEX5 monoubiquitination and PEX2 is the 
E3 ligase involved in PEX5 polyubiquitination (Platta et al., 2009), although it remains 
to be seen if this is the case in plants. A quality control mechanism also appears to be 
in place for PEX7, as the GTPase rabE1c has been found to be involved in PEX7 
degradation in Arabidopsis (Cui et al., 2013), and PEX7 degradation that was reliant 
on PEX20 and PEX5 was reported in yeast (Hagstrom et al., 2014). To meet either 
fate of recycling or degradation, PEX5 must be exported from the peroxisome 
membrane. For receptor recycling, a membrane-anchored AAA ATPase (ATPases 
associated with various cellular activities) complex is required (reviewed in Grimm et 
al., 2016). 
1.3.4 The receptor recycling complex 
Three peroxins, PEX1, PEX6 and APEM9 (aberrant peroxisome morphology-9) are 
required for the PTS receptor(s) to be recycled back to the cytosol for subsequent 
rounds of peroxisomal import (Figure 7). The AAA ATPase complex is comprised of 
PEX1 and PEX6. PEX1 and PEX6 are anchored to the cytosolic side of the membrane 
by APEM9 (through the association of APEM9 with PEX6) (Goto et al., 2011), and this 
complex seems to be important for both the PTS1 and PTS2 import cycles in 
Arabidopsis. This has been found through genetic studies of the three peroxins. When 




apem9i), the result is reduced PTS1 and PTS2 import (Nito et al., 2007; Goto et al., 
2011). This suggests a link between receptor recycling and cargo protein import. 
 
Figure 7|  Receptor recycling in the plant peroxisomal matrix protein import 
pathway. (Cross et al., 2016). Copyright clearance license obtained from Elsevier; 
license number 3881361447160. © Elsevier. 
Disruption of APEM9, by T-DNA insertion at either the N- or C-terminal portion of the 
protein causing frameshift, results in a lethal phenotype (Goto et al., 2011). This 
highlights the importance of receptor recycling for the peroxisomal matrix protein 
import process. In APEM9, a missense mutation (apem9-1; Gly278Glu) results in 
reduced PTS1 and PTS2 import (Goto et al., 2011; Li et al., 2014). In PEX6, a 
mutation in the C-terminal portion of the protein (pex6-1; Arg766Gln) reduces PEX5 
levels, whereas a mutation in the N-terminal portion (pex6-2; Leu328Phe) does not 
seem to affect PEX5 levels (Zolman and Bartel, 2004; Burkhart et al., 2013). This 
could be due to the location of the mutation, or it could be that the change in chemical 
properties upon the Arg→Gln mutation in pex6-1 results in a more defective 
phenotype than the more conservative Leu→Phe mutation. 
The role of PEX1 and PEX6 is to export PEX5 from the peroxisome membrane back 
into the cytosol, and this has been demonstrated in mammalian and yeast systems 
(Miyata et al., 2012; Platta et al., 2005). It is thought that conformational changes 
occur in the AAA ATPases in response to ATP consumption, which could allow PEX5 
to be pulled out of the peroxisome membrane (Platta and Erdmann, 2007). A co-factor 
of PEX6, AWP1 (associated with PRK1), is an important protein for mammalian PEX5 




to monoubiquitinated PEX5 (Miyata et al., 2012). This suggests that AWP1 could be 
involved in pulling PEX5 from the peroxisome membrane and into the cytosol. A more 
recent study in Saccharomyces cerevisiae shows that the position of the 
monoubiquitination site, near the N-terminus of Pex5p, is important for a functional 
PEX5 receptor, and the nature of the cysteine residue itself is important for efficient 
PEX5 recycling (Schwartzkopff et al., 2015). In this study, Schwartzkopff and 
colleagues showed that mutation of the cysteine at the monoubiquitination site of 
PEX5 to alanine (PEX5C6A) resulted in a non-functional PTS1-import receptor; 
mutation of the cysteine to lysine (PEX5C6K) resulted in polyubiquitination of PEX5C6K, 
so this receptor was still functional but much less efficient at recycling, as proteasomal 
degradation took place much more readily (Schwartzkopff et al., 2015). Receptor 
recycling is an important part of the import pathway as this regenerates PEX5 to the 
cytosol where it can bind another PTS1-containing cargo protein. 
Recent electron micrographs of the PEX1/6 AAA ATPase complex from yeast have 
revealed that this complex is a hexamer comprising a trimer of dimers: each dimer 
consisting of a monomer of PEX1 and a monomer of PEX6 (Ciniawsky et al., 2015). 
This work has shown that rotational movement of the complex in response to ATP 
appears to be responsible for the export of PEX5 from the membrane, and that this 
export may require partial or complete unfolding of PEX5 (Ciniawsky et al., 2015). The 
receptor recycling stage of plant peroxisomal matrix protein import still requires 
unravelling and it will be exciting to see how this process works in plants, and how this 
differs from mammals and fungi. 
1.3.5 Export-driven import 
Recent publications are suggesting that there is a link between import of PTS1-cargo 
and export of the PEX5 protein back to the cytosol. A link between these two 
processes was first suggested when parallels were drawn between peroxisomal 
protein import and the endoplasmic reticulum-associated degradation (ERAD) 
pathway, with similarities between the exit of misfolded proteins from the ER 
membrane and the exit of PEX5 from the peroxisome membrane being remarked upon 
(Schliebs et al., 2010). Models of an export-driven import process have been produced 
for human peroxisomal protein import (Brown et al., 2014), and PEX5 has also 
recently been found halted at the peroxisomal membrane in a monoubiquitinated state 
when a bulky tag (representing PTS1-cargo that cannot be released) was added to the 




system, for studying in vitro interactions important for peroxisomal import, was set up 
recently by the Baker laboratory (Bhogal et al., 2016), which showed that the 
interaction between PEX5 (the PTS1 receptor) and PEX14 (part of the membrane 
docking complex for PTS receptors) in A. thaliana was independent of cargo, yet 
dependent on ATP. This could mean that the export of PEX5 from the peroxisomal 
membrane (an ATP-dependent process) is dependent on the actions of the docking 
and translocation machinery (DTM). 
It has been suggested, in the mammalian import system, that the RING complex 
(section 1.3.3) acts as part of the importomer and that export of the PEX5 protein from 
the membrane could be linked to the cargo unloading process (Brown et al., 2014). In 
yeast, two stable complexes were isolated, one containing Pex14p, Pex17p (a 
component of the translocation import machinery in yeast) and a small amount of 
Pex13p, and the other containing the three RING finger peroxins Pex2p, Pex10p and 
Pex12p (Agne et al., 2003). Interestingly, these two complexes were associated into a 
larger complex in the presence of Pex8p, a crucial peroxin for peroxisomal protein 
import in yeast (Agne et al., 2003). Possible links between the cargo import 
components and the receptor export components have also been found in plants, as it 
was found that levels of PEX12 are enhanced when PEX13 is truncated, suggesting a 
compensatory mechanism (Mano et al., 2006), and also APEM9 has been found to 
interact with PEX13 (Li et al., 2014). 
Three models for the dynamics of the PEX5 protein in cargo delivery and export into 
the cytosol have been proposed for the mammalian PTS1 import system (Brown et al., 
2014): 1) PEX5 could be pulled from the membrane by PEX1/6 in a process twinned 
with cargo unloading; 2) the two processes, PEX5 being pulled from the membrane 
and cargo unloading, could be separate; 3) the two processes are cooperatively 
coupled – as a monoubiquitinated PEX5 is extracted from the membrane, this allows a 
cargo-loaded PEX5 protein to release its cargo into the peroxisomal matrix. 
PEX5:PEX14 have been found in a 1:5 ratio under natural conditions (Gouveia et al., 
2000), and a 1:1 ratio when export of PEX5 is blocked (Meinecke et al., 2010). This 
suggests a build-up of PEX5 at the DTM when cargo-unloaded PEX5 cannot be 




1.3.6 A focus on the PTS1-mediated import pathway 
Subsequent sections of this introduction will focus on the PTS1 protein import 
pathway, for the following reasons: 80% of matrix proteins contain a C-terminal PTS1 
and are imported into the peroxisome via the PTS1-mediated import pathway; in some 
organisms, for example the diatom Phaeodactylum tricornutum, the PTS2 pathway 
seems to be completely lost and the PTS1 pathway is responsible for all protein import 
into peroxisomes (Gonzalez et al., 2011); and the PTS1-mediated import pathway has 
been studied more extensively than the PTS2-mediated import pathway. More 
available data addressing the PTS1-mediated import pathway will allow for an 
informed attempt at the manipulation of this pathway in this study. 
1.4 PEX5 structure and function 
PEX5 is a modular protein, with the C-terminal domain crucial for PTS1 binding and 
the N-terminal domain involved in interaction with PEX7, possibly translocation, and 
recycling of PEX5 (Figure 8). It was thought that the N-terminus could inhibit 
peroxisome membrane docking and translocation prior to cargo binding, with Hsp70 
needed to produce a PTS1-binding competent state of PEX5 (Harano et al., 2001). 
Recent research suggests that this is not the case, as fluorescence anisotropy studies 
have shown that full-length PEX5 and just the C-terminal domain (PEX5-C) both bind 
to a representative PTS1 sequence YQSKL-CO2H with very similar affinity (Harper et 
al., 2003; Skoulding et al., 2015). Also, co-immunoprecipitation of PEX5 with PEX14 





Figure 8|  A simplified representation of AtPEX5. Monoubiquitination (conserved 
cysteine residue) and polyubiquitination (conserved lysine residues) sites are located 
near the N-terminus of AtPEX5 and this region is highlighted by an asterisk. (Cross et al., 
2016). Copyright clearance license obtained from Elsevier; license number 
3881361447160. © Elsevier. 
PEX5 contains nine WxxxF/Y (Trp-x-x-x-Phe/Tyr) pentapeptide repeats (Figure 8) 
which were found to be crucial in the interaction of PEX5 with PEX14 (Schliebs et al., 
1999). These repeats bind to the N-terminal portion of PEX14, as demonstrated by: 
size exclusion chromatography of H. sapiens PEX5 with and without an N-terminal 
fragment of PEX14 (Schliebs et al., 1999); competition analysis of H. sapiens PEX5 
versus the peptide WAQEF for binding to the 78 N-terminal residues of PEX14 
(Saidowsky et al., 2001); pull-down of PEX5 with progressive N-terminal deletions of 
PEX14 (Madrid and Jardim, 2005); in vivo analysis of PTS1 cargo import with site-
directed mutants of PEX14 (Su et al., 2009); and structural determination of the 
PEX14 interacting with peptides from the PEX5 sequence, by nuclear magnetic 
resonance (Neufeld et al., 2009 (PDB file 2W84); Neuhaus et al., 2014 (PDB file 
4BXU)). 
The PEX7 binding site within PEX5 contains a conserved serine residue (S213 in 
Homo sapiens PEX5 (HsPEX5), S318 in Arabidopsis thaliana (AtPEX5)) and is 
between sets of the WxxxF/Y repeats that associate PEX5 with PEX14 (Schliebs et 
al., 1999; Woodward and Bartel, 2005). Binding of PEX5 to the PTS1 sequence occurs 
by interaction of PTS1 with the TPR (tetratricopeptide repeat) domain. 
1.4.1 The N-terminal domain of PEX5 
The N-terminal domain of PEX5 is largely unfolded, as suggested by Carvalho and 




extended N-terminal domain (Carvalho et al., 2006; Shiozawa et al., 2009). Insertion of 
PEX5 into the membrane via the N-terminus, as hypothesised in the transient pore 
model, was thought to be cargo-protein dependent (Gouveia et al., 2003). It has, 
however, been found that a mutation in PEX5 (N526K in HsPEX5L), which diminishes 
PTS1 binding by PEX5, results in a PEX5 variant able to insert into the peroxisome 
membrane in an in vitro import system (Carvalho et al., 2007b). This shows that PEX5 
can have the ability to insert into the membrane in the absence of bound cargo protein. 
This was also supported by the finding that PEX5 could bind to PEX14 without prior 
binding to PTS1 cargo (Lanyon-Hogg et al., 2014). 
1.4.2 The C-terminal domain of PEX5, and PTS1 binding 
As stated, the C-terminal domain of PEX5 binds cargo proteins via their PTS1 
sequence. The disordered nature of the N-terminal domain of PEX5 means that it has 
only been possible to crystallise the C-terminal domain (PEX5-C). The structure of 
PEX5-C:PTS1 reveals that PEX5-C is composed mainly of two sets of three 
tetratricopeptide repeats (TPRs), comprising TPRs 1-3 and TPRs 5-7. These two 
binding faces make up the PTS1-binding site (with TPR4 acting as a linker), which 
contains conserved asparagine residues that can make polar interactions with the 
backbone of the PTS1 sequence. Many other conserved amino acids in the PEX5 
binding site are responsible for side chain interactions of the PTS1 sequence, either 
directly or indirectly via water molecules (Gatto et al., 2000; Stanley et al., 2006; 
Sampathkumar et al., 2008; Fodor et al., 2012; Fodor et al., 2015). 
Each TPR usually consists of two antiparallel α-helices (D'Andrea and Regan, 2003) in 
a helix-turn-helix motif, but TPR3 was found in an X-ray crystal structure to be present 
as one elongated helix (Kumar et al., 2001 (PDB file 1HXI)). Each TPR is a 34-amino 
acid sequence which can act as an ‘interaction scaffold’ (Allan and Ratajczak, 2011). 
When many copies of consensus TPRs are synthesised in one chain, they appear to 
group together in sets of 3 TPRs to form binding sites with the overall structure 
resembling a spiral (D'Andrea and Regan, 2003). The TPRs of PEX5 are unusual in 
that TPRs 1-3 and TPRs 5-7 group together to form an overall binding site for 
interacting proteins. This has been confirmed through mutation of specific residues in 
both sets of the 3 TPRs of PEX5, showing that both sets of TPRs play a role in PTS1-
binding. Figure 9, an I-TASSER-predicted structural model of the C-terminal domain 
of A. thaliana PEX5 (AtPEX5-C) (without the flexible WxxxF/Y repeat region – 




YQSKL is bound to the TPR domain of PEX5. The I-TASSER-predicted model was 
based on five PDB ‘hits’ with well-aligning primary sequences (in order of sequence 
similarity (most → least): PDB files 1FCH (chain A) (Gatto et al., 2000), 3CVN (chain 
A) (Sampathkumar et al., 2008), 3CV0 (chain A) (Sampathkumar et al., 2008), 4EQF 
(chain A) (Bankston et al., 2012), and 1W3B (chain A) (Jinek et al., 2004)). 
The “7C-loop”, which is found downstream from TPR7 (highlighted in Figure 9), could 
be important in cargo binding as a notable change in its position has been observed 
upon PTS1-binding (Stanley et al., 2006). This is expected to convert PEX5 from a 
relatively open conformation to a closed, more ring-like conformation, though the 
function of this movement in PTS1-cargo import is not yet clear (Stanley et al., 2006). 
 
Figure 9|  The predicted structural model of the AtPEX5 TPR domain with YQSKL 
(from the structure of HsPEX5-C:PTS1 (1FCH)) (consensus PTS1) bound. The PTS1 
sequence is recognised between two arch-like groups of three TPRs, TPR1-3 (coloured 
blue) and TPR5-7 (coloured purple); TPR4 (coloured red) seems to act as a hinge region 
between the two groups. The structural model of AtPEX5-C was produced using 
I-TASSER (Zhang, 2008; Roy et al., 2010; Yang et al., 2015; Yang and Zhang, 2015) 
(peptide: (Gatto et al., 2000), PDB file 1FCH). TPR, tetratricopeptide repeat. 
It has been suggested that TPRs move in a rigid nature in response to PTS1 binding, 
which seems to transform the TPR domain to a closed, almost circular, conformation 
(Stanley et al., 2006). The rigid movement of the TPR domain in response to PTS1 




another research group have found that TPR5 and 6 could mediate the change in 
structure upon cargo binding (Stanley et al., 2007). 
Important TPRs for the binding of PTS1 sequences to HsPEX5 are TPR2, 3, 6 and 7. 
These TPRs contain residues that have been found to be significant for PTS1 binding. 
The four conserved asparagine residues of HsPEX5L, N415, N526, N534 and N561 
(N537, N628, N636 and N663 in AtPEX5, respectively), are found in close proximity to 
PTS1 in all current crystal structures of the cargo-bound HsPEX5 TPR domain (Gatto 
et al., 2000; Stanley et al., 2006; Fodor et al., 2012). The PTS1 ‘pocket’ of PEX5 
contains three key regions: the hydrophobic pocket that commonly associates with 
leucine at the C-terminal position, another pocket that associates with a small amino 
acid such as serine, and negative residues that usually associate with lysine or 
arginine via a water molecule. The overall interactions within the PTS1 binding site can 
be seen in the interaction plot within Figure 10. 
 
Figure 10|  PEX5 recognition of the three C-terminal residues of a PTS1. An 
interaction plot is shown, using AtPEX5 numbering, based on existing PEX5-C:PTS1 
crystal structures. 
Figure 9 and Figure 10 show that there appear to be specified regions in the PTS1-
binding site of PEX5 for interaction with the side chains present in the PTS1. The 
sequence used to represent a PTS1 in Figure 10, SKL-CO2H, was originally found in 




be one of the most common PTS1 sequences, and the general PTS1 consensus was 
thereafter defined as having the properties: [small]-[basic]-[hydrophobic]-CO2H 
(Lametschwandtner et al., 1998). 
A range of natural PTS1 sequences are now known, and numerous PEX5:PTS1 
crystal structures reveal differences in the PTS1 sequence. HsPEX5S was crystallised 
with the model PTS1 peptide YQSKL (Gatto et al., 2000). HsPEX5L has been 
crystallised with sterol carrier protein 2 (mSCP2) as the PTS1 protein, of which the 
PTS1 is AKL (Stanley et al., 2006). The unusual PTS1 of alanine-glyoxylate 
aminotransferase (AGT), crystallised with HsPEX5L, is KKL (Fodor et al., 2012). Other 
PTS1 variations are seen in X-ray crystal structures of TbPEX5 and MmPEX5-like 
protein. Some examples of these, and HsPEX5 PTS1 binding, are shown in Figure 
11. 
 
Figure 11|  The overall shape of the PTS1-binding site of PEX5, bound to a range 
of PTS1 sequences. A = HsPEX5 with YQSKL, B = TbPEX5 with FNELSHL, C = 
HsPEX5 with AGT (5 C-terminal aa = PKKKL), D = HsPEX5 with mutated AGT (5 C-
terminal aa = PKAAL), E = MmPEX5-like protein with SRLSSNL (Gatto et al., 2000 
(1FCH), Sampathkumar et al., 2008 (3CV0), Fodor et al., 2012 (3R9A), Fodor et al., 




Through observation of the structures of the PEX5 TPR domain in complex with the 
two PTS1-containing proteins, mSCP2 and AGT, it can be seen that the shape of the 
PTS1-binding site is adaptable. For example, the pocket seems to expand in order to 
accommodate the PTS1 sequence –KKL (Figure 11, C). Recent crystal structures 
show the binding of PEX5 to two mutated PTS1 sequences (KKL→AKL and 
KKL→AAL) at the C-terminus of a PTS1 protein AGT (Fodor et al., 2015). The PTS1 
mutation KKL→AAL (Figure 11, D) allowed AGT to bind with higher affinity to PEX5 
than the PTS1 mutation resulting in a canonical PTS1 sequence (KKL→AKL). This 
suggests that the overall size reduction of the PTS1 resulted in compensatory 
compaction of the PTS1-binding site. The dynamic nature of the PTS1 binding site 
could be the reason that PEX5 can bind to so many variants of PTS1. 
Point mutations that have been discovered or created in the TPR domain of PEX5 are 











N537S TPR3 PTS1:  
PTS2:  




N628K TPR6 PTS1:  
PTS2:  
Dodt et al., 1995 
PpPEX5 
N460K 
N628K TPR6 PTS1:  
PTS2:  
Dodt et al., 1995 
HsPEX5L 
N526K 
N628K TPR6 PTS1:  
PTS2:  
Carvalho et al., 
2007b; Ebberink 
et al., 2009 
HsPEX5L 
R557W 
R659W TPR7 PTS1:  
PTS2:  
Ebberink et al., 
2009 
Table 2|  Point mutations in the PEX5 TPR domain and their peroxisomal import 
effects. Mutations of the equivalent residues to N537 and N628 in Arabidopsis thaliana 
PEX5 resulted in defective PTS1-mediated import but functional PTS2-mediated import. 
Mutation of the equivalent residue to R659 in Arabidopsis thaliana PEX5 resulted in 
defective PTS1- and PTS2-mediated import. Alignments were performed using BioEdit 
(sequence alignment editor). Hs, Homo sapiens; Pp, Pichia pastoris. 
Binding experiments have also been performed with PEX5 variants, and the effects of 
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N504A TPR2  (Y2H binding seen) Klein et al., 2001 
ScPEX5 
E361K 
D505K TPR2  (Y2H binding seen) Klein et al., 2001 
ScPEX5 
E363A 
D507A TPR2  (Y2H binding seen) Klein et al., 2001 
ScPEX5 
I389D 
V533D TPR3  (no Y2H binding seen) Klein et al., 2001 
ScPEX5 
N393A 
N537A TPR3  (no Y2H binding seen) Klein et al., 2001 
ScPEX5 
N393D 
N537D TPR3  (no Y2H binding seen) Klein et al., 2001 
ScPEX5 
N393S 
N537S TPR3  (no Y2H binding seen) Klein et al., 2001 
ScPEX5 
N393Y 
N537Y TPR3  (no Y2H binding seen) Klein et al., 2001 
ScPEX5 
E394A 
E538A TPR3  (Y2H binding seen) Klein et al., 2001 
ScPEX5 
L404P 
L548P TPR3  (no Y2H binding seen) Klein et al., 2001 
ScPEX5 
L465P 
V598P TPR5  (no Y2H binding seen) Klein et al., 2001 
ScPEX5 
N503A 
N636A TPR6  (Y2H binding seen) Klein et al., 2001 
ScPEX5 
N503D 
N636D TPR6  (Y2H binding seen) Klein et al., 2001 
ScPEX5 
N503Y 
N636Y TPR6  (Y2H binding seen) Klein et al., 2001 
ScPEX5 
S504A 
S637A TPR6  (Y2H binding seen) Klein et al., 2001 
ScPEX5 
N505A 
V638A TPR6  (Y2H binding seen) Klein et al., 2001 
ScPEX5 
R526A 
R659A TPR7  (Y2H binding seen) Klein et al., 2001 
ScPEX5 
S534L 
S667L TPR7  (Y2H binding seen) Klein et al., 2001 
ScPEX5 
N537A 
N670A TPR7  (Y2H binding seen) Klein et al., 2001 
Table 3|  Point mutations in the PEX5 TPR domain and their PTS1-binding effects. 
The mutation which resulted in defective PTS1-mediated import in vivo (HsPEX5S 
N489K) still appears to bind a representative PTS1 peptide with a relatively high affinity. 
Key residues, that result in loss of PTS1 binding when mutated, are those equivalent to 
N537 and V533 in Arabidopsis thaliana PEX5. Alignments were performed using BioEdit 
(sequence alignment editor). Hs, Homo sapiens; Sc, Saccharomyces cerevisiae; TPR, 




In all of the studies reported in Table 3, [S]-[K]-[L]-CO2H was used as the 
representative native PTS1 sequence. This signal sequence is, however, extremely 
variable and many sequences can function as PTS1s. 
1.5 What makes a PTS1 sequence? 
As previously stated, the first PTS1 sequence discovered was -SKL at the C-terminus 
of wild-type firefly luciferase. This protein is found in cells of the lantern organ of the 
firefly, in which it is localised to peroxisomes (Keller et al., 1987). The -SKL sequence 
of luciferase was found to have the ability to target luciferase to insect peroxisomes as, 
when the three C-terminal residues were removed, luciferase was no longer imported 
into peroxisomes and was found in the cytosol (Gould et al., 1987; Gould et al., 1988; 
Gould et al., 1989). Mutations were then carried out in the three C-terminal residues of 
luciferase in order to define what constitutes a PTS1. At this point, the original 
consensus sequence was defined as [S/A/C]-[K/R/H]-[L]-CO2H (Gould et al., 1989). 
Peroxisomal protein import was found to be conserved across yeast, plants, insects 
and mammals when firefly luciferase was expressed in each of these cell types and 
was transported into peroxisomes in all cases (Gould et al., 1990). In one example, a 
short C-terminal sequence from peroxisomal protein glycolate oxidase (-[R]-[A]-[V]-[A]-
[R]-[L]-CO2H) was found to target β-glucuronidase, a non-peroxisomal protein, to plant 
peroxisomes (Volokita, 1991). 
The PEX5:PTS1 interaction is used as a means by which peroxisomes can be 
visualised (Monosov et al., 1996). In order to do this, a PTS1 sequence is attached to 
the C-terminus of a fluorescent protein. In Figure 12, CFP-PTS1 has been imported 
into peroxisomes, which highlights the peroxisomes in the moss (Physcomitrella 





Figure 12|  Peroxisomes in the moss Physcomitrella patens, visualised using CFP-
PTS1. Image courtesy of Yasuko Kamisugi. 
Binding of naturally-occurring PTS1 sequences by PEX5 has been measured 
quantitatively using fluorescence anisotropy. This assay involves the titration of an 
increasing concentration of protein against a fixed concentration of fluorescently 
labelled peptide (representing a PTS1 sequence). Anisotropy can then be used to 
calculate the dissociation constant (Kd) for each interaction tested. The affinity of PEX5 
for strong PTS1 sequences is typically very high, with ~nM dissociation constants 
(Gatto et al., 2003; Harper et al., 2003; Skoulding et al., 2015). 
A number of mutational studies have been performed to look at the binding of a wide 
range of PTS1 sequences to wild-type PEX5 (Klein et al., 2001; Gatto et al., 2003; 
Maynard et al., 2004; Maynard and Berg, 2007; Ghosh and Berg, 2010). One research 
group created Saccharomyces cerevisiae PEX5 mutants and investigated their binding 
to a PTS1 sequence, SKL (Klein et al., 2001). Several PEX5 mutations resulted in loss 
of wild-type PTS1 interaction (Table 3). A suppressor screen was also carried out by 
Klein and colleagues to find mutations that could allow the binding of PEX5 to another 
C-terminal sequence, SEL, which is a non-PTS1 when attached to the C-terminus of 
GFP (Distel et al., 1992). [S]-[E]-[L]-CO2H has also been used as a negative control for 
PEX5 binding (Dodt et al., 1995; Gatto et al., 2000) and peroxisomal import (Gould et 
al., 1989). Mutations that allowed the interaction of PEX5 with SEL were E361K, 
N503D, N503Y and S534L (shown in Table 3, along with equivalent AtPEX5 
residues). Figure 10 shows that these equivalent AtPEX5 residues are all predicted to 




In plants, chimeric genes have been constructed by Hayashi and colleagues, which 
include the addition of PTS1 variant sequences onto the C-terminus of the non-
peroxisomal protein β-glucuronidase. Immunoelectron-microscopy was then used to 
look at the cellular location of these gene products (Hayashi et al., 1997). Yeast-two-
hybrid screens have also been performed with large libraries of peptides representing 
variant PTS1 sequences (Lametschwandtner et al., 1998). The results of these studies 
were collectively used to define a PTS1 consensus sequence. 
1.5.1 Variation to the PTS1 by mutation, and the effect on 
peroxisomal import and on PEX5 binding 
Many mutations to the PTS1 sequence have been performed and, as this study will 
focus on altering the two C-terminal PTS1 residues, mutants of interest and their 




{protein}-C-terminus Localised to 
peroxisomes? 
Reference 
{β-glucuronidase}-SKL  (efficiently) Hayashi et al., 1997 
{β-glucuronidase}-SRL  (efficiently) Hayashi et al., 1997 
{β-glucuronidase}-SIL  Hayashi et al., 1997 
{β-glucuronidase}-SGL  Hayashi et al., 1997 
{β-glucuronidase}-SSL  Hayashi et al., 1997 
{β-glucuronidase}-SHL  Hayashi et al., 1997 
{β-glucuronidase}-SRI  (detectably) Hayashi et al., 1997 
{β-glucuronidase}-SRV  Hayashi et al., 1997 
{β-glucuronidase}-SRM  (efficiently) Hayashi et al., 1997 
{β-glucuronidase}-SRS  Hayashi et al., 1997 
{β-glucuronidase}-SRE  Hayashi et al., 1997 
{β-glucuronidase}-SRK  Hayashi et al., 1997 
{eYFP}-VHIQVRHSSM  (weakly) Lingner et al., 2011 
{eYFP}-TENERIKSML  Lingner et al., 2011 
{eYFP}-TEGDRIRSLL  Lingner et al., 2011 
{eYFP}-VQVRVGHSNM  Lingner et al., 2011 
{eYFP}-SQINQAKSQL  Lingner et al., 2011 
{eYFP}-DTSPRTKSTL  Lingner et al., 2011 
{eYFP}-NNTPLIASRV  (weakly) Lingner et al., 2011 
{eYFP}-VAKTTRPSRV  Lingner et al., 2011 
{eYFP}-LHKEDLKSHI  Lingner et al., 2011 
{eYFP}-LSRDVIPSEL   (weakly) Lingner et al., 2011 
{eYFP}-LATPDLRSFM  Lingner et al., 2011 
{eYFP}-ASIPLLISRF  Lingner et al., 2011 
{eYFP}-DKFSAIPSGL  (weakly) Lingner et al., 2011 
{eYFP}-SLFNKLRSKV  Lingner et al., 2011 
{eYFP}-SDIFPKPSEM Lingner et al., 2011 
{eYFP}-ISVPFLISPL  (weakly) Lingner et al., 2011 
{eYFP}-DFQPLPPSPL Lingner et al., 2011 
{eYFP}-NNIPMSPSGI Lingner et al., 2011 
{eYFP}-SSIKAMLSTI  (weakly) Lingner et al., 2011 
{eYFP}-VAKTTRPSRM  (efficiently) Skoulding et al., 2015 
{eYFP}-VAKTTRPSRI  (efficiently) Skoulding et al., 2015 
{eYFP}-VAKTTRPSRV  (weakly) Skoulding et al., 2015 
{eYFP}-VAKTTRPSRY  (detectably) Skoulding et al., 2015 
{eYFP}-VAKTTRPSRK  Skoulding et al., 2015 
{eYFP}-VAKTTRPSNV  (weakly) Skoulding et al., 2015 
{eYFP}-VAKTTRPSTV  Skoulding et al., 2015 
Table 4|  Point mutations in PTS1 and the resulting effect on peroxisomal import in 
plants. Many more PTS1 sequences than those displaying the properties [small]-[basic]-




Binding experiments have also been performed with plant PTS1 variants, and the 
binding affinities measured. These PTS1 variants are summarised in Table 5. 
C-terminal sequence Ki < 5,000 nM? Reference 
VAKTTRPSKL  Skoulding et al., 2015 
VAKTTRPSRL  Skoulding et al., 2015 
VAKTTRPSRM  Skoulding et al., 2015 
VAKTTRPSRI  Skoulding et al., 2015 
VAKTTRPSRV  Skoulding et al., 2015 
VAKTTRPSRY  Skoulding et al., 2015 
VAKTTRPSNV  Skoulding et al., 2015 
YQSKL  Skoulding et al., 2015 
YQSKV  Skoulding et al., 2015 
VAKTTRPSNM Skoulding, 2011 
YQSEL Skoulding, 2011 
Table 5|  Point mutations in PTS1 and the resulting effect on plant PEX5 binding. 
Only ‘strong’ PTS1 sequences (as determined in vivo) had a Ki below 5 μM, as 
determined by fluorescence anisotropy competition assays, where the fluorescent 
peptide being out-competed was lissamine-YQSKL. 
1.5.2 Extension of the PTS1 consensus through in silico 
predictions 
As previously stated, the PTS1 sequence had been thought of as having a clear 
consensus of [small]-[basic]-[hydrophobic]-CO2H. With the increased availability of 
genomic and proteomic data, it has been possible for researchers to identify which 
proteins are naturally present in the peroxisome and, therefore, to predict and test the 
elements needed for a functional PTS1 sequence (Neuberger et al., 2003a; Neuberger 
et al., 2003b; Lingner et al., 2011; Reumann et al., 2012). For A. thaliana PTS1 
sequences, the website AraPerox provides a comprehensive list of major, minor, and 
rare PTS1 sequences (Reumann et al., 2004). A server called PredPlantPTS1 
(Lingner et al., 2011; Reumann et al., 2012) uses a positional weight matrix (PWM) 
scoring system to be able to predict whether a protein will be imported into the 
peroxisome via the PTS1 import pathway or not, when given the C-terminal 14 amino 
acids of the primary sequence of the protein. Peroxisomal targeting prediction scores, 
as determined by PredPlantPTS1, have recently been compared to in vitro binding 




onion epidermal cells (Skoulding et al., 2015). This work showed that there was 
agreement between these methods, although in some cases the in vivo import 
experiments were more sensitive than in vitro assays (Skoulding et al., 2015). 
A recent paper summarising all possible PTS1 sequences stated that ‘canonical’ 
residues that can be found in each position are: [S/A]-[R/K]-[L/M/I]-CO2H, and ‘non-
canonical’ residues that can be found in each position are: [P/C/F/V/G/T/L/K/I/Q]-
[S/N/L/M/H/G/E/T/F/P/Q/C/Y/D/A]-[V/Y/F]-CO2H (Reumann et al., 2016). Reumann 
and colleagues state that, for a peptide to function as a plant PTS1, at least two 
canonical residues must be present. This means that, even when only considering the 
three C-terminal residues, there are over 80 possible native PTS1 sequences. 
1.6 Peroxisomes and synthetic biology 
Peroxisomes are attractive organelles for synthetic biology, as they maintain a barrier 
to the cytosol while allowing the import of folded, large and sometimes oligomeric 
proteins. Import of the majority of these proteins is determined only through a short 
signal sequence (reviewed in Baker et al., 2016). Peroxisomal protein import, 
therefore, appears to be an exploitable system for the creation of a synthetic organelle 
within the cell. 
Peroxisomal protein import has previously been manipulated for optical control of 
peroxisomal protein trafficking (Spiltoir et al., 2016). This was performed using a 
construct with a ‘caged’ PTS1, which becomes uncaged from the rest of the protein 
when blue light is used so the PTS1 is then free to bind to PEX5 and transport the full 
protein into the peroxisome. Very recently, the fungal peroxisome was used as a 
model in which non-peroxisomal proteins were imported into the peroxisome and then 
carried out a non-peroxisomal pathway inside peroxisomes (DeLoache et al., 2016). 
This was achieved through out-competition of a natural PTS1 sequence using 
enhancing residues on a PTS1 sequence to create an ‘enhanced PTS1’ (DeLoache et 
al., 2016). Peroxisomes have also been suggested as suitable organelles for 
engineering in a recent review (Kessel-Vigelius et al., 2013), which highlights their 
potential to: accommodate novel pathways and compartmentalise these within the cell, 
allow fully folded proteins to be transported across the peroxisome membrane, and 




1.7 Directed evolution and orthogonality 
Directed evolution has been used by other research groups to achieve orthogonality, 
for example in the case of a v-Src tyrosine kinase which was re-designed by mutation 
to bind to a radioactive analogue of ATP rather than the natural ATP substrate (Liu et 
al., 1998). Downstream targets of the kinase could then be identified by their labelling 
with the radioactive ATP analogue. Another example of achieving orthogonality 
through directed evolution is in the re-design of a conserved protein-protein interaction 
to produce an interaction that would not have any cross-interference with native cell 
pathways (Speltz et al., 2015; Pratt et al., 2016). This interaction was successfully 
used as a method of specific in-cell imaging, when one of the binding partners was 
genetically fused to a fluorescent protein and the other binding partner was genetically 
fused to the protein of interest for visualisation (Pratt et al., 2016). 
A classic example of an orthogonal system is the orthogonal ribosome. Orthogonal 
ribosomes were created to allow the incorporation of unnatural amino acids (UAAs) 
into protein sequences during protein synthesis. This process can then introduce 
desired properties to a protein. The creation of orthogonal ribosomes has been carried 
out using saturation mutagenesis of selected residues in a specific region of the 
ribosomal A-site. This region is important for tRNA (transfer RNA) binding so, with the 
introduction of tRNA molecules aminoacylated with UAAs, orthogonal ribosomes can 
be screened to recognise these. UAAs are then incorporated into the protein sequence 
(Wang et al., 2007; Bain et al., 1989). Orthogonal tRNA-synthetases have also been 
produced (Xie and Schultz, 2006). The method used was random mutagenesis which 
can often result in vast library numbers: the library of tRNA-synthetases produced was 
reported at ~109 mutants. 
In order to hijack the peroxisome with a new non-PTS1 sequence which is imported 
preferentially by a mutant of the PEX5 protein, an orthogonal interaction will have to be 
created. The importance of an orthogonal interaction is that it can function alongside, 
yet independently of, the natural pathway. We aim to use directed evolution to create 




1.8 Objectives of this study 
The aim of this study is to evolve a novel PEX5:PTS1-style interaction, which will be 
termed PEX5*:PTS1*. PEX5*:PTS1* will be distinct from interactions seen for the 
natural import of PTS1-cargo proteins. This interaction will allow for the direction of 
non-peroxisomal proteins to the matrix of the peroxisome. As the function of 
peroxisomes is determined by their protein content (Reumann and Bartel, 2016), the 
overall aim will be to re-purpose the peroxisome. Binding of a range of non-PTS1 
sequences (PTS1* candidates) will be tested with a polyhistidine-tagged truncated 
construct of Arabidopsis thaliana PEX5 (AtPEX5) comprising only the C-terminal, 
PTS1-binding domain of PEX5. By creating a mutant library of truncated PEX5, or 
His6-AtPEX5(340-728), the objective is to find a variant of His6-AtPEX5(340-728) that 
binds a non-PTS1 yet shows minimal, or ideally no, binding activity with natural PTS1 
sequences. The binding will be optimised by subjecting the successful PTS1* binder to 
further mutations. The optimised PEX5*:PTS1* pair will then be provided to Dr Rupesh 
Paudyal for in vivo testing. 
Specific goals of the study are to: 
 Develop a screen that will allow the testing of His6-AtPEX5(340-728) variants 
with PTS1 and non-PTS1 sequences 
 Use the above steps to create and optimise an orthogonal PEX5*:PTS1* 
interaction and test binding using fluorescence anisotropy 
 Provide the optimised PEX5*:PTS1* pair to R. Paudyal for in vivo testing in a 
model plant organism (the moss Physcomitrella patens). 
Success in this project could lead to the targeting of user-defined proteins to the 
peroxisome. If orthogonal binding of PEX5 and PTS1 can be determined in vitro, the 
next objective will be to move this system in vivo (for experiments to be carried out by 
R. Paudyal) and incorporate a switch between natural PTS1-mediated import and the 
designed orthogonal pathway. 
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Chapter 2  
Attempted Rational Design of the PEX5*:PTS1* Orthogonal 
Interaction and Initial Screen Development 
 
2.1 Introduction 
As described in Chapter 1 (Figure 3), the peroxisomal targeting signal-1 (PTS1) 
mediated import pathway allows the peroxisomal import of proteins possessing a C-
terminal PTS1 sequence. This process requires the binding of the PTS1 by the 
receptor peroxin-5 (PEX5). The binding site for the PTS1 is located in the C-terminal 
domain of PEX5, and PEX5 is a modular protein, so a construct comprising only this 
part of the protein has been used for binding studies (termed PEX5-C). Previous work 
at the University of Leeds had shown that A. thaliana PEX5-C had a similar PTS1-
affinity to the full-length A. thaliana PEX5 protein (Skoulding, 2011; Skoulding et al., 
2015). Additionally, the full-length PEX5 protein was much less stable than the C-
terminal domain alone (Skoulding, 2011), so the A. thaliana PEX5-C construct 
(AtPEX5-C) was used for all work presented in this chapter. This construct had 
previously been cloned into vector pET-28b by Sarah Gunn (former student of the 
University of Leeds) to include an N-terminal His6 tag for purification (Gunn, 2008). 
The aim of this study is to create an orthogonal AtPEX5-C:PTS1 interaction, which will 
be termed AtPEX5-C*:PTS1*. Rational design of the AtPEX5-C binding site was 
attempted, which required a structural model in order to predict mutations that would 
change the binding specificity of the protein. No crystal structure of A. thaliana PEX5 
has yet been obtained; however, there are a number of crystal structures showing 
PEX5-C, in complex with PTS1 sequences, from H. sapiens and T. brucei (Gatto et al., 
2000; Stanley et al., 2006; Stanley et al., 2007; Sampathkumar et al., 2008; Fodor et 
al., 2012). The first HsPEX5-C:PTS1 structure (Gatto et al., 2000) was used to perform 
homology modelling of the AtPEX5-C protein (Skoulding, 2011), which showed that 
the two proteins (HsPEX5-C and AtPEX5-C) are predicted to have almost identical 
structure in the tetratricopeptide repeat (TPR) helices of the PTS1-binding site. The 




colleagues is 38% (sequence similarity = 53%) with 96% coverage (performed using 
BLAST (blastp)). Sequence identity of HsPEX5-C TPRs 1-3 and 5-7, as stated by 
UniProtKB (TPRs 1-3 = 335-436 and TPRs 5-7 = 488-589), with all equivalent 
sequence in AtPEX5-C (TPRs 1-3 ≈ 457-558 and TPRs 5-7 ≈ 590-691) is 47% 
(sequence similarity = 65%) with 100% coverage (Altschul et al., 1990 (BLAST); 
Apweiler et al., 2004 (UniProtKB)) (alignments were performed using BioEdit 
(sequence alignment editor). An alignment of all AtPEX5-C residues predicted by I-
TASSER as being involved in PTS1 binding (18 residues), with equivalent residues in 
the HsPEX5-C construct used by Gatto and colleagues was performed. This alignment 
was performed using BLAST (blastp), after equivalent residues had been determined 
using BioEdit (sequence alignment editor), and revealed a sequence identity of 83% 
and a sequence similarity of 88% (Altschul et al., 1990). 
This chapter will describe the expression and purification of AtPEX5-C and a binding 
study carried out with this protein and a representative PTS1 sequence. Also 
explained will be the selection of potential PTS1* sequences and the subsequent 
selection of target amino acids in the AtPEX5-C protein for mutagenesis. In vitro 
testing of combinations of AtPEX5-C variants and their designed binding peptides will 
then be covered, along with the development of screening methodologies to allow 
investigation into the binding of multiple AtPEX5-C variants to peptides in one assay. 
2.2 Expression and purification of AtPEX5-C 
Expression of the AtPEX5-C protein from the AtPEX5-C gene in pET-28b plasmid was 
performed by autoinduction (section 6.10.2). Purification of AtPEX5-C was then 
achieved by affinity chromatography using cobalt-agarose resin (section 6.10.4). The 
stages of purification of AtPEX5-C were analysed by SDS-PAGE (section 6.11) and 





Figure 13|  Purification SDS-PAGE gel for AtPEX5-C. A band at approximately 50 kDa 
was seen on SDS-PAGE with Quick Blue coomassie stain (10), which was confirmed as 
AtPEX5-C using western blotting (WB) of a duplicate gel with α-PEX5 antibody. Filled 
arrowhead highlights the presence of AtPEX5-C. M, protein standard markers; 1, non-
induced BL21-Gold (DE3) cells containing His6-AtPEX5-C.pET-28b; 2, autoinduced 
BL21-Gold (DE3) cells containing His6-AtPEX5-C.pET-28b; 3, pellet after cell lysis; 4, 
supernatant after cell lysis; 5, supernatant after incubation with cobalt-agarose resin; 6-9, 
buffer washes 1-4 of cobalt-agarose resin; 10, elution of protein using 200 mM imidazole; 
WB, elution lane in western blot of duplicate gel. 
Analysis of purification fractions by SDS-PAGE and western blotting (Figure 13) 
confirmed that the AtPEX5-C protein was being isolated. Gel filtration was then 
performed to assess the purity of the protein, and electrospray ionisation mass 
spectrometry was used to confirm the mass of the purified protein (Figure 14). The 
calculated mass of AtPEX5-C with a hexahistidine tag was 45,580.3 Da, and the 





Figure 14|  A) Gel filtration trace for AtPEX5-C. B) Mass spectrum and 
deconvoluted mass data (inset) for AtPEX5-C. Predicted elution volume based on 
protein monomer mass: 145.4 mL. Actual elution volume (large peak): 146.2 mL. 
Expected mass: 45,580.3 Da. Observed mass: 45,580.3 Da. 
The SDS-PAGE gel, western blot, and mass spectrum together confirmed that the 
AtPEX5-C protein had been successfully isolated. Two peaks could be observed in the 
gel filtration trace, the larger of which corresponded to the approximate size of 
monomeric AtPEX5-C (predicted elution volume: 145.4 mL, and actual elution volume: 
146.2 mL). The smaller peak in the gel filtration trace corresponded to the approximate 
size of the dimeric species of AtPEX5-C (predicted elution volume: 114.0 mL, and 
actual elution volume: 112.3 mL). This could be due to the presence of five WxxxF/Y 
(typically PEX14-binding) repeats (where x is any amino acid) in the protein construct 
which could promote self-association: PTS1 import has been observed in plants in the 
absence of PEX14, so it is possible that PEX5 could be self-associating in this case to 
form a pore through which PTS1 proteins can be imported into peroxisomes (Monroe-
Augustus et al., 2011). AtPEX5-C could also be forming disulfide bonds between 





With purity and a correct mass confirmed, the AtPEX5-C protein was carried forward 
for in vitro binding studies using synthetic peptides corresponding to PTS1 and non-
PTS1 sequences. 
2.3 Synthesis of a ‘native’ PTS1 peptide and a subsequent 
binding study with AtPEX5-C 
The first PTS1 sequence was identified as –Ser-Lys-Leu-CO2H, or –SKL>1, and this 
was found at the C-terminus of firefly luciferase (Gould et al., 1987; Gould et al., 
1988). This short signal sequence was discovered to be responsible for the import of 
the luciferase protein into peroxisomes, where luciferase is found in the lantern organ 
of the firefly (Keller et al., 1987). The fusing of the –SKL> sequence at the C-terminus 
of a non-peroxisomal protein, chloramphenicol acetyltransferase (CAT), was able to 
redirect this protein to the peroxisome (Mullen et al., 1997). As peroxisomal import 
research developed, –SKL> was found to be one of the most common PTS1 
sequences found on proteins destined for the peroxisome. 
To date, several studies on the PEX5:PTS1 interaction have been performed. The first 
crystal structure of PEX5 in complex with a PTS1 sequence was solved by Gatto and 
colleagues (Gatto et al., 2000 (1FCH)). This structure featured the C-terminal domain 
of H. sapiens PEX5 (HsPEX5-C) in complex with the pentapeptide H2N-Tyr-Gln-Ser-
Lys-Leu-CO2H, or YQSKL. Three crystal structures of PEX5-C in complex with a PTS1 
sequence terminating in –SKL> have now been published (Gatto et al., 2000 (1FCH); 
Sampathkumar et al., 2008 (3CVP and 3CVQ)). Isothermal titration calorimetry (ITC) 
has also been used to study the PEX5-C: –SKL> interaction using peptides with 
varying sequences upstream of the C-terminal –SKL> and the dissociation constants 
calculated were between 14 nM and 145 nM (Mesa-Torres et al., 2015). As YQSKL is 
the peptide sequence best characterised in complex with PEX5-C, YQSKL has been 
used to represent a native PTS1 sequence in this work. 
In order to study the PEX5:PTS1 interaction in vitro, the peptide sequence YQSKL 
was synthesised on solid support using Fmoc solid phase peptide synthesis (SPPS) 
                                               
1 The ‘>’ symbol represents the C-terminus of a protein where only a portion of the polypeptide 




(Merrifield, 1963) (Scheme 1). Characterisation of this peptide is shown in Figure 15 
and confirms that a peptide of the correct mass had been synthesised and that this 
peptide was pure. 
 
Scheme 1|  Outline of synthesising peptides by Fmoc SPPS, using a tripeptide as 
an example. In this technique, peptides are synthesised from C-terminus to N-terminus. 
After synthesis peptides are cleaved from the solid support (resin), yielding the free 
carboxylic acid group. Shown in red are acid-labile groups (the activated 2-chlorotrityl 
chloride on resin), and shown in blue are base-labile groups (the Fmoc protecting group). 





Figure 15|  A) Structure of the PTS1 pentapeptide YQSKL. B) Isotopic distribution 
in mass spectrum of YQSKL. C) Analytical HPLC trace of YQSKL. Expected [M+H]+: 
638.3508 g/mol. Observed [M+H]+: 638.3513 g/mol. The analytical HPLC trace confirms 
peptide purity. 
An N-terminal fluorescent label (lissamine-rhodamine) was added to the peptide in 
order to use the resulting fluorescent peptide in a binding assay. From this point 
onwards, lissamine-rhodamine will be referred to as lissamine. Lissamine was added 
before cleavage of the peptide from the solid support resin (Scheme 1). 
Characterisation of lissamine-YQSKL is shown in Figure 16 and confirms that a pure 





Figure 16|  A) Structure of the fluorescent PTS1 pentapeptide lissamine-YQSKL. B) 
Isotopic distribution in mass spectrum of lissamine-YQSKL. C) Analytical HPLC 
trace of lissamine-YQSKL. Expected [M+2H]2+: 589.7485 g/mol. Observed [M+2H]2+: 
589.7491 g/mol. The analytical HPLC trace confirms peptide purity. 
With AtPEX5-C purified and YQSKL synthesised and labelled, fluorescence anisotropy 
could be used to assess binding. Fluorescence anisotropy is a technique which can be 
used to calculate the dissociation constant of an interaction when one binding partner 
is significantly smaller than the other and fluorescently labelled. A small fluorescently 
labelled ligand will tumble quickly in solution, relative to the fluorescence lifetime, due 
to its small size. When the fluorophore attached to the ligand is excited by light in a 
particular orientation of polarisation, the light emitted by the fluorophore will be in 
various orientations of polarisation. When an increasing concentration of ligand-
binding protein is titrated into the ligand solution, more of the ligand will become 
increasingly bound to the protein. This slows down the tumbling rate of the fluorescent 
ligand until the maximum amount of ligand is bound to the protein. At this point the 




polarisation orientation of light emitted by the fluorophore when compared to the 
polarisation orientation of light used to excite the fluorophore (Figure 17). 
 
Figure 17|  The principle behind fluorescence anisotropy as a technique for the 
detection of protein-peptide interactions. The fluorophore attached to a binding 
peptide is excited with linear polarised light. If light emitted is in various orientations of 
polarisation, this suggests that the fluorophore is bound to a small ligand. If, however, 
polarised light emitted remains linear, the fluorophore is part of a large complex which 
indicates protein binding of the ligand. Figure adapted from (Skoulding, 2011). 
For the fluorescence anisotropy carried out in this work, the final ligand concentration 
used was constant at 100 nM and protein concentration was increased from 0 µM to 
13.3 µM final concentration (Figure 18). The equation which was used to calculate 
anisotropy is shown in Chapter 6 (Experimental) section 6.14.7. The Kd of the 





Figure 18|  AtPEX5-C (0–13.3 μM final concentration) versus amount of lissamine-
YQSKL bound in the presence of 100 nM peptide, measured using fluorescence 
anisotropy. ‘Low anisotropy’ and ‘high anisotropy’ examples are shown on the graph to 
demonstrate where protein binding is seen. A quadratic equation was used to fit the 
curves using OriginPro 9.1, assuming a one-to-one model of binding. 
Fluorescence anisotropy has been used by other researchers to measure the affinity 
of the PEX5-C:PTS1 interaction (Gatto et al., 2000; Harper et al., 2003; Maynard et al., 
2004; Gunn, 2008; Ghosh and Berg, 2010; Lanyon-Hogg et al., 2014; Skoulding et al., 
2015). The low nanomolar Kd obtained in this study is consistent with previously 
published PEX5:PTS1 dissociation constants (Ghosh and Berg, 2010; Gunn, 2008). 
The tightest affinity seen for human PEX5 binding to lissamine-YQSKL is a Kd of 
2.7 nM (Ghosh and Berg, 2010), and for Arabidopsis PEX5 with lissamine-YQSKL, the 
tightest affinity found was a Kd of 3.10 nM (Gunn, 2008). 
2.4 Potential PTS1* peptide sequences 
In order to evolve an orthogonal PEX5*:PTS1* interaction, both binding partners of the 
PEX5:PTS1 interaction must be altered. As this was a large multidimensional problem, 
it was decided to start by designing potential PTS1* sequences which would not 
function as PTS1 sequences and use these for the evolution of the PEX5* protein. 
Taking the most common native PTS1 sequence –SKL> as an example, an obvious 
substitution to make in the peptide sequence in an attempt to disrupt binding would be 
the exchange of the positively charged lysine for a negatively charged residue, for 




sequence of firefly luciferase by the Subramani laboratory in 1989 in order to 
investigate PTS1 binding requirements (Gould et al., 1989). Another substitution made 
at the time was the exchange of the C-terminal leucine to valine. Both of these 
substitutions resulted in firefly luciferase residing in the cytosol (Gould et al., 1989). 
More recent work has expanded on the reasons behind this lack of peroxisomal 
targeting when these substitutions are made. For example the crystal structure solved 
of HsPEX5-C:YQSKL in 2000 (Gatto et al., 2000) revealed a pocket of acidic side 
chains surrounding the lysine residue in the PTS1, and a hydrophobic region of side 
chains surrounding the side chain carbons in the C-terminal leucine of the PTS1 
(Gatto et al., 2000). 
Quantitative binding studies have been performed for the peptide sequences YQSEL 
and YQSKV with AtPEX5-C (Skoulding, 2011; Skoulding et al., 2015). The inhibition 
constant (Ki) of YQSKV with AtPEX5-C, when out-competing lissamine-YQSKL in a 
fluorescence anisotropy competition assay, was determined as 32,400 ± 4800 nM, and 
the Ki of YQSEL was >100,000 nM (Skoulding, 2011; Skoulding et al., 2015). These Ki 
values are in comparison to the calculated Ki of YQSKL being 166 ± 23 nM, 
demonstrating that YQSKV has approximately 195-fold weaker binding to AtPEX5-C 
than YQSKL, and YQSEL has over 600-fold weaker binding to AtPEX5-C than 
YQSKL. The peptides YQSEL and YQSKV, therefore, were chosen as potential PTS1* 
sequences in this work. 
Along with published in vivo and in vitro data on the PEX5:PTS1 interaction (reviewed 
in Smith and Aitchison, 2013, and Lanyon-Hogg et al., 2010), in silico work has also 
been carried out in order to determine what defines a PTS1 sequence (Reumann, 
2011; Lingner et al., 2011; Reumann et al., 2012; Chowdhary et al., 2012). The 
prediction server PredPlantPTS1 was developed (Lingner et al., 2011; Reumann et al., 
2012) to allow the prediction of whether a sequence of amino acids will be imported 
into the peroxisome if it were located at the C-terminus of a protein. The two chosen 
potential PTS1* sequences were predicted to be non-peroxisomal using the 
PredPlantPTS1 prediction. 
In this chapter, fluorescence anisotropy was used to assess the Kd of fluorescently 
labelled peptides directly, rather than using unlabelled peptide to compete bound 
peptide from the binding site of AtPEX5-C. A peptide that combined the two previous 
changes to the PTS1 sequence, resulting in lissamine-YQSEV, was also used as this 




reasoned that this peptide would have an even lower affinity to AtPEX5-C than either 
lissamine-YQSEL or lissamine-YQSKV. 
YQSEL, YQSKV and YQSEV were synthesised on solid support using Fmoc solid 
phase peptide synthesis as was performed for YQSKL (section 2.3), and lissamine 
was then coupled to the N-terminus of each of these peptides. Fluorescence 
anisotropy was carried out using each of these peptides with AtPEX5-C in order to 
determine dissociation constants (Figure 19). 
 
Figure 19|  Wild-type AtPEX5-C (0–13.3 μM final concentration) versus amount of 
lissamine-YQSKL, -YQSEL, -YQSKV, or -YQSEV bound in the presence of 100 nM 
(final concentration) peptide, measured using fluorescence anisotropy. Order of 
peptide binding affinity with AtPEX5-C, from high to low: lissamine-YQSKL > lissamine-
YQSKV > lissamine-YQSEL > lissamine-YQSEV. A quadratic equation was used to fit 
the curves using OriginPro 9.1, assuming a one-to-one model of binding. 
When compared to the representative PTS1 sequence YQSKL, the three potential 
PTS1* sequences tested behaved as expected. The dissociation constants for these 










Lissamine-YQSKL 1.1 0.6 
Lissamine-YQSEL 29,000 1400 
Lissamine-YQSKV 1300 100 
Lissamine-YQSEV >100,000 - 
Table 6|  Dissociation constants and standard errors for binding of a 
representative PTS1 sequence and three potential PTS1* sequences to AtPEX5-C. 
Dissociation constants were determined using fluorescence anisotropy and show that 
lissamine-YQSKV displays >1000-fold lower binding affinity than lissamine-YQSKL, 
lissamine-YQSEL displays >25,000-fold lower binding affinity than lissamine-YQSKL, 
and lissamine-YQSEV displays >90,000-fold lower binding affinity than lissamine-
YQSKL. 
The three peptides selected as potential PTS1* sequences were all determined to 
have much lower binding affinities to AtPEX5-C than the ‘native’ PTS1 sequence 
YQSKL. The potential PTS1* sequence with the highest affinity for the AtPEX5-C was 
subject to in vivo testing in moss (Physcomitrella patens) by Dr Rupesh Paudyal, the 
postdoctoral researcher working on the in vivo aspects of this project (Figure 20). 
 
Figure 20|  In vivo import experiment in Physcomitrella patens, with images 
captured 24 h after particle bombardment of vectors containing genes coding for 
RFP-YQSRL or GFP-YQSKV. Peroxisomes are shown as the bright regions on the 
RFP-YQSRL image, and these regions are not highlighted by GFP-YQSKV so it can be 
concluded that YQSKV as a C-terminal sequence does not induce peroxisomal targeting 
of GFP. Images courtesy of Rupesh Paudyal. 
It can be concluded, as a result of Figure 20, that all three potential PTS1* sequences 
are appropriate sequences to use as potential PTS1*. This means that the evolution of 




2.5 Variants of AtPEX5-C designed for altered peptide-binding 
specificity 
Variants of the AtPEX5-C protein were produced with the aim of enhancing binding of 
AtPEX5-C to the potential PTS1* peptides determined in section 2.4. A homology 
model of AtPEX5-C had previously been produced at the University of Leeds 
(Skoulding, 2011) which revealed the similarity between the HsPEX5-C and AtPEX5-C 
structures. In this work, the web server I-TASSER was used to obtain a predicted 
AtPEX5-C protein structure model in order to model the effects of particular mutations 
(Zhang, 2008; Roy et al., 2010; Yang et al., 2015; Yang and Zhang, 2015). The 
I-TASSER model of AtPEX5-C was aligned with the HsPEX5-C:YQSKL crystal 
structure determined by the Berg laboratory (Gatto et al., 2000) to determine the 
approximate position of the PTS1 peptide in the AtPEX5-C binding site (Figure 21). 
 
Figure 21|  Predicted model of AtPEX5-C aligned with HsPEX5-C:YQSKL crystal 
structure. The predicted structural model of AtPEX5-C (I-TASSER) is shown in cyan, 
the HsPEX5-C crystal structure is shown in pale yellow and the YQSKL crystal structure 
is shown in orange (Gatto et al., 2000 (1FCH); Zhang, 2008; Roy et al., 2010; Yang et 
al., 2015; Yang and Zhang, 2015 (I-TASSER)). Structural overlay was performed in 
PyMOL by the overlay of α-carbons in the polypeptide chain. Residues 505, 507, 536 
and 601 were chosen for mutation due to their proximity to the PTS1 sequence in this 
structural prediction, and these residues of interest are shown in ‘stick’ form. 
Four residues were initially selected as being potentially important for binding to PTS1 
due to their proximity to the PTS1 sequence: D505, D507, T536 and N601 (Figure 





Figure 22|  Alignment of relevant portions of PEX5 from a range of organisms to 
assess conservation of the highlighted residues. Organism names are coloured by 
kingdom: green text, plantae; blue text, excavata; pink text, animalia; orange text, fungi. 
Highlighted in yellow are matching residues, highlighted in green are residues with 
identical charge, and highlighted in cyan are residues with differing electronic or steric 
properties. Alignment was performed using BioEdit (sequence alignment editor). 
Residues D505, D507, T536 and N601 were targeted by site-directed mutagenesis 
(Figure 23) in order to carry out a substitution mutation at each position. The variant 
E361K in S. cerevisiae was identified as binding to a non-PTS1 sequence –SEL> in a 
yeast-two-hybrid screen by the Distel laboratory (Klein et al., 2001).  For this reason, it 
was decided to make the equivalent variant in Arabidopsis (D505K), along with 
another charge substitution mutation, D505H, in the hope that these AtPEX5-C 
variants would bind to lissamine-YQSEL. D505R was not produced as it was decided 
that the arginine side chain would extend too far into the AtPEX5-C binding pocket to 
allow for a PTS1 or PTS1* sequence to fit into the binding site. The double variant 
D505K-D507K was also produced, as residue 507 forms part of the acidic pocket 
surrounding the lysine residue of the PTS1, as seen by Gatto and colleagues (Gatto et 
al., 2000). The side chains of T536 and N601 lie in close proximity to the side chain of 
the C-terminal PTS1 amino acid, so it was decided to extend each of these side chains 




possibly encourage preferential acceptance of valine over leucine as the C-terminal 
PTS1 residue as a result of steric bulk. This could be achieved by making the variants 
T536N and N601Q. 
Site-directed mutagenesis was used to produce selected variants of AtPEX5-C. In 
order to create mutations in the AtPEX5-C gene, overlapping primers were used in 
which the appropriate codon in the genetic sequence was substituted for a codon 
which would code for the desired amino acid. A QuikChange kit was used, along with 
linear PCR to produce all selected variants (Figure 23) (Chapter 6 (Experimental) 
section 6.5). 
 
Figure 23|  Schematic of site-directed mutagenesis. Overlapping primers are used, 
which contain the codon (which will insert the desired amino acid) at approximately the 
middle of each primer. Linear amplification of the entire plasmid is performed, followed 
by digestion of the parent DNA, which has been methylated by E. coli (plasmid 
containing the wild-type gene). 
Selected AtPEX5-C variant proteins were expressed and purified, and electrospray 






Figure 24|  Mass spectra of AtPEX5-C variant proteins. The deconvoluted masses 
are shown underneath the broad peak spectrum for each species. A) Expected mass for 
D505K: 45,593.4. Observed mass for D505K: 45,593.2. B) Expected mass for D505H: 
45,602.4. Observed mass for D505H: 45,604.1. C) Expected mass for T536N: 45,593.3. 
Observed mass for T536N: 45,594.2. D) Expected mass for N601Q: 45,594.3. Observed 
mass for N601Q: 45,593.8. E) Expected mass for D505K-D507K: 45,606.5. Observed 
mass for D505K-D507K: 45,604.9. In spectra B, D, and E, the mass + approximately 
76 g/mol, and the mass + approximately (2*76 g/mol) is observed. These peaks 
correspond to the mass of the protein + 2-mercaptoethanol. AtPEX5-C has two surface-
exposed cysteine residues (not near the PTS1-binding site), which are available to react 
with 2-mercaptoethanol and TCEP was used to reduce these disulfide bonds with 




Circular dichroism was performed on the five variants of AtPEX5-C in comparison to 
wild-type AtPEX5-C to determine whether any major changes to secondary structure 
had occurred as a result of each of the mutations (Figure 25). As the C-terminal 
domain of AtPEX5-C is predicted to be almost entirely α-helical, it was expected that 
troughs in the CD profiles at 208 nm and 222 nm would be seen. 
 
Figure 25|  Circular dichroism profiles of five AtPEX5-C variants produced in 
comparison to that of wild-type AtPEX5-C. All variant proteins have a similar 
secondary structure to wild-type AtPEX5-C. Troughs are apparent at 208 nm and 
222 nm, indicating that all proteins adopt an α-helical secondary structure. 
The variants of AtPEX5-C produced showed almost identical CD spectra to wild-type 
AtPEX5-C, suggesting that the mutations did not cause misfolding of the protein at a 
secondary structure level. Fluorescence anisotropy was therefore carried out on these 
five variants of the protein with the chosen potential PTS1* peptides (chosen in section 
2.4). If enhanced binding of the AtPEX5-C variants was seen with the potential PTS1* 
peptides YQSEL or YQSKV, the aim would then be to combine mutations in the 
protein in order to promote binding to YQSEV. 
Fluorescence anisotropy results are plotted so that the binding of the ‘native’ PTS1 
YQSKL and the potential PTS1* peptide are shown with wild-type AtPEX5-C and the 
appropriate variant of AtPEX5-C on the same plot (Figure 26). In the following graphs, 




YQSEL is shown in red circles, and lissamine-YQSKV is shown in blue triangles. With 
AtPEX5-C variants, lissamine-YQSKL is shown in green diamonds, lissamine-YQSEL 
is shown in purple stars, and lissamine-YQSKV is shown in orange triangles. 
 
Figure 26|  Wild-type or variant AtPEX5-C (ranging from 0–13.3 μM final concentration) 
versus amount of lissamine-YQSKL, -YQSEL, or -YQSKV bound in the presence of 
100 nM peptide, measured using fluorescence anisotropy. Binding curves for wild-type 
AtPEX5-C with lissamine-YQSKL are shown in black squares, those for wild-type AtPEX5-C 
with lissamine-YQSEL are shown in red circles, and those for wild-type AtPEX5-C with 
lissamine-YQSKV are shown in blue triangles. Binding curves for variants of AtPEX5-C with 
lissamine-YQSKL are shown in green diamonds, those for variants of AtPEX5-C with 
lissamine-YQSEL are shown in purple stars, and those for variants of AtPEX5-C with 
lissamine-YQSKV are shown in orange downward triangles. A quadratic equation was used to 




The AtPEX5-C variant D505K did not appear to bind either the ‘native’ PTS1 peptide 
YQSKL or the potential PTS1* peptide YQSEL with any notable affinity (Figure 26, B). 
This was in contrast to results from the Distel laboratory, as work by the Distel 
laboratory had demonstrated binding of this variant of the ScPEX5 protein to a C-
terminal –SEL> sequence (Klein et al., 2001). However, it may be that there is a 
distinct difference between the binding interactions for S. cerevisiae PEX5:PTS1 
versus A. thaliana PEX5:PTS1 (Lametschwandtner et al., 1998; Kragler et al., 1998), 
or the interaction seen by the Distel laboratory could have been a false positive from 
the yeast-two-hybrid assay. 
The D505H variant of AtPEX5-C does not show a great deal of variance from wild-type 
AtPEX5-C in terms of its peptide binding profile (Figure 26, C). In proteins, the pKa of 
the imidazole of the histidine side chain is approximately 6.5–7.0 (Cantor and 
Schimmel, 1980). As the fluorescence anisotropy assay was carried out at pH 7.5, this 
meant that approximately 15% of the histidine side chains would have been 
protonated under these conditions. The H505 side chain, therefore, predominantly 
removed charge from the acidic pocket in the PTS1-binding site. It appeared that this 
removal of charge had a very slight effect on binding specificity but the binding of the 
protein to YQSEL was still much weaker than the binding to YQSKL. 
The mutation T536N did result in the binding affinity to the two peptides being 
changed; however, this change appeared to shift the binding curves of both peptides 
to the right (Figure 26, D). It appears that the effects of this mutation are just to impair 
overall PTS1 binding. AtPEX5-C variant N601Q showed a similar peptide binding 
profile to T536N (Figure 26, E). The overall PTS1 peptide binding affinity, however, 
was slightly higher with variant N601Q than with T536N. 
The variant of AtPEX5-C with a double mutation, D505K-D507K, shows the desired 
pattern of peptide binding specificity. This AtPEX5-C variant results in the impairment 
of PTS1 binding affinity, while the binding affinity for a non-PTS1 sequence is 
increased (Figure 26, F). Peroxisomal import of a protein possessing a particular C-
terminal PTS1 sequence can be predicted based on the affinity for that PTS1 
sequence to PEX5 in vitro (the Kd for the interaction) (Skoulding et al., 2015). The 
affinity of the AtPEX5-C D505K-D507K variant to lissamine-YQSEL appears to fall far 
short of the predicted affinity threshold for strong peroxisomal protein import in vivo 
(~500 nM) (Maynard and Berg, 2007; Skoulding et al., 2015). YQSKV is a non-PTS1 




this work, the calculated Kd for the interaction of wild-type AtPEX5-C with lissamine-
YQSKV was 1300 ± 100 nM. The calculated Kd for the interaction of AtPEX5-C 
D505K-D507K with lissamine-YQSEL was 10,600 ± 400 nM (approximately 8-fold 
weaker affinity than wild-type AtPEX5-C with lissamine-YQSKV) (Table 7). It can 










Lissamine-YQSKL 1.1 0.6 
Lissamine-YQSEL 29,000 1000 
Lissamine-YQSKV 1300 100 
D505K 
Lissamine-YQSKL 96,000 12,000 
Lissamine-YQSEL 46,600 5200 
D505H 
Lissamine-YQSKL 7.8 1.9 
Lissamine-YQSEL 16,500 1300 
T536N 
Lissamine-YQSKL 330 40 
Lissamine-YQSKV 23,000 5200 
N601Q 
Lissamine-YQSKL 150 10 
Lissamine-YQSKV 11,200 800 
D505K-D507K 
Lissamine-YQSKL 42,900 5300 
Lissamine-YQSEL 10,600 400 
Table 7|  Summary of dissociation constants and standard errors for binding of a 
representative PTS1 sequence and two potential PTS1* sequences to AtPEX5-C 
and variants. Dissociation constants were determined using fluorescence anisotropy. 
Through the generation of five AtPEX5-C variants, it was possible to alter peptide 
binding specificity and slightly enhance binding to a new, non-PTS1, peptide sequence 
(lissamine-YQSEL). Unfortunately this interaction was predicted to be much too weak 
to allow import of this sequence into peroxisomes in vivo, so it became apparent that 
this interaction could not easily be changed by rational design through binding 
predictions. For this reason, it was necessary to develop a screen by which a larger 




2.6 Screen development for the study of PEX5:PTS1 binding 
by colony blotting 
As the initial rational design experiments had not resulted in an orthogonal pair, it was 
decided that a higher throughput screen would be developed in order to allow 
coverage of a larger number of protein-peptide combinations. Fluorescence anisotropy 
was initially used as a screen idea; however, it was not possible to express and purify 
each AtPEX5-C variant from a library on a small enough scale to allow for 
differentiation between positive and negative controls. Colony blotting was chosen as 
the technique to develop into a screen, as it had previously been shown by Tom 
Lanyon-Hogg (former student of the University of Leeds) that horseradish peroxidase 
(HRP) conjugated to the peptide YQSKL (HRP-YQSKL) binds to AtPEX5-C in a dot 
blot where HRP-YQSEL does not (Lanyon-Hogg, 2012). 
In order to test whether colony blotting would be a viable method for identifying 
AtPEX5-C variants that bind to a particular peptide, an initial dot blotting experiment 
was carried out using purified protein and HRP-conjugated peptides (Figure 27). Each 
HRP-conjugated peptide was produced by the addition of a Cys-Gly-Gly-Gly peptide 
linker at the N-terminus of the pentapeptide of interest, and reaction of the resulting 
peptide with HRP-maleimide (Scheme 2). Maleimide reacts covalently with the free 
thiol group of cysteine, so this reaction will leave HRP-CGGG-pentapeptide. HRP-





Scheme 2|  HRP-maleimide coupling to peptide with an N-terminal cysteine. Here, 
the peptide CGGGYQSKL is shown as an example. Peptides were purified under 
reducing conditions and the conjugation reaction with HRP-maleimide was carried out in 
the presence of TCEP to prevent the formation of disulfide bonds between peptides. 
All of the potential PTS1* peptides tested by fluorescence anisotropy in section 2.4 
(lissamine-YQSEL, lissamine-YQSKV, and lissamine-YQSEV) were conjugated to 
HRP for use in colony blot screening. Reactions were carried out using an excess of 
peptide, and unreacted peptide was dialysed out of the reaction (and monitored by the 
disappearance of the UV trace corresponding to peptide) after capping of any 
unreacted maleimide sites using 2-mercaptoethanol. 
Dot blots were initially used to test whether colony blotting was viable as a screening 
concept. These dot blots involved the dotting of purified protein onto nitrocellulose 
membrane, and the blotting of this membrane with HRP linked to peptide. If the 
peptide bound to the protein in question, a bright dot would be observed following 
luminol-based HRP detection. In the optimisation of colony blotting, it was decided that 
the positive control would be wild-type AtPEX5-C with HRP-YQSKL, as the wild-type 
AtPEX5-C:Lissamine-YQSKL interaction had a Kd of 1.1 ± 0.6 nM (section 2.3). The 
negative peptide control was decided as HRP-YQSEL, as the lissamine-YQSEL 
peptide shows very weak binding affinity with either wild-type AtPEX5-C (section 2.4) 
or the variant D505K (section 2.5). The negative protein control would be the 
AtPEX5-C variant D505K, which was found in section 2.5 not to bind to lissamine-





Figure 27|  Dot blot of two AtPEX5-C variants with two different peptides 
conjugated to HRP. HRP-YQSKL binds selectively to wild-type AtPEX5-C over a non-
PTS1 binding variant of the protein. The amount of purified protein used was spotted on 
nitrocellulose membrane in serial dilutions ranging from 500 ng to 3.91 ng (7 serial 
dilutions; 8 dots). The presence of HRP was visualised by luminol-based detection. 
This dot blotting experiment proved that an HRP-conjugated peptide could selectively 
identify a peptide-binding variant of the AtPEX5-C protein. The positive control of wild-
type AtPEX5-C with HRP-YQSKL showed evidence of binding whereas negative 
controls, wild-type AtPEX5-C with HRP-YQSEL, and AtPEX5-C D505K with HRP-
YQSKL and HRP-YQSEL, did not appear to show binding. The next stage was to test 
whether this selectivity could still be seen when blotting colonies as opposed to 
purified protein. In order to test this, a published method of colony blotting was used 
(The QIAexpressionist, 2001). This protocol involves the transfer of transformed cells 
onto nitrocellulose membrane and subsequent expression of genes by incubation of 
this nitrocellulose membrane on solid selection media containing IPTG. Cells on the 
nitrocellulose membrane are then lysed by transfer of the nitrocellulose onto filter 
paper soaked with a range of buffers (see Chapter 6 (Experimental) section 6.12.4), 
and blotting is carried out after a blocking step, as per western or dot blotting. In the 
initial experiments for optimising colony blotting as a screen, protein controls with 
different known binding affinities to YQSKL were used and all colonies were tested 





Figure 28|  Colony blot of induced BL21 (DE3) cells containing either wild-type 
AtPEX5-C, or AtPEX5-C D505K compared to untransformed induced BL21 (DE3) 
cells. HRP-YQSKL appears to bind more strongly to cells containing wild-type 
AtPEX5-C, with low background seen for cells containing AtPEX5-C D505K and for 
untransformed cells. The presence of HRP was visualised by luminol-based detection. 
Two different concentrations of HRP-YQSKL were used (200 nM or 1 µM) for blotting. 
As can be seen in Figure 28, cells containing the wild-type variant of AtPEX5-C can 
easily be identified as those expressing a protein that binds to HRP-YQSKL. The 
difference between ‘binder’ and ‘non-binder’ is clearer when using a higher 
concentration of the HRP-conjugated peptide, so a final concentration of 350 nM for 
HRP-conjugated peptides was used (Figure 29). Further optimisation of the colony 
blotting protocol described above was required in order to use this technique as a 
screen. Optimisations included a lower percentage of milk used in blocking buffer, 
along with a longer blocking step, and a crucial optimisation was the use of a colony 
picker to perform re-arraying and gridding of cells for much easier identification of 
specific colonies (method described in Chapter 6 (Experimental) section 6.12.4). 





Figure 29|  Colony blot optimisation using variants of AtPEX5-C and different HRP-
conjugated peptides. Labelled in the figure are protein variants expressed within each 
colony tested. These colonies were tested in replicate by incubation with either HRP-
YQSKL or HRP-YQSEL. The presence of HRP was visualised by luminol-based 
detection. 
The protein variants tested in Figure 29 were chosen as they displayed a range of 
dissociation constants when binding to YQSKL (section 2.5). Wild-type AtPEX5-C had 
a dissociation constant of 1.1 ± 0.6 nM, AtPEX5-C N601Q had a dissociation constant 
of 150 ± 10 nM, and AtPEX5-C D505K had a dissociation constant of 96,000 ± 12,000 
nM. This allowed testing of the sensitivity of the assay. Although slight detection of 
colonies expressing AtPEX5-C N601Q using HRP-YQSKL was seen, the background 
levels of staining by HRP-YQSEL surpassed this. This result was not seen as a 
problem as it could mean that only the strongest peptide-binding proteins would be 
identified. This method provided a way of selectively identifying colonies which 
contained protein able to bind strongly to a maleimide-peptide. The colony blotting 
screen could then be taken forward to screen a library of AtPEX5-C variants. 
The aim of developing a screen was to enable the study of a library of AtPEX5-C 
mutants. It was decided to create randomised libraries of the proteins rather than the 
peptides, as this would give a greater level of variation in the libraries due to protein 
folding possibilities. Saturation mutagenesis was employed in order to produce protein 
variant libraries. Saturation mutagenesis works in the same way as site-directed 
mutagenesis (Figure 23); however, a larger number of mutagenesis primers are used, 




replaced with a degenerate codon. This means that various different specified codons 
can be inserted (in the manufacturing of the primer library) in place of the original 
codon at that position in the DNA sequence (Figure 31). Multiple degenerate codons 
can be included in the same mutagenesis primer, providing the resulting residues are 
close to one another in the primary sequence of the protein. 
Four positions in the protein were initially chosen for saturation mutagenesis: D505, 
D507, V533 and T536. Position D505 was chosen because previous research into 
mutation of the equivalent residue in S. cerevisiae PEX5 had shown that it is possible 
for this variant of the protein to bind to a non-PTS1 sequence, YQSEL (Klein et al., 
2001). Positions D507, V533 and T536 in the protein were chosen due to apparent 
proximity to the binding peptide in existing crystal structures (Gatto et al., 2000; 
Stanley et al., 2006; Stanley et al., 2007; Sampathkumar et al., 2008; Fodor et al., 
2012). If these four residues were targeted in the same library and replaced with any 
of the 20 amino acids, a library of 160,000 protein variant combinations would be 
produced (including all wild-type possibilities). A reduction in library size was possible 
by splitting the four residues into two libraries with 200 protein variant combinations 
each. If hits were found in each of these saturation libraries, the mutations from both 
libraries could be combined, which may improve binding to PTS1*. This approach is 
known as CASTing (Combinatorial Active site Saturation Testing) (Reetz et al., 2006). 
Library 1 was varied at positions D505 and D507, and library 2 was varied at positions 
V533 and T536 (Figure 30). It was decided that library 1 could be produced to allow 
variation within the acidic pocket of the PTS1-binding site, and library 2 could be 
produced to allow size variation at the hydrophobic region accommodating the C-





Figure 30|  Models of the AtPEX5-C protein variant libraries 1 and 2. Library 1 (A) 
contains two acidic residues surrounding the basic side chain of the -2 amino acid of the 
representative PTS1 peptide. Library 2 (B) contains two residues which appear to form 
part of the hydrophobic pocket for interaction with the hydrophobic side chain of the -1 
(C-terminal) amino acid of the representative PTS1 peptide (Gatto et al., 2000 (1FCH); 
Zhang, 2008; Roy et al., 2010; Yang et al., 2015; Yang and Zhang, 2015 (I-TASSER)). 
In order to produce these protein variant libraries, degenerate codons were used in the 
mutagenesis primers. Saturation mutagenesis primers used for making these libraries 
are shown in Appendix B. Three different degenerate codons were selected in order to 
give an appropriate level of variation in the library whilst keeping library sizes 
manageable. This reduced library sizes further, from 200 protein variant combinations 
in each library (if any of the 20 amino acids were used) to less than 90 protein variant 
combinations in each. 
Positions 505 and 507 in the protein (targeted in library 1) form an acidic region by 
which AtPEX5-C has been found to interact with a basic residue in the PTS1 
sequence, YQSKL (Gatto et al., 2000; Stanley et al., 2006; Stanley et al., 2007; 
Sampathkumar et al., 2008; Fodor et al., 2012). With one of the potential PTS1* 
sequences being YQSEL, it was decided to include all possible basic residues at both 
positions in library 1. For this reason, ‘VRN’ was selected as the degenerate codon to 
use at both positions. ‘V’ means either C, A or G as a base in that position, ‘R’ means 
either A or G, and ‘N’ means any of the bases can be placed at that position. Using the 
codon ‘VRN’ gave the possibility of nine amino acids, Gln, His, Arg, Lys, Asn, Ser, Glu, 





Figure 31|  All possible codons produced from a degenerate codon in a saturation 
mutagenesis primer (to generate library 2). Here, the forward primer for the 
generation of protein variant library 2 is shown as an example. 
From study of existing crystal structures of PEX5-C:PTS1, positions 533 and 536 both 
appear to be part of the hydrophobic region by which the C-terminal PTS1 residue can 
interact (Gatto et al., 2000; Stanley et al., 2006; Stanley et al., 2007; Sampathkumar et 
al., 2008; Fodor et al., 2012). For V533, the intention was to replace this with any non-
polar hydrophobic amino acid. The degenerate codon ‘VYN’ was therefore used at this 
position in the mutagenesis primer (Figure 31). ‘Y’ means either T or C as a base in 
that position. Using the codon ‘VYN’ gave the possibility of seven amino acids, Leu, 
Ile, Met, Val, Pro, Thr, or Ala, occurring at position 533 in the resulting protein. For 
Thr536, it was decided that largely uncharged hydrophilic or hydrophobic residues 
would be beneficial at this position in the protein, so the degenerate codon ‘NVY’ was 




Gly, Ser, Arg, Cys, Asp, Asn, His, Tyr, Ala, Thr, or Pro, occurring at position 536 in the 
resulting protein. 
In the resulting protein libraries, library 1 should have contained 81 possibilities, and 
library 2 should have contained 77 possibilities. As library 1 was the largest, a number 
of colonies were taken from a transformation, grown in selection media, and cells sent 
for DNA sequencing in a 96-well plate to assess coverage of the library (Beckman 
Coulter Genomics). A good sequencing read was obtained for 88 of the 96 colonies, 
and mutations found in these 88 colonies are shown in Figure 32. 
 
Figure 32|  Sequencing results from 88 colonies of saturation library 1. Some 
combinations appear to be favoured over others, but overall there is a good distribution 
of mutations. 
As 43 unique mutants of the AtPEX5-C protein were identified in only 88 colonies, the 
coverage achieved was 53.1% ((43/81)*100). Using the web server GLUE-IT, it is 
possible to calculate the expected coverage of a library obtained using variable 
codons (Firth and Patrick, 2008 (GLUE-IT)). For library 1, two variable codons ‘VRN’ 
were used. With a library size of 88, the expected library coverage, as calculated by 
GLUE-IT, was 59.3% (48.04 expected distinct amino acid variants). This predicted 
coverage is 6.2% higher than the actual coverage obtained so library sizes were 
increased from predictions made by GLUE-IT in order to allow for sufficient coverage. 
The predicted size of the library to screen which would be sufficient to achieve 95% 
coverage of the library was calculated as at least 362 colonies for library 1, and at 




IT)). Screens were performed using 384-well plates, with 4 wells used for a control 
region (Figure 33), so 380 colonies were screened per 384-well plate. It was decided 
that sufficient coverage of each of the libraries could be obtained by screening two 
384-well plates (760 colonies) for each library, as the resulting expected coverage of 
library 1 was 99.7% and expected coverage of library 2 was 99.1% (Firth and Patrick, 
2008 (GLUE-IT)). Cells from each of the colonies from the library were grown in 384-
well plates, and were then transferred to nitrocellulose membrane, resulting in roughly 
uniform colony growth in grid format on nitrocellulose membrane. The overall 
screening method is outlined in Chapter 6 (Experimental) section 6.12.4. A brief 
outline of the colony blotting method developed, along with results for a small number 
of colonies from library 1 screened with HRP-YQSKL (including the control region) are 
shown in Figure 33. 
 
Figure 33|  An outline of the colony blotting method and a screen result when 
testing with HRP-YQSKL. The control region shows that ‘YQSKL-binding control’ 
colonies expressing wild-type AtPEX5-C bind to HRP-YQSKL, whereas ‘non YQSKL-
binding control’ colonies expressing AtPEX5-C D505K do not. 
The colony blotting method successfully identified proteins able to bind the HRP-
conjugated peptide. Sequencing of a number of ‘positive’ colonies from this screen 
revealed that these colonies contained any combination of the two acidic amino acids 
at positions 505 and 507. With this in mind, colony blot screening was performed using 
all potential PTS1* sequences (determined in section 2.4), conjugated to HRP. A 





Figure 34|  A selection of colony blotting screen results. In the example shown of 
library 1 screened with HRP-YQSKL, specific colonies are identified by HRP-YQSKL. In 
the other three examples, where HRP-conjugated to any of the potential PTS1* peptides 
was used, all colonies appear to be identified by the HRP-peptide. The control region of 
colonies is highlighted by an orange outline for the screen treated with HRP-YQSKL. 
The control region of four colonies established and shown in Figure 33 are located in 
the top left-hand corner of each of the screen experiments shown in Figure 34 
(highlighted in Figure 34, A). This control region only applied for membranes treated 
with HRP-YQSKL as it was not possible to establish variants of AtPEX5-C that could 
bind to the other three HRP-peptide conjugates before the screening process. The 
results for 384 colonies are shown for each screen (2 x 384-colony screens were 
performed for each, so 760 colonies minus the control regions). Libraries 1 and 2 were 
screened with all HRP-conjugated peptides. Results of colony blotting with HRP-
YQSKL (Figure 34, A) show that selective identification of a small number of colonies 
from the 380 colonies shown was possible, demonstrating that the screen worked well 
when blotting with HRP-YQSKL. Sequencing also confirmed that these colonies 
identified were all wild-type revertants (or similar) of the AtPEX5-C protein. 
Results of the colony blotting therefore showed that the screen was a viable method 
for identifying protein variants able to bind to HRP-YQSKL. With all potential PTS1* 




any true binding proteins. This could be due to the potential PTS1* peptides having 
some form of binding with a component of the cell lysate or with the nitrocellulose 
membrane itself. Further screen optimisation in the time available did not result in any 
improvement on the level of high background binding seen with these peptides. The 
technique was also time consuming and unreliable, as it was not possible to achieve 
completely uniform growth of colonies and some colonies would become detached 
from the nitrocellulose membrane during the blotting process. Furthermore, it had not 
been demonstrated that this technique could be used to identify intermediate peptide-
binding proteins. For these reasons, colony blotting was abandoned as a method of 
screening. 
2.7 Summary 
In order to examine the binding properties of the C-terminal TPR domain of AtPEX5 
(AtPEX5-C), this portion of the AtPEX5 protein was expressed in E. coli and purified. A 
peptide representing a native PTS1 sequence was synthesised and coupled to 
lissamine, which enabled the dissociation constant (Kd) of the interaction to be 
determined using fluorescence anisotropy. This Kd was consistent with published 
findings. Three potential PTS1* peptide sequences were synthesised for use in 
fluorescence anisotropy with variants of AtPEX5-C. The five variants of AtPEX5-C 
were produced by site-directed mutagenesis at selected residues within the protein, 
based on published crystal structures of homologous proteins. The Kd values obtained 
from these variants with potential PTS1* sequences are shown in Table 7. This 
allowed comparison of Kd values with in vivo targeting efficiency of these sequences 
as determined by Dr Rupesh Paudyal (the postdoctoral researcher working on the in 
vivo aspects of this project). 
It became apparent that a higher throughput method than rational design would be 
needed to identify any AtPEX5-C* proteins so screening by colony blotting was 
developed and optimised. This screen successfully identified variants of the protein 
able to bind to a representative PTS1 sequence conjugated to HRP. Colony blotting 
was, however, an unsuitable technique for use with our potential PTS1* peptide 
sequences so an alternative method of screening was required. 
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Chapter 3  
Development of a Pull-Down Method of Screening AtPEX5-C 
for Binding to Peptides within a Library 
 
3.1 Introduction 
Previous attempts to find an orthogonal PEX5*:PTS1* pair through screening a large 
library of protein variants against a small library of peptides were unsuccessful 
(Chapter 2, section 2.6). A new approach was needed, so the procedure was 
reversed: a large library of peptides would be used to try to identify binding interactions 
against a small library of protein variants. In order to do this, it would have to be 
possible to co-isolate AtPEX5-C variants with their binding peptides. An example of 
successful published co-isolation of the PEX5-C:PTS1 complex is the pull-down of 
lissamine-YQSKL using A. thaliana PEX5-C in the presence of nickel-agarose resin 
(Lanyon-Hogg et al., 2014). 
The idea of this pull-down method of screening was that if a library of pentapeptides 
representing PTS1 and non-PTS1 sequences was mixed with purified protein 
possessing a His6 tag, binding peptides could be pulled out of the mixture via the His6 
tag of the protein, using resin with a coordinating metal ion (Figure 35). The next 
stage would be to separate these binding peptides from the resin used for pull-down, 






Figure 35|  Scheme of the pull-down-LC-MS screening concept. Purified protein is 
mixed with a library of peptides. Cobalt-agarose resin is then used to capture protein 
using its His6-tag. Protein, along with binding peptides, is eluted from cobalt-agarose 
resin. LC-MS analysis of the elution fraction allows the separation of binding peptides 
from one another and characterisation can then be performed for the identification of 
binding peptides. 
This chapter will describe the development and optimisation of a pull-down screen in 
order to selectively identify protein-binding peptides from a library. A comparison of 
these identified peptides with PTS1 sequences predicted by bioinformatics will be 
presented for screen validation. 
3.2 Synthesis of a library of N-terminally labelled peptides 
3.2.1 Assembly of a peptide library 
It was decided to randomise the two C-terminal amino acids of the pentapeptide library 




most variation in binding would be achieved (Chapter 2, section 2.4; Gatto et al., 
2000). Randomisation of the two C-terminal residues of the pentapeptide YQSKL left 
400 different peptide possibilities to synthesise. It was not necessary to prepare each 
peptide separately, as split-and-pool synthesis was used to prepare mixtures of 
peptides directly (Figure 36). The full peptide library was synthesised in four separate 
batches, for reasons that will be explained in this chapter, and then combined for 
screening. 
Coupling reactions of each of the amino acids in the split-and-pool synthesis was 
carried out as before (for standard solid phase peptide synthesis) (Chapter 2, section 
2.3). Following the assembly of the peptide libraries, a hydrophobic N-terminal 
fluorophore was used to label the peptides. This modification would increase the 
retention time of peptides on the C18 column used for LC-MS, improving separation of 






Figure 36|  Main steps in the split-and-pool synthesis of a small peptide library. 
Here, 2-chlorotrityl chloride resin loaded with five different amino acids is pooled and split 
for coupling of the next five amino acids. Coupling of three N-terminal amino acids, Ser, 
Gln, and finally Tyr (at the N-terminus) leaves a library of pentapeptides with two 
randomised amino acids at the C-terminus. Acid-labile groups are in red, base-labile 
groups are in blue. 
3.2.2 Determination of a suitable N-terminal label for peptides 
Two fluorescent labels were considered for the N-terminus of the peptide library, a 




schemes for coupling onto the N-terminus of a pentapeptide YQSxx (where x is any 
amino acid), are shown in Figure 37. 
 
Figure 37|  The schemes for the final coupling conditions for a coumarin moiety 
(A) and a dansyl moiety (B) to the N-terminus of a pentapeptide YQSxx, where x 
represents any amino acid. Both moieties contain aromatic groups, which will 
contribute to the hydrophobicity of the overall peptide. The acid-labile activated 2-
chorotrityl chloride group on resin is shown in red. 
After optimisation, the efficiency of the coumarin moiety coupling to peptides was only 
approximately 20%, whereas coupling of the dansyl moiety to peptides was 
approximately 90%. In order to determine which N-terminal label would be most 
suitable for the assay in terms of their effect on binding of the peptide to AtPEX5-C, 
fluorescence anisotropy could be used. Competition assays were performed, 
monitoring the fluorescence anisotropy of lissamine-rhodamine-YQSKL upon its 
displacement from the AtPEX5-C binding site by an increasing concentration of either 




details of the assay, see Chapter 6 (Experimental) section 6.14.6). By measuring the 
anisotropy it was possible to calculate the half-maximal inhibitory concentration (IC50). 
The log(IC50) was then used to calculate inhibition constant (Ki) (Nikolovska-Coleska et 
al., 2004; Skoulding et al., 2015) for coumarin-YQSKL and for dansyl-YQSKL in order 
to compare these with the Ki for unlabelled YQSKL (Figure 38). The error in Ki was 
calculated by a Monte Carlo error estimation approach (Skoulding et al., 2015), using 
the errors obtained for Kd (of the AtPEX5-C:lissamine-YQSKL interaction) and for IC50 
of the competitor peptide. Simulations were performed (2000 in total), based on 
simulated Kd and IC50 values around the observed mean. The standard deviation of 
each of these 2000 simulations was then used to estimate the error on Ki (Nikolovska-





Figure 38|  Fluorescence anisotropy competition assays using a fixed 
concentration of lissamine-YQSKL (30 nM final concentration), and of AtPEX5-C 
(200 nM final concentration), and competitor peptide (ranging from 0–1 mM final 
concentration).  A) Coumarin-YQSKL versus unlabelled YQSKL. B) Dansyl-YQSKL 
versus unlabelled YQSKL. Unlabelled YQSKL appears to out-compete lissamine-
YQSKL more effectively than coumarin-YQSKL, whereas dansyl-YQSKL appears to out-
compete lissamine-YQSKL slightly more effectively than unlabelled YQSKL. Data were 
fitted to a one-site competition model using OriginPro 9.1. 
Using a fluorescence anisotropy competition assay with coumarin-YQSKL as the 
competing peptide, it was calculated that the log(IC50) for coumarin-YQSKL was 4.68 ± 
0.10 nM, whereas the log(IC50) for unlabelled YQSKL was 3.59 ± 0.03 nM. This 
equated to a Ki of coumarin-YQSKL being 280 ± 170 nM, whereas the Ki of unlabelled 
YQSKL was 22 ± 12 nM. The coumarin appeared to be having an adverse effect on 




relatively unaffected by the N-terminal dansyl label, as the log(IC50) for dansyl-YQSKL 
was 3.38 ± 0.10 nM. This equated to a Ki of dansyl-YQSKL being 13 ± 9 nM, which is 
very similar to the Ki of unlabelled YQSKL. 
The use of a dansyl label at the peptide N-terminus was preferable to a coumarin label 
as a dansyl moiety at the N-terminus of the binding peptide did not appear to 
adversely affect binding of the peptide to AtPEX5-C. A dansyl moiety was therefore 
coupled to the N-terminus of the library of peptides for screening. 
3.3 Peptide library characterisation 
The peptide library was analysed by LC-MS, using a C18 column prior to electrospray 
ionisation, and m/z determined using a Bruker maXis impact Q-TOF mass 
spectrometer (Chapter 6 (Experimental) section 6.15.2). As many peptides were 
injected into the mass spectrometer in one run, the individual spectra of all peptides 
were effectively combined with one another. A base peak chromatogram shows the 
most abundant peak at each time point across an eight minute LC-MS run. This 
highlights the problematic issue of separating individual peptides out of this mixture 
(Figure 39). 
 
Figure 39|  Base peak chromatogram for an LC-MS run of the entire peptide library, 
dansyl-YQSxx, where x is any amino acid. Many peaks are present and it is not 
possible to take useful characterisation information away from this analysis. 
The raw data (the mass spectrum) for a selected time point, 3.1–3.3 minutes, within 
this LC-MS run is shown in Figure 40. Peptides were predicted to range from 743.3–
1001.4 g/mol in molecular weight with an N-terminal dansyl label. It can be seen that a 




were seen between the range of 2 and 6.5 minutes for an eight-minute LC-MS run. 
This shows the difficulty faced in terms of characterising each of these peptides 
individually. 
 
Figure 40|  Masses observed for singly charged ions between 3.1 and 3.3 minutes 
for an eight minute LC-MS run of all peptides in the library. Singly charged ions 
between 743 and 1002 m/z are shown. There are many peaks to discriminate from one 
another. 
The size range of peptides in the library was calculated by drawing the smallest 
peptide (dansyl-YQSGG) and the largest peptide (dansyl-YQSWW) in ChemDRAW 
and taking the mass values provided by ChemDRAW to define the mass range. In 
order to calculate the masses of all peptides in the library from their formulas, Pipeline 
Pilot was used (by Stuart Warriner) to quickly enumerate the library. With the formulas 
and, hence, masses of peptides in the library known, it was possible to look for each of 
these masses in the mass spectrum of the peptide library and begin to characterise 
each of the dansyl-labelled peptides separately. 
3.3.1 Extraction of ion chromatograms based on exact masses of 
peptides 
Although the masses of all peptides in the library had been obtained, it was apparent 
that some peptides had identical predicted nominal masses. The nominal mass of a 
peptide is the average of the mass of all possible isotopes. This problem of identical 
nominal masses is illustrated in Table 8, where a selection of four pairs of peptides are 




Pair Peptide sequence Nominal mass Exact mass 
1 
Dansyl-YQSGQ 814.3 814.2956 
Dansyl-YQSGK 814.3 814.3320 
2 
Dansyl-YQSNN 857.3 857.3014 
Dansyl-YQSDI 857.3 857.3266 
3 
Dansyl-YQSQE 886.3 886.3240 
Dansyl-YQSAW 886.3 886.3393 
4 
Dansyl-YQSQW 943.4 943.3534 
Dansyl-YQSKW 943.4 943.3898 
Table 8|  Nominal masses and exact masses for four pairs of peptides. In the case 
of each peptide pair, the nominal masses are identical and only exact masses are 
unique. 
As is apparent in Table 8, nominal masses could not be relied upon for efficient 
characterisation in this situation. Analysis of peptides by high resolution mass 
spectrometry was therefore crucial for identifying peptides uniquely within the library. 
Exact masses were needed and it was possible to obtain these using the Bruker 
maXis impact Q-TOF mass spectrometer. LC-MS runs could therefore be processed 
by extracting ion chromatograms for the exact mass of each of the peptides in the 
library. 
The peptides dansyl-YQSQE and dansyl-YQSAW have the same predicted nominal 
mass (Table 8) and are the most similar in exact mass, so this pair was used for 
graphical representation in order to show the requirement for an accurate mass 





Figure 41|  Distinct identification of two peptides with very similar exact masses. 
A) Base peak chromatogram of all peptides in the library. B1) Extracted ion 
chromatogram for the exact mass of dansyl-YQSQE with an error of 0.1 g/mol. B2) 
Extracted ion chromatogram for the exact mass of dansyl-YQSQE with an error of 
0.02 g/mol. B3) Extracted ion chromatogram for the exact mass of dansyl-YQSQE with 
an error of 0.008 g/mol. C1) Extracted ion chromatogram for the exact mass of dansyl-
YQSAW with an error of 0.1 g/mol. C2) Extracted ion chromatogram for the exact mass 
of dansyl-YQSAW with an error of 0.02 g/mol. C3) Extracted ion chromatogram for the 
exact mass of dansyl-YQSAW with an error of 0.008 g/mol. 
Figure 41 shows that it was possible to identify individual peaks for each peptide. 
Adding extracted ion chromatograms (EICs) therefore provided a way to separate 
individual peptides from the mixture. After an LC-MS run of the full peptide library, data 
were processed so that an extracted ion chromatogram for the exact mass of each 
peptide, ± 0.008 g/mol, would be shown. This process was automated (Appendix D, 
section D.2) so that EICs were added for the exact masses of each of the peptides in 






Figure 42|  Extracted ion chromatograms for dansyl-labelled peptides in the full 
library run by LC-MS. 
By using extracted ion chromatograms, even overlapping peaks could be detected 
(Figure 42). In a library of peptides with the two C-terminal residues randomised, there 
is also the problem of multiple peptides in the library having identical exact masses. 
For example, the positional isomers dansyl-YQSKW and dansyl-YQSWK have 
identical exact masses and there were many other positional isomers in the library. 
Tandem mass spectrometry was used for conclusive characterisation in these cases. 
3.3.2 The use of tandem mass spectrometry for further 
characterisation 
There were a number of peptides in the library with identical exact masses to one 
















Table 9|  Three groups of peptides in the full peptide library along with their exact 
masses. It can be seen that each group of peptides have identical exact masses. 
Provided the retention times for these peptides were different after LC-MS, it was 
possible to use tandem mass spectrometry to identify the unique retention time for 
each peptide. Tandem mass spectrometry is a fragmentation technique which involves 
the isolation of particular peptide ‘precursor’ ions (some of which are displayed in 
Figure 40) and the fragmentation of these via collisions with an inert gas (Steen and 
Mann, 2004). This leads to the production of ‘product’ ions which can then be 
analysed. The most likely fragmentation pattern for a peptide is by fragmentation at the 
amide bonds, which leads to the production of ‘b’ and ‘y’ ions (Figure 43). Unique 
product ions can then be identified. Taking group 3 (Table 9) as an example, product 
ions predicted after fragmentation of the two peptides dansyl-YQSKF and dansyl-





Figure 43|  Illustration of the ions generated after the fragmentation of a generic 
peptide. A table of predicted masses of ‘product’ ions generated after the 
fragmentation of dansyl-YQSKF and dansyl-YQSFK is also shown, with masses in 
g/mol. Predicted masses of product ions were generated using the Fragment Ion 
Calculator (db.systemsbiology.net:8080/proteomicsToolkit/FragIonServlet.html). 
Two different unique ions (y1 and b4) can be seen after the simulated fragmentation of 
dansyl-YQSKF and dansyl-YQSFK. These ions are both generated by fragmentation 
of the final amide bond in the peptide chain, the bond that will always be located 
between the two randomised C-terminal residues in this study. The y1 ion was chosen 
for the separate identification of all peptides in the library with identical exact masses, 
as this was the smallest unique ion. Figure 44 shows the peaks identified as either 
dansyl-YQSKF or dansyl-YQSFK, after extraction of ion chromatograms based on the 
exact mass of each peptide (section 3.3.1). These were seen as two distinct peaks 
because of the difference in retention times of the two peptides. Tandem mass spectra 
are shown for the time points in the mass spectrum where each of these two peaks 






Figure 44|  The use of tandem mass spectrometry for identification of unique 
peptides. Top panel: extracted ion chromatograms corresponding to dansyl-YQSKF 
and dansyl-YQSFK. i) Tandem mass spectrum for peak (i), in which the y1 ion of 
phenylalanine can be seen. ii) Tandem mass spectrum for peak (ii), in which the y1 ion 
of lysine can be seen. 
It can be concluded from Figure 44 that peak (i) corresponds to dansyl-YQSKF and 
peak (ii) corresponds to dansyl-YQSFK. By performing analysis in this way for all 
positional isomers, and indeed all peptides with identical exact masses, it was possible 
to acquire unique peptide identifiers using retention time and mass. These unique 
peptide identifiers were termed ‘retention time & mass’, or ReT-mass, identifiers in this 
study. In order to assign ReT-mass identifiers quickly, the process of searching for y1 
ions in tandem mass spectra was automated on the mass spectrometer (Appendix D, 
section D.2). 
Tandem mass spectrometry was a valuable technique for the unique identification of a 
number of peptides. In some cases, however, even tandem mass spectrometry will not 




constitutional isomers, so the y1 ions generated by the presence of either of these 
amino acids at the C-terminus of a peptide will have identical masses. For this reason, 
the entire library of peptides was synthesised as four separate sub-libraries. This 
ensured that full characterisation could be carried out, and as many ReT-mass 
identifiers as possible could be assigned, before the full-peptide library was 
assembled. 
3.3.3 Sorting of peptides into sub-libraries based on mass 
The entire library of peptides was split into four groups before synthesis. This was 
achieved by splitting amino acids into two groups based on mass. During the split-and-
pool synthesis (Figure 36), these amino acids were combined in such a way that four 
sub-libraries of peptides were produced. Exact masses of peptides had already been 
enumerated virtually (by Stuart Warriner, using Pipeline Pilot) and calculated based on 
the formulas of the peptides. This allowed the virtual sorting of peptides into sub-
libraries so that the maximum amount of peptides with identical exact masses to one 
another was two. If the entire peptide library had been synthesised in one mixture, the 
maximum amount of peptides with identical exact masses to one another would have 
been six. Sorting amino acids into two groups meant that amino acids with identical 
exact masses (leucine and isoleucine) and amino acids differing by a methyl group (for 
example, serine and threonine) could be separated. Cysteine was excluded from 
peptide sub-libraries due to its propensity to form disulfide bonds, which could 
complicate analysis. Amino acids in each of the groups (1 or 2), along with 
combinations of these groups required for the production of each sub-library, are 
displayed in Figure 45. 
 
Figure 45| The amino acid composition of each of the four sub-libraries. Sequences 
are written from N- to C-terminus and sub-libraries were varied at the two C-terminal 
residues. In red, group 1 amino acids; in blue, group 2 amino acids. 
The four peptide sub-libraries were run on the mass spectrometer separately by LC-




identify 361 peptides. It was, however, not possible to identify any of the methionine-
containing peptides in their unoxidised state, and carrying out peptide library cleavage 
under reducing conditions compromised the yield of other peptides in the libraries, so 
methionine was excluded from analysis. 
After exclusion of methionine-containing peptides, a total library of 324 peptides had 
been successfully synthesised. It was possible to obtain unique ReT-mass identifiers 
for 234 of these peptides, with the use of tandem mass spectrometry in some cases 
(Figure 44). This enabled the production of a master list comprising peptide 
sequences and retention times, termed the ‘master Seq-ReT list’ in this study. In the 
case of 45 pairs of peptides, the LC retention times for the positional isomers were 
identical so it was not possible to obtain unique ReT-mass identifiers for these 90 
peptides; however, the peaks could be assigned as belonging to the pair. A table of all 
peptide retention times, along with sequences, are shown in Appendix D, section 
D.1.1. In the case of the 45 pairs of peptides indistinguishable from one another, one 
of the peptides from each pair was included in the master Seq-ReT list and is shown in 
the table in Appendix D, section D.1.1 in pale blue, and the other peptide from the pair 
is shown in the table in Appendix D, section D.1.2. 
3.3.4 Data processing after an LC-MS run 
In order to accelerate analysis, data were automatically processed. The extracted ion 
chromatograms (EICs) were automatically generated on the mass spectrometer and 
the peak data (mass, retention time, and area under EIC) were exported as a ‘.csv’ file 
for each LC-MS run. VBA was then used to create macros in Microsoft Excel which 
would process the data from each exported ‘.csv’ file. These macros compared the 
mass and retention time data for each LC-MS run with the reference data obtained 
during the development of the assay (the master Seq-ReT list), in some cases 
applying a small compensating retention time drift. This allowed rapid and consistent 
assignment of each peak to the corresponding peptide sequence. 
In the case of peptide pairs without unique ReT-mass identifiers, the macros would 
assign the appropriate area-under-EIC to the sequence of the peptide in the master 
Seq-ReT list. This area-under-EIC would also then automatically be assigned to the 
other peptide from the pair. VBA was also used to plot the area-under-EIC data 
against peptide sequences corresponding to these EICs. This was presented in a heat 




terminal or ‘-1’ amino acid and the y-axis displays the ‘-2’ amino acid of the peptide 
(Figure 46). Details of the function of each of the macros created and used in this 
study, and the code for each, are shown in Appendix D, section D.3. 
 
Figure 46|  Peptides that were present in each sub-library after LC-MS analysis. A) 
Sub-library 1.1, B) Sub-library 1.2, C) Sub-library 2.1, and D) Sub-library 2.2. For 
sub-libraries 1.1 and 2.2, diamonds represent positional isomer peptides with identical 
retention times. For sub-libraries 1.2 and 2.1, each type of symbol (either diamond or 
circle) represents a pair or peptides with identical retention times. These symbols 
therefore represent peptides without unique retention time & mass (ReT-mass) 
identifiers. The squares are shaded according to the area-under-EIC for each peptide. 
It was possible to assign an area-under-EIC to all peptides in each of the sub-libraries, 
which meant that all peptides in the full library were characterised. It was then decided 
to run the full peptide library by LC-MS in order to test the characterisation of this 




3.3.5 An LC-MS run and processing of the full peptide library 
A sample containing all peptide sub-libraries combined was run by LC-MS (Figure 42) 
and results showing the area-under-EIC for each peptide in the sample are shown in 
heat map format (Figure 47). 
 
Figure 47|  Peptides present after processing an LC-MS run of the full peptide 
library. Peptides were detected at varying intensities; however, all peptides in the full 
library were detected. Amino acids on each axis are sorted from hydrophobic to 
hydrophilic, as determined by the Sigma-Aldrich Hydrophobicity Index (Sereda et al., 
1994; Monera et al., 1995). 
As can be seen from the heat maps of the LC-MS runs of peptides alone, the signal of 
each peptide present in the full peptide library varied greatly from one another. This 
could have been due to the mass difference between peptides, as peptide sub-
libraries were resuspended based on the average mass in the sub-library. However, 
more importantly, the absolute area would be affected by how well each of the 
peptides ionised, with peptides containing positively charged basic side chains ionising 
much more effectively. It was therefore important that, when using this technique to 
interpret screening results, the semi-quantitative presence or absence of each of the 
peptides being pulled down was treated as more significant than the absolute intensity 




3.4 Development and optimisation of a peptide pull-down 
screen 
An initial test pull-down-LC-MS experiment was carried out using 40 μM purified wild-
type AtPEX5-C and 5 μM of each peptide in peptide sub-library 1.2. This allowed us to 
investigate whether YQSKL, the representative PTS1 sequence used in this study, 
was pulled down by the wild-type protein. The screen was carried out by incubating 
purified protein with peptide sub-library 1.2 for 1 hour at 4°C. This protein-peptide 
mixture was then added to cobalt resin followed by a 1h incubation at 4°C. Five buffer 
wash steps were performed, followed by a 30 minute (4°C) incubation with buffer 
containing 200 mM imidazole to release protein from the cobalt resin. When carrying 
out these initial screens, fluorescence intensity was measured at 550 nm to identify the 
amount of dansyl fluorophore in each fraction (Figure 48). Controls in the absence of 
protein or peptide were treated identically. 
 
Figure 48|  Fluorescence intensity measurements at 550 nm in order to track 
dansyl levels in all stages of preliminary pull-down screen experiments. 
By tracking the dansyl fluorescence through the stages of the screen (Figure 48), it 
could be observed that the wild-type AtPEX5-C protein appeared to be releasing some 
peptide upon elution from the cobalt resin. This increase in fluorescence was not 
observed in the controls. This elution fraction was analysed by LC-MS to identify which 
peptides of library 1.2 were present after having presumably been bound to the wild-
type AtPEX5-C protein. Results of the LC-MS run are shown in Figure 49, compared 





Figure 49|  A) LC-MS of elution fraction of a pull-down-LC-MS screen for wild-type 
AtPEX5-C with sub-library 1.2. B) Sub-library 1.2 before screen. Wild-type AtPEX5-C 
is almost exclusively isolating peptides with a C-terminal leucine, which shows selectivity 
when compared with peptide sub-library 1.2 before screening. 
Selective pull-down of peptides was clearly occurring. By comparing the results from 
this pull-down-LC-MS screen with previously published in vivo peroxisomal import 
experiments (Lingner et al., 2011; Skoulding et al., 2015), it was possible to reveal 
whether the wild-type AtPEX5-C protein was selectively identifying PTS1 sequences. 
Within the entire sub-library 1.2 (comprising 81 peptides), there are only six 
experimentally validated C-terminal tripeptide PTS1 sequences, and a total of nine 
predicted PTS1s (Lingner et al., 2011; Chowdhary et al., 2012): –SKY, –SDL, –SPL,  
–SFL, –SGL, –SHL, –SNL, –SSL, and –SKL. Of these nine sequences, eight were 
identified in the pull-down-LC-MS screen, demonstrating that the experiment does 
indeed enable identification of PTS1 sequences. 
3.5 Further optimisation of the pull-down screen and 
validation 
The pull-down screen protocol was further modified in order to allow the pull-down of a 
larger number of peptides. As the initial experiment had used 40 μM purified protein 
and 5 μM of each peptide in the library, this in theory would mean that 8 very tight 
protein-binding peptides could occupy all available protein binding sites. This would 
leave only the tightest protein-binding peptides available for analysis. It was expected 
that any new peptide binding seen with an AtPEX5-C variant would not have a 
particularly high affinity so the concentration of purified protein used in the screen was 




sensitivity of the instrument so lower concentrations of overall peptide libraries were 
needed. 
The pull-down-LC-MS protocol was modified slightly to include three extra wash steps, 
to account for the full peptide library being used, and elution of the peptides by use of 
6M urea in the buffer to unfold the protein coordinated to resin to release bound 
peptides. The unfolded protein remained bound to the cobalt resin, enabling more 
straightforward LC-MS analysis (Figure 50). 
 
Figure 50|  Modified pull-down-LC-MS protocol, using 6M urea to isolate peptides. 
Cobalt-agarose resin is used to capture protein, after incubation with a library of 
peptides, using its His6-tag. Binding peptides are released by unfolding the protein, which 
allows LC-MS analysis of binding peptides. 
Concentrations of peptides in the libraries were set at approximately 500 nM of each 
peptide for all preliminary experiments in this section. The concentration of purified 




libraries were combined for these experiments, enabling screening of the full library of 
324 peptides, and the peptides pulled down with each concentration of purified protein 
are shown in Figure 51. 
 
Figure 51|  A) Pull-down-LC-MS screen using 25 μM wild-type AtPEX5-C and 
approximately 500 nM each peptide in the full library. B) Pull-down-LC-MS screen 
using 12.5 μM wild-type AtPEX5-C and ~500 nM each peptide in the full library. C) 
Pull-down-LC-MS screen using 5 μM wild-type AtPEX5-C and ~500 nM each 
peptide in the full library. D) Pull-down-LC-MS screen using 2.5 μM wild-type 
AtPEX5-C and ~500 nM each peptide in the full library. Screens (A) and (B) show a 
very similar overall peptide binding profile. The full-range of peptide binding appears to 
be lost in screen (C) and appears to be further limited in screen (D). 
Following the range of concentration tests performed with wild-type AtPEX5-C, it was 
decided that the optimum concentrations that would be tested while providing sufficient 
information on the peptide binding profile was 12.5 μM purified protein and ~500 nM 
each peptide. This allowed a wide range of peptides to be pulled down by the protein 
while using a low enough concentration of protein to allow any screen repeats from 




500 μL, meaning that 284.9 μg (6.25 nanomoles) protein and approximately 0.217 μg 
(0.25 nanomoles) of each peptide was used. 
These data also allowed the first opportunity to fully compare the sequences that were 
pulled down across the library with experimentally validated and predicted PTS1 
sequences. In order to carry out this comparison, the pull-down-LC-MS data were 
compared with in silico PTS1 prediction software (Lingner et al., 2011; Reumann et al., 
2012) to assess whether the peptides identified by pull-down-LC-MS were also 
predicted PTS1 sequences. The PredPlantPTS1 server uses a positional weight 
matrix (PWM) to assign an amino acid at a particular position in the extreme C-
terminal sequence of a given protein with a prediction score (Skoulding et al., 2015, 
supplementary information). The PWM created by the Reumann research group, 
based on in silico predictions, is displayed in Figure 52. 
 
Figure 52|  Positional weight matrix (PWM) used by the Reumann research 
laboratory. This is used to assign a PTS1 prediction score to each amino acid in the 14 
C-terminal amino acids of a protein. (Reumann et al., 2012; Skoulding et al., 2015). 
Res. -14 -13 -12 -11 -10 -9 -8 -7 -6 -5 -4 -3 -2 -1 Res.
A -0.1 -0.1 -0.1 0.01 -0 -0.1 -0.1 -0.1 -0.1 -0 -0 0.34 -0.2 -0.2 A
R -0.1 -0.1 0.01 -0.1 -0.1 -0.1 -0.1 -0.1 0.03 -0.1 0.03 -0.2 0.46 -0.2 R
N -0.1 -0.1 -0.1 -0.1 -0 -0.1 -0.1 -0.1 -0.1 -0.1 -0.1 -0.2 0.01 -0.2 N
D -0.1 -0.1 -0.1 0.02 -0 -0 -0.1 -0.1 -0.1 -0.2 -0.2 -0.2 -0.2 -0.1 D
C -0.1 -0.1 -0.2 -0.1 -0.2 -0.2 -0.1 -0 -0.2 -0.1 -0.2 0.12 -0.1 -0.2 C
Q -0.1 -0.1 -0.1 -0 -0.1 -0.1 0 -0 -0 -0.1 -0 -0.1 -0.1 -0.2 Q
E -0.1 -0.1 -0.1 -0.1 -0.1 -0 -0.2 0 -0.1 -0.1 -0.2 -0.2 -0.1 -0.1 E
G -0.1 -0.1 -0.1 -0 -0.1 -0.1 -0 -0.1 -0.1 -0.1 -0.2 -0.2 -0.2 -0.1 G
H -0.1 -0 -0.1 -0.1 -0 0.01 -0 -0 -0.1 -0.1 0.03 -0.1 -0.1 -0.2 H
I -0 -0.1 -0.1 -0.1 -0.1 -0.1 -0 -0.1 -0 0 -0.1 -0.2 -0.1 0.33 I
L -0.1 -0.1 -0.1 -0.1 -0.1 -0.1 -0.1 -0.1 -0 -0 -0.1 -0.2 -0.1 0.66 L
K -0.1 -0.1 -0.1 -0 -0.1 0 -0.1 -0 -0 -0.1 0 -0.1 0.44 -0.2 K
M -0.1 -0 0 -0.1 -0.1 -0.1 -0.1 -0.1 0.07 -0 -0.1 -0.1 -0.1 0.64 M
F -0.1 -0.2 -0.1 -0.1 -0.1 -0 -0.1 -0.2 -0.1 -0 -0.1 -0 -0.2 -0.1 F
P -0.1 -0.1 -0.1 -0.1 0.03 -0.1 -0.1 0.02 -0.1 0.03 0 0.13 -0.2 -0.2 P
S -0.1 -0.1 -0.1 -0 -0.1 -0.1 0 -0.1 -0 -0.1 -0.1 0.48 -0.1 -0.2 S
T -0.1 -0.1 -0 -0 0 -0.1 -0.1 -0.1 -0 -0.1 -0.1 -0.1 -0.2 -0.2 T
W 0.15 0.15 0 0.01 -0.1 -0.1 -0.2 -0.1 -0.3 -0.2 -0.1 -0.3 -0.2 -0.2 W
Y 0.01 -0 -0.1 -0.3 -0.1 0.02 -0.1 -0.1 0 -0.1 0.01 -0.1 -0.1 -0.2 Y
V -0.1 -0 -0 -0.1 0 -0.1 -0.1 -0.1 -0.1 -0.1 -0.1 -0.1 -0.2 -0.1 V





A comparison between the data obtained from the pull-down-LC-MS results with the 
PredPlantPTS1 server was carried out. The positional weight matrix (PWM) algorithm 
used by PredPlantPTS1 was applied to each of the peptide sequences in the full 
library screened with wild-type AtPEX5-C. The way in which PWM score is assigned to 
a peptide sequence is by addition of the individual amino acid scores at each position, 
as determined by the PWM (Figure 52). A graph was plotted to show the peptides 
ranked by ‘PWM score’ and to highlight which peptides were found by the pull-down-
LC-MS screen (Figure 53). 
 
Figure 53|  (A) and (B) All peptides in the full library ranked by positional weight 
matrix (PWM) score. A) In green are peptides identified in figure 17B. B) In green 
are peptides identified in figure 17B, excluding those with an identical ReT-mass 
identifier to another peptide, and excluding those with a C-terminal histidine. A 
higher PWM score designates that the peptide sequence is more likely to act as a PTS1 
sequence. A threshold score for peroxisomal import is given by PredPlantPTS1 as 0.412 




By ranking peptide sequences by their PWM score, it was possible to determine 
whether the expected peptide sequences were being pulled down by wild-type 
AtPEX5-C. Overall, it appears that the peptides that were identified by pull-down-LC-
MS were some of the highest PWM scoring peptides. This conclusion was made 
clearer when peptides with a C-terminal histidine and all peptides without unique ReT-
mass identifiers were removed. 
In order to study the peptides identified by the pull-down-LC-MS screen by comparison 
with more recent research, peptides in sub-library 1.2 that were predicted to be 
canonical PTS1 sequences irrespective of their PWM scores, based on experimental 
validation of each amino acid at each of the three C-terminal positions (Chowdhary et 
al., 2012), were recorded. This allowed the study of only predicted canonical PTS1 
sequences in the context of the pull-down-LC-MS screen. These PTS1 sequences 
were then sorted by PWM score (Reumann et al., 2012). Of these sequences, the 
peptide sequences identified in the pull-down-LC-MS screen were then highlighted in 
green (Figure 54). 
 
Figure 54|  Predicted canonical PTS1 sequences in the full peptide library ranked 
according to their positional weight matrix (PWM) score. Displayed on the x-axis are 
the two C-terminal residues from each pentapeptide sequence. Upstream residues are 
H2N-Y-Q-S- for all peptides. In green are peptides identified in the pull-down-LC-MS 
screen. The PWM threshold value for the pull-down-LC-MS screen was predicted as 
approximately 0.65 (shown on graph). 
The conclusion from analysis shown in Figure 54 was that the PWM score threshold 




YQSRY are likely to be underscored according to PredPlantPTS1 (Skoulding et al., 
2015). This is because the set of plant PTS1 sequences used to train PredPlantPTS1 
did not contain any PTS1s with a C-terminal tyrosine, as this is a relatively new 
discovery in plants (Waller et al., 2010; Skoulding et al., 2015). A PWM score of 0.65 
represents a moderate PTS1 sequence so this appeared to be a good threshold to 
have for finding the orthogonal PEX5*:PTS1* interaction. The screen, therefore, was 
able to identify a range of binding peptides which should be able to act as moderate 
and strong PTS1 sequences. 
3.6 Summary 
A pull-down-LC-MS screen was successfully developed and optimised, and was used 
to identify which peptides from a library were binding to a purified protein. The pull-
down-LC-MS screen was carried out with wild-type AtPEX5-C against the full peptide 
library synthesised in section 3.2.1. This screen correlates with in silico work which is 
based on a number of in vivo and in vitro PEX5:PTS1 studies (Lingner et al., 2011; 
Reumann et al., 2012; Skoulding et al., 2015). It is also a relatively recent discovery 
that the -2 residue in the PTS1 sequence is much more flexible than previously 
thought, with the previous knowledge being that only a basic residue could be 
accepted at this position (Chowdhary et al., 2012). The results from the pull-down-LC-
MS screen developed in this study agree with this finding. At this point it was 
confirmed that the screen was producing reliable results, so the next stage was to use 
the pull-down-LC-MS screen to investigate the peptide-binding properties of a range of 
AtPEX5-C variants. 
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Chapter 4  
Pull-Down-LC-MS Screening of AtPEX5-C Variants, and 
Quantitative Testing and Optimisation of AtPEX5-C* 
Binding to PTS1* 
 
4.1 Introduction 
A selective pull-down-LC-MS screen had been established (Chapter 3) which could be 
used to successfully identify PTS1 sequences when using wild-type AtPEX5-C as the 
target protein. This screen could now be used to aid in the development of an 
orthogonal AtPEX5-C:PTS1 binding pair (termed AtPEX5-C*:PTS1* in this study). 
Using the approach of screening a large library of peptides against a small library of 
protein variants, it could be possible to identify whether any mutations in AtPEX5-C 
lead to a significant enough change in the peptide-binding profile to begin to define the 
AtPEX5-C* protein. 
This chapter will describe the selection and production of various AtPEX5-C protein 
mutants to use as a small protein library, and the screening of these AtPEX5-C 
variants using the developed pull-down-LC-MS screen (Chapter 3). A summary of pull-
down-LC-MS screening results will be presented, and the combination of mutations in 
certain AtPEX5-C variants, to define a preliminary AtPEX5-C*:PTS1* pair, will be 
explained. Also described will be approaches used to further enhance AtPEX5-C* 
binding to the preliminary PTS1* sequence, including the calculation of dissociation 
constants for the interaction, further mutagenesis of the AtPEX5-C* protein, and the 
addition of upstream residues to the preliminary PTS1*. This chapter will conclude with 
the in vivo testing of the optimised binding pair, which was carried out by Dr Rupesh 




4.2 Screening of a small library of AtPEX5-C variants using 
pull-down coupled with LC-MS 
A small library of protein variants was produced by site-directed mutagenesis (Chapter 
2, Figure 23; Chapter 6 (Experimental) section 6.5). Following over-expression, 
proteins were purified using affinity chromatography and buffer-exchanged ready for 
analysis. These protein variants were then tested with the synthesised dansyl-coupled 
peptide library. In the creation of the protein variant library, mutations were targeted to 
the PTS1-binding site of the AtPEX5-C protein (Figure 55). Some protein variants had 
already been produced (Chapter 2, section 2.5), so these were also expressed and 
purified for screening. 
 
Figure 55|  Mutations made in AtPEX5-C for pull-down-LC-MS screening. The mutations 
are grouped according to the change they provided in the binding site, and a plot of predicted 
interactions of some of these protein residues towards a representative PTS1 (YQSKL) is 
shown for review. Residue numbers shown on the interaction plot above are representative of 
A. thaliana PEX5 residue numbers. 
The AtPEX5-C variants (Figure 55) were characterised by mass spectrometry 
(Appendix C) before the peptide-binding preferences were determined by screening 
with the previously developed pull-down-LC-MS method (Chapter 3). Pull-down-LC-
MS screens were performed as previously described (Chapter 3, Figure 51, B). In 
total, 25 protein variants were analysed for their binding properties to the dansyl-




seen. These four classes of behaviour are shown in Figure 56. All other AtPEX5-C 
variant screen results are presented in Appendix E. 
 
Figure 56|  Pull-down-LC-MS screen results for four AtPEX5-C variants, 
representing the four types of binding seen. A) S667A, similar peptide-binding profile 
to wild-type AtPEX5-C. B) D505K, no peptides far above background level pulled down. 
C) F613A, only the strongest PEX5-binding peptides pulled down. D) D505H, binding to 
non-PTS1 peptide sequences seen. Shading represents the area-under-EIC (extracted 
ion chromatogram) for each of the peptides after pull-down-LC-MS. 
The 25 protein variants tested were grouped according to the four main binding 
patterns, and the result of these groupings is shown in Table 10. Group 1 (Figure 56, 
A) contains protein variants that pulled down the same peptides, generally, as wild-
type AtPEX5-C. Group 2 (Figure 56, B) contains protein variants that showed the 
same peptide-binding profile of the ‘peptide only’ control, so showed a background 
intensity of peptide pull-down. Group 3 (Figure 56, C) contains protein variants that 
showed pull-down of only the strongest PTS1 sequences, as defined by 
PredPlantPTS1 (Lingner et al., 2011; Reumann et al., 2012). Group 4 (Figure 56, D) 
contains protein variants that showed pull-down of non-PTS1 sequences, as defined 









intensity of peptides 
pulled down 
3. Only strong 
native PTS1s 
pulled down 
4. Pull-down of 
non-PTS1 
peptides seen 
D505A D505K V533A D505H 
D507A D505K-D507K V533W T536W 
D507K N537A T536N N601A 
T536A N628A N537T  
E538A R659A N537Q  
N601Q N663A F613A  
Y647F  A632G  
S667A  N636A  
Table 10|  Summary of the peptide binding changes seen with each AtPEX5-C 
variant. Proteins are grouped into four categories based on their apparent peptide-
binding profile. 
AtPEX5-C protein variants in group 1 (Table 10) showed a similar peptide-binding 
profile to wild-type AtPEX5-C. After sequence conservation analysis of PEX5 proteins 
across different organisms (Figure 57), it was found that none of the residues targeted 
in group 1, with the exception of Y647, were conserved across species. This 
suggested that these residues were not essential for the function of the protein, and so 
it was not particularly surprising that change was tolerated at each of these positions. 
AtPEX5-C protein variants in group 2 (Table 10) showed a very low level of peptide 
pull down, in a similar way to the peptide-only background control screen. Residues 
N537, N628, R659, and N663 show complete conservation across species (Figure 
57). Residues D505 and D507 exhibit conservation of a negative charge, as only 
acidic residues are found in these positions. This could explain why peptide binding is 
abolished with mutation of residues 537, 628, 659, and 663 to alanine, whereas 
peptide binding is only abolished with mutation of residues 505 and 507 from an acidic 
to a basic residue. 
Interestingly, AtPEX5-C protein variants in group 3 (Table 10) showed pull-down of 
only the strongest PTS1 sequences, largely dansyl-YQSKL and dansyl-YQSRL. 
Changes made in the group 3 AtPEX5-C variants, with the exception of N636A, are 
related to size and not property changes, so the maintenance of some PTS1 peptide 




PTS1 binding. This was seen by Fodor and colleagues, as mutation of C-terminal 
PTS1 residues of the protein AGT to smaller residues led to compensatory compaction 
of the PTS1-binding site, as confirmed by crystal structures (Fodor et al., 2015). 
 
Figure 57|  Sequence conservation analysis of the highlighted residues by 
alignment of PEX5 proteins. Highlighted in yellow are matching residues, highlighted in 
green are residues with similar properties, and highlighted in cyan are residues with 
differing properties. Alignments were performed using BioEdit (sequence alignment 
editor). Organisms are colour-coded based on kingdom: green text, Plantae; blue text, 
Excavata; pink text, Animalia; orange text, Fungi. Numbers above the alignments 




Excitingly, three AtPEX5-C variants (D505H, T536W, and N601A) all pulled down non-
PTS1 sequences (Table 10, group 4). D505H pulled down dansyl-YQSFY and 
dansyl-YQSYY, and T536W pulled down dansyl-YQSKA and dansyl-YQSRA. The two 
residues were also reasoned to be far enough away from one another in the binding 
site that mutation of one should not have an adverse effect on the other. Wild-type 
AtPEX5-C did not pull down dansyl-YQSFY, dansyl-YQSYY, dansyl-YQSKA, or 
dansyl-YQSRA. In an effort to enhance the pull-down of these non-PTS1 sequences, 
the mutations D505H and T536W were combined, resulting in the protein variant 
D505H-T536W. Pull-down-LC-MS screen results from D505H, T536W, and D505H-
T536W are shown in Figure 58. 
 
Figure 58|  Pull-down-LC-MS screen results for three AtPEX5-C variants, two 
single variants (D505H and T536W) and a variant combining the two mutations. A) 
D505H, non-PTS1 peptide sequences dansyl-YQSFY and dansyl-YQSYY are pulled 
down. B) T536W, non-PTS1 peptide sequences dansyl-YQSKA and dansyl-YQSRA are 
pulled down. C) D505H-T536W, similar peptide-binding profile to wild-type AtPEX5-C. 
Shading represents the area-under-EIC (extracted ion chromatogram) for each of the 




The combination of mutations D505H and T536W did not enhance the pull-down of 
peptides with a C-terminal alanine, as was hoped for (Figure 58, C). D505H and 
N601A both showed pull-down of the sequences dansyl-YQSFY and dansyl-YQSYY, 
which was not seen for wild-type AtPEX5-C. As both D505H and N601A pulled down 
the same non-PTS1 sequences, the two mutations in the protein were combined to 
create D505H-N601A in the hope that pull-down of dansyl-YQSFY and dansyl-YQSYY 
would be enhanced. Pull-down-LC-MS screen results from D505H, N601A, and 
D505H-N601A are shown in Figure 59. 
 
Figure 59|  Pull-down-LC-MS screen results for three AtPEX5-C variants, two 
single mutants (D505H and N601A) and a variant combining the two mutations. A) 
D505H, non-PTS1 peptide sequences dansyl-YQSFY and dansyl-YQSYY are pulled 
down. B) N601A, the same non-PTS1 peptide sequences dansyl-YQSFY and dansyl-
YQSYY are pulled down. C) D505H-N601A, non-PTS1 peptide sequences dansyl-
YQSFY and dansyl-YQSYY appear to be pulled down more strongly than with either of 
the single variant AtPEX5-C proteins. Shading represents the area-under-EIC (extracted 
ion chromatogram) for each of the peptides after pull-down-LC-MS. Peptides of interest 
are highlighted by square outlines. 
The combination of mutations D505H and N601A did appear to enhance the pull-down 




subsequently produced, from the I-TASSER-predicted model of AtPEX5-C (Chapter 1, 
Figure 9) with the peptide from crystal structure 1FCH (Gatto et al., 2000) in its PTS1-
binding site. The structural homology model was produced in an attempt to rationalise 
the observation that the double variant D505H-N601A exhibited enhanced pull-down 
of aromatic peptides. Results of pull-down-LC-MS screens for wild-type AtPEX5-C and 
for AtPEX5-C D505H-N601A are shown in Figure 60, along with structural modelling 
of the interactions that were predicted to occur. 
 
Figure 60|  Structural models and pull-down-LC-MS screen results for wild-type 
AtPEX5-C and an AtPEX5-C variant with mutations combined (D505H-N601A) as a 
result of the initial screening. A1) Structural model of YQSKL (1FCH) bound to wild-
type AtPEX5-C. A2) Pull-down-LC-MS screen result for wild-type AtPEX5-C. Dansyl-
YQSFY and dansyl-YQSYY are not pulled down. B1) Structural model of YQSFY bound 
to AtPEX5-C D505H-N601A. B2) Pull-down-LC-MS screen result for D505H-N601A. 
Dansyl-YQSFY and dansyl-YQSYY are pulled down. (Zhang, 2008; Roy et al., 2010; 
Yang et al., 2015; Yang and Zhang, 2015 (I-TASSER)) (Gatto et al., 2000 (1FCH 
peptide)). Shading represents the area-under-EIC (extracted ion chromatogram) for each 
of the peptides after pull-down-LC-MS. Peptides of interest are highlighted by square 
outlines. 
It appeared that the interactions alluded to in the pull-down screen were theoretically 
possible, as predicted through structural modelling (Figure 60). The D505H mutation, 




could allow π-stacking to occur with an aromatic residue at position -2 of the binding 
peptide. The N601A mutation, through enlargement of the PTS1-binding pocket of 
AtPEX5-C, could allow a larger hydrophobic residue such as tyrosine to be 
accommodated at the C-terminus of the binding peptide. 
It had been established throughout this study that an AtPEX5-C variant with a double 
mutation, D505H-N601A, displayed apparent enhanced binding to peptide sequences 
dansyl-YQSFY and dansyl-YQSYY. The next stage was to validate the results 
obtained by pull-down-LC-MS, using fluorescence anisotropy, and to attempt further 
optimise the binding of AtPEX5-C D505H-N601A to YQSFY and YQSYY. We also now 
had a pull-down-LC-MS screen at our disposal to further optimise binding. 
4.3 Quantitative binding analysis using fluorescence 
anisotropy to assess the reliability of results obtained by 
pull-down-LC-MS screening 
Increased binding to two aromatic peptides, dansyl-YQSFY and dansyl-YQSYY, had 
been found when mutations D505H and N601A were applied to AtPEX5-C (section 
4.2). In order to test whether this binding was genuine, YQSFY and YQSYY were 
synthesised with an N-terminal lissamine tag, as was performed for previous peptides 
(Chapter 2, section 2.3; Chapter 6 (Experimental) section 6.13.4). Characterisation of 
these peptides is shown in Chapter 6 (Experimental) section 6.18. It was then possible 
to carry out fluorescence anisotropy with the AtPEX5-C variants D505H, N601A, and 
D505H-N601A along with peptides synthesised, in order to compare binding properties 
of these proteins with wild-type AtPEX5-C. 
Fluorescence anisotropy carried out with lissamine-YQSFY revealed that this peptide 
appeared to show some level of self-association (high anisotropy values at low protein 
concentration; data not shown), which made the calculation of dissociation constant 
(Kd) problematic, and which could present issues within an in vivo import system. For 
these reasons, the peptide YQSFY was abandoned as a candidate PTS1* sequence 






Figure 61|  Fluorescence anisotropy results, assessing the binding of lissamine-
YQSKL and lissamine-YQSYY (peptides fixed at 100 nM final concentration) to 
wild-type AtPEX5-C, and to three variants of AtPEX5-C (concentration of proteins: 
0–13.3 μM final concentration). A) wild-type AtPEX5-C with lissamine-YQSKL and 
lissamine-YQSYY. B) AtPEX5-C D505H with lissamine-YQSKL and lissamine-YQSYY. 
C) AtPEX5-C N601A with lissamine-YQSKL and lissamine-YQSYY. D) AtPEX5-C 
D505H-N601A with lissamine-YQSKL and lissamine-YQSYY. A quadratic equation was 
used to fit the curves using OriginPro 9.1, assuming a one-to-one model of binding. 
The results from the quantitative binding assays (Figure 61) correlated well with the 
pull down-LC-MS screen results for variant AtPEX5-C proteins D505H, N601A, and 
D505H-N601A. The combination of AtPEX5-C mutations that had previously resulted 
in enhancement of YQSYY binding as seen in the pull-down-LC-MS screen, did 
genuinely enhance this binding property. Dissociation constants determined from the 
fluorescence anisotropy experiments, performed to validate the results of the pull-












Lissamine-YQSKL 1.1 0.6 
Lissamine-YQSYY 2700 200 
D505H 
Lissamine-YQSKL 30 7.0 
Lissamine-YQSYY 960 80 
N601A 
Lissamine-YQSKL 22 8 
Lissamine-YQSYY 2300 400 
D505H-N601A 
Lissamine-YQSKL 108 15 
Lissamine-YQSYY 603 70 
Table 11|  Dissociation constants (determined using fluorescence anisotropy) for 
wild-type AtPEX5-C and for variants of interest, when tested with lissamine-
YQSKL and lissamine-YQSYY. Differences in binding affinities between lissamine-
YQSKL and lissamine-YQSYY (the increase seen for lissamine-YQSKL binding over 
lissamine-YQSYY binding): wild-type AtPEX5-C ≈ 2454-fold, AtPEX5-C D505H ≈ 32-fold, 
AtPEX5-C N601A ≈ 105-fold, AtPEX5-C D505H-N601A ≈ 5.6-fold. 
Binding of AtPEX5-C to YQSYY, when compared to YQSKL, had been significantly 
improved through mutation of two residues in the PTS1-binding site, and this had been 
found using the pull-down-LC-MS screen developed in this study. When tested 
quantitatively by fluorescence anisotropy, a ~2454-fold difference in binding affinities 
had been successfully reduced to a ~5.6-fold difference in binding affinity between 
lissamine-YQSKL and lissamine-YQSYY, by mutation of the two residues in the PTS1-
binding site (D505 and N601). The pull-down-LC-MS screen developed in this study 
had successfully aided in the finding and enhancement of a non-natural interaction, 
and the use of this screen as a method of finding new interactions had now been 
validated through the finding that the AtPEX5-C variant D505H-N601A did bind to 
YQSYY much more strongly than wild-type AtPEX5-C bound to this peptide. 
Unfortunately, the AtPEX5-C variant D505H-N601A was still binding to lissamine-
YQSKL with greater affinity than lissamine-YQSYY. To overcome this problem, the 
approach decided upon was to further mutate the protein, using information about 





4.4 Further mutation of the preliminary AtPEX5-C* and 
subsequent analysis of peptide binding 
It had been possible, through pull-down-LC-MS with a small protein library and 
subsequent combination of mutations of interest, to decrease binding affinity to 
lissamine-YQSKL by ~98-fold while increasing the binding affinity to lissamine-YQSYY 
by ~4.5-fold, relative to wild-type AtPEX5-C. This alteration of binding affinities still 
resulted in a variant of AtPEX5-C that bound to lissamine-YQSKL with a ~5.6-fold 
stronger affinity than it bound to the non-natural PTS1 peptide lissamine-YQSYY. 
Further mutation of AtPEX5-C was required, in an attempt to close this gap in binding 
affinities. 
It was reasoned that the histidine at position 505, in the AtPEX5-C variant D505H-
N601A, was allowing possible ring interactions to occur with an aromatic side chain of 
the binding peptide. It could therefore be possible that phenylalanine would work more 
favourably in position 505. For this reason, AtPEX5-C D505F-N601A was produced. 
After performing the pull-down-LC-MS screening (section 4.2), it had been possible to 
deduce that certain residues were non-essential for the peptide binding of the PTS1-
pocket of AtPEX5-C as PTS1 binding still occurred after mutation of these residues. 
One of these residues, D507, is in close proximity to D505, and mutation of D507 to 
alanine had little effect on peptide binding profile (section 4.2, and Appendix E). This 
meant that the side chain of D507 was not essential for peptide binding and so it could 
be altered. The favourable position of residue 507, in close proximity to residue 505, 
also made this amino acid an obvious choice for mutation with aromatic residues. It 
was therefore decided to produce the AtPEX5-C variants D505H-D507H-N601A, and 
D505F-D507F-N601A. 
The three AtPEX5-C variants (D505F-N601A, D505H-D507H-N601A, and D505F-
D507F-N601A) were expressed, purified using cobalt affinity chromatography, and 
buffer-exchanged for analysis. Mass spectrometry was carried out for characterisation 
of proteins (Appendix C). The AtPEX5-C variants were then screened using pull-down-
LC-MS (Figure 62), and quantitative binding data were obtained after testing with 





Figure 62|  Pull-down-LC-MS screen results for three new variants of AtPEX5-C, 
compared to that of wild-type AtPEX5-C. A) Wild-type AtPEX5-C. B) D505F-N601A, 
minimal evidence of peptide pull-down is observed and peptides identified are seen in 
wild-type AtPEX5-C pull-down-LC-MS. C) D505H-D507H-N601A, the peptide-binding 
profile appears to be changed from that of wild-type AtPEX5-C. D) D505F-D507F-
N601A, minimal evidence of any peptide pull-down is observed. Shading represents the 
area-under-EIC (extracted ion chromatogram) for each of the peptides after pull-down-
LC-MS. 
It is apparent from Figure 62 that the peptide-binding profile of AtPEX5-C is 
significantly altered as a result of the mutations made. The AtPEX5-C variant of 
interest as a result of these screens appeared to be AtPEX5-C D505H-D507H-N601A. 
Where residues have been substituted with phenylalanine, the resulting peptide-
binding profile is very similar to that of a background intensity of peptides pulled down 






Figure 63|  Fluorescence anisotropy results after rational mutation of AtPEX5-C, 
assessing the binding of lissamine-YQSKL and lissamine-YQSYY (peptides fixed 
at 100 nM final concentration) to wild-type AtPEX5-C, and to three variants of 
AtPEX5-C (concentration of proteins: 0–13.3 μM final concentration). A) wild-type 
AtPEX5-C with lissamine-YQSKL and lissamine-YQSYY. B) AtPEX5-C D505F-N601A 
with lissamine-YQSKL and lissamine-YQSYY. C) AtPEX5-C D505H-D507H-N601A with 
lissamine-YQSKL and lissamine-YQSYY. D) AtPEX5-C D505F-D507F-N601A with 
lissamine-YQSKL and lissamine-YQSYY. A quadratic equation was used to fit the curves 
using OriginPro 9.1, assuming a one-to-one model of binding. 
Mutation of D507 did result in a change in peptide binding profile of AtPEX5-C. For the 
AtPEX5-C variants D505F-N601A and D505H-D507H-N601A, lissamine-YQSKL 
binding and lissamine-YQSYY binding appear to be almost identical in affinity. For the 
AtPEX5-C variant D505F-D507F-N601A, the binding affinity for lissamine-YQSYY is 
stronger than that for YQSKL; however, the binding affinities are very weak. For all of 
these variants, their binding affinity to lissamine-YQSYY is weaker than the binding 
affinity of YQSKV to wild-type AtPEX5-C, which has previously been shown not to 
import into moss peroxisomes in vivo (Chapter 2, Figure 20 (R. Paudyal)). Even for 
the variant with the strongest binding affinities to lissamine-YQSKL and lissamine-
YQSYY (D505H-D507H-N601A), these binding affinities are 1400 ± 100 nM for 




affinity of lissamine-YQSKV to wild-type AtPEX5-C was stronger than both of these at 
1300 ± 100 nM. 
One possibility was that a histidine or phenylalanine at position 507 of AtPEX5-C 
increased steric bulk and partially hindered the binding of any peptides. Valine and 
threonine were therefore trialled in position 507 to analyse whether this would change 
the peptide binding profile in the desired way, without reducing overall binding affinity 
beyond the approximate level needed for peroxisomal protein import. The resulting 
AtPEX5-C variants decided upon were D505H-D507V-N601A and D505H-D507T-
N601A. These proteins were expressed, purified, buffer-exchanged, and characterised 
by mass spectrometry (Appendix C) before analysis. The results of pull-down-LC-MS 






Figure 64|  Pull-down-LC-MS results and fluorescence anisotropy data (100 nM 
fixed peptide final concentration, with concentration of proteins ranging from 0 to 
13.3 μM final concentration) for two new AtPEX5-C variants. A1) D505H-D507V-
N601A pull-down-LC-MS. B1) D505H-D507T-N601A pull-down-LC-MS, showing strong 
pull-down of dansyl-YQSYY. Shading represents the area-under-EIC (extracted ion 
chromatogram) for each of the peptides after pull-down-LC-MS. A2) D505H-D507V-
N601A fluorescence anisotropy with lissamine-YQSKL and lissamine-YQSYY. B2) 
D505H-D507T-N601A fluorescence anisotropy with lissamine-YQSKL and lissamine-
YQSYY. A quadratic equation was used to fit the curves, assuming a one-to-one model 
of binding. 
Of the two new AtPEX5-C variants (Figure 64), D505H-D507T-N601A appeared to 
have the optimal peptide binding profile for this study as binding affinities were similar 
with both lissamine-YQSKL and lissamine-YQSYY. This meant that AtPEX5-C D505H-
D507T-N601A may allow the import of the non-PTS1 sequence YQSYY, albeit with 
continued import of very strong PTS1 sequences. A strategy was in place for the 
improving of the strength of the current preliminary PTS1* sequence YQSYY, using 
upstream residues (section 4.5), so AtPEX5-C D505H-D507T-N601A was termed 
AtPEX5-C* from this point onwards. 
The resulting mutations which had been made in AtPEX5-C* are shown on a structural 




of the residues and the corresponding surface. Circular dichroism, for comparison with 
wild-type AtPEX5-C, and the mass spectrum with deconvoluted mass data of the 
AtPEX5-C* protein are also shown in Figure 65. 
 
Figure 65|  Structural models of wild-type AtPEX5-C in complex with YQSKL 
(1FCH) (A) and AtPEX5-C* in complex with YQSYY (B), circular dichroism of wild-
type AtPEX5-C overlaid with that of AtPEX5-C* (C), and mass spectrum with 
deconvoluted mass data (inset) for AtPEX5-C* (D). For structural models (A) and (B), 
residues coloured red = acidic, those coloured blue = basic, those coloured cyan = polar, 
and those coloured orange = hydrophobic. (Zhang, 2008; Roy et al., 2010; Yang et al., 
2015; Yang and Zhang, 2015 (I-TASSER)) (Gatto et al., 2000 (1FCH peptide)). C) 
AtPEX5-C* (D505H-D507T-N601A) has a similar circular dichroism trace and, therefore, 
secondary structure to wild-type AtPEX5-C. D) Expected mass for AtPEX5-C* (D505H-




It was clear, from Figure 65, C, that the mutations applied to create AtPEX5-C* had 
not given rise to misfolding of the protein at a secondary structure level. Both circular 
dichroism traces, that of wild-type AtPEX5-C and of AtPEX5-C*, displayed troughs at 
208 nm and 222 nm which showed that both proteins adopt an α-helical structure. 
Dissociation constants (Kd values), determined by fluorescence anisotropy for wild-
type AtPEX5-C, AtPEX5-C D505H-N601A, and AtPEX5-C* (D505H-D507T-N601A) 
are shown in Table 12 to highlight the gradual improvement seen in relative binding 
affinities of the protein for lissamine-YQSKL and lissamine-YQSYY through mutation 









Lissamine-YQSKL 1.1 0.6 
Lissamine-YQSYY 2700 200 
D505H-N601A 
Lissamine-YQSKL 108 15 
Lissamine-YQSYY 603 70 
D505H-D507T-
N601A 
Lissamine-YQSKL 97 20 
Lissamine-YQSYY 110 50 
Table 12|  Dissociation constants (determined using fluorescence anisotropy) for 
wild-type AtPEX5-C and for new variants of interest, when tested with lissamine-
YQSKL and lissamine-YQSYY. Differences in binding affinities between lissamine-
YQSKL and lissamine-YQSYY (the increase seen for lissamine-YQSKL binding over 
lissamine-YQSYY binding): wild-type AtPEX5-C ≈ 2454-fold, AtPEX5-C D505H-N601A ≈ 
5.6-fold, AtPEX5-C D505H-D507T-N601A ≈ 1.1-fold. 
Dissociation constants (Table 12) confirm that a semi-rational approach had been 
successful in improving the binding affinity of AtPEX5-C for lissamine-YQSYY by ~25-
fold and in decreasing its binding affinity for lissamine-YQSKL by ~88-fold. The 
resulting AtPEX5-C variant (termed AtPEX5-C*) showed a binding affinity for 
lissamine-YQSKL only ~1.1-fold higher than its binding affinity for lissamine-YQSYY. 
The next stage of the research was to test these proteins with longer candidate PTS1* 
peptides, to attempt to strengthen the binding affinity of AtPEX5-C* for the preliminary 
PTS1* (YQSYY) by ensuring that a suitable upstream peptide sequence was 




4.5 The addition of upstream residues to the preliminary 
PTS1* with the aim of altering binding affinity 
It is becoming increasingly apparent that the PTS1 sequence can no longer be defined 
as a simple tripeptide (Mullen et al., 1997; Brocard and Hartig, 2006; Lingner et al., 
2011; Chowdhary et al., 2012). The PTS1 has most recently been re-defined as a 14-
amino acid C-terminal sequence, with each of these residues affecting the affinity of 
the overall sequence for the PTS1-binding site of PEX5 (Reumann et al., 2012). Up to 
this point, the PTS1 sequences being studied were pentapeptides; however, upstream 
residues had to be considered as these could have a significant effect on the binding 
affinity (Brocard and Hartig, 2006; Reumann et al., 2012; Chowdhary et al., 2012). The 
PWM scoring matrix, which can be used to assign a plant peroxisomal import 
prediction score to a peptide (PredPlantPTS1 (Lingner et al., 2011; Reumann et al., 
2012)), was used to predict a range of sequences that could be added upstream of the 
sequence YQSYY in order to potentially improve binding affinity to AtPEX5-C*. 
The PWM scoring matrix is shown in Figure 66 to illustrate how a total PWM score of 
a peptide is calculated. In this example, a route though the matrix is illustrated in 
Figure 66 to show the PWM score of an example 14-aa peptide sequence, with the 
pentapeptide YQSYY at the C-terminus. To highlight the importance of upstream 
residues in the ability of a sequence to target proteins to the peroxisome, Figure 66 
shows how a short peptide sequence defined as a non-PTS1 (YQSYY) can be 
transformed into a sequence defined as a PTS1, as determined by its PWM score, 





Figure 66|  The PWM scoring matrix (Reumann et al., 2012; Skoulding et al., 2015, 
supplementary information), with a route through the matrix shown for the 
calculation of the PWM score of the peptide WWRDPYSPMYQSYY. The PWM score 
of a peptide is calculated by the sum of all numbers assigned to the individual residues 
occurring at each position in the peptide. In this example, the addition of the nine 
residues, shown in blue, to YQSYY (shown in green) means that 0.47 is added to the 
total PWM score. This redefines the sequence from a non-PTS1 sequence to a PTS1 
sequence, as determined by PredPlantPTS1 (Lingner et al., 2011; Reumann et al., 
2012). 
In the example shown in Figure 66, YQSYY has a PWM score of 0.07, whereas 
WWRDPYSPMYQSYY has a PWM score of 0.54. The peroxisomal import threshold, 
as defined by the Reumann research group and by Skoulding and colleagues, is 0.15–
0.412 (PredPlantPTS1) (Reumann et al., 2012; Skoulding et al., 2015). A C-terminal 
tyrosine is also likely to be underweighted in the PWM scoring matrix (discussed in 
Chapter 3, section 3.5) so the real PTS1 prediction score of WWRDPYSPMYQSYY 
could potentially be higher than 0.54. As a result of the addition of particular upstream 
residues to YQSYY, the total sequence score is pushed above the threshold for 
peroxisomal protein import. This illustrates the importance of upstream residues for the 
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Total PWM score of YQSYY = 0.07




peroxisomal targeting ability of a PTS1 sequence. It was reasoned that the YQSYY 
sequence could be enhanced as a stronger importing sequence if the appropriate 
upstream residues were added, and that the resulting sequence may be able to out-
compete many of the natural PTS1 sequences for binding to AtPEX5-C*. 
The eventual application of the orthogonal PEX5*:PTS1* import system was in P. 
patens (Physcomitrella patens; moss) cells, so it was important to know the types of 
PTS1 sequence commonly seen in this organism. A visiting postdoctoral researcher, 
Dr Heba Ebeed, conducted a study of P. patens homologues to PTS1 proteins from A. 
thaliana (Arabidopsis thaliana; thale cress). PTS1 proteins from A. thaliana had been 
studied much more extensively than those from P. patens, and they were the basis of 
the creation of the PredPlantPTS1 prediction software (Lingner et al., 2011; Reumann 
et al., 2012). H. Ebeed collated all major, minor and rare PTS1 sequences from A. 
thaliana using AraPerox (Reumann et al., 2004) and produced a record of P. patens 
homologues to each of these A. thaliana PTS1 proteins (Appendix F). The 14 C-
terminal residues from each P. patens homologue were also included in the database 
produced by H. Ebeed. These C-terminal sequences were used as the predicted P. 
patens PTS1 sequences in this study. 
H. Ebeed’s results, showing P. patens homologues for A. thaliana PTS1 proteins, were 
used to investigate what the ‘competition’ would be for the orthogonal sequence in the 
P. patens cell. The resulting P. patens predicted PTS1 sequences were ordered 
according to their PWM score (PredPlantPTS1) (Lingner et al., 2011; Reumann et al., 
2012). The highest scoring sequence was termed ‘MossHigh’, as this was the 
predicted strongest competing PTS1 sequence in moss cells. ‘MossHigh’ comes from 
the 14 C-terminal residues of an oxidoreductase in moss. The lowest scoring 
sequence was termed ‘MossLow’; however, ‘MossLow’ is the homologue of a rare 
PTS1 protein in A. thaliana and comes from the 14 C-terminal residues of a 
phosphatase in moss. Therefore, it was not known whether the MossLow sequence 
would act as the lower boundary of moss PTS1 sequences, or as a non-PTS1 control 
in vivo. The PWM score of MossHigh was 1.39 and that of MossLow was 0.41 (Table 
13). 
Six candidate PTS1* sequences were designed (PTS1*a-f), all terminating in YQSYY-
CO2H, with differing upstream residues (Table 13). This provided a range of PTS1* 
sequences that could be tested in vivo in order to identify the optimal sequence that 




sequences were designed using Excel and VBA (code written by Dr Stuart Warriner) 
to create a ‘PWM optimiser’ worksheet which would generate a range of upstream 
sequences to fit a target overall PWM score. 
Peptide name Peptide sequence PWM score 
MossHigh SHIQTEAERLYSKL 1.39 
MossLow IIAAVDASYNSSTL 0.41 
PTS1*a WIAGDNSQHYQSYY -0.2 
PTS1*b WHGAAESKFYQSYY 0 
PTS1*c WHWQVHSEIYQSYY 0.16 
PTS1*d WWATVHSQRYQSYY 0.28 
PTS1*e WWWDVHQHRYQSYY 0.4 
PTS1*f WWRDPYSPMYQSYY 0.54 
YQSKL YQSKL 1.45 
YQSYY YQSYY 0.07 
Table 13|  Peptides chosen for in vivo testing, along with sequences and 
positional weight matrix (PWM) scores for each peptide. PWM scores were assigned 
using the PWM determined for PredPlantPTS1 (Lingner et al., 2011; Reumann et al., 
2012). 
The MossHigh and MossLow sequences were synthesised and coupled to lissamine in 
order to test the binding affinity of these sequences with wild-type AtPEX5-C, and with 
AtPEX5-C D505H-D507T-N601A (AtPEX5-C*). PTS1*a and PTS1*f were also 
synthesised and coupled to lissamine to test the predicted strongest and weakest 
PTS1* sequences. Characterisation of these four lissamine-labelled peptides can be 
seen in Chapter 6 (Experimental) section 6.18.14 (lissamine-MossHigh), 6.18.15 
(lissamine-MossLow), 6.18.16 (lissamine-PTS1*a), and 6.18.17 (lissamine-PTS1*f). 
It was predicted that the peptide sequences would rank in order of PWM score in their 
affinities for wild-type AtPEX5-C; however, it was not known what would happen when 
these sequences were tested with AtPEX5-C*. In addition, it was unclear if the very 
strong upstream residues in PTS1*f would lead to increased binding affinity of YQSYY 
to wild-type AtPEX5-C. Fluorescence anisotropy results for wild-type AtPEX5-C and 
AtPEX5-C*, with the lissamine-labelled peptides MossHigh, MossLow, PTS1*a, and 





Figure 67|  Fluorescence anisotropy testing with 14-aa peptides representing the 
strongest and weakest PTS1 sequences in moss, and peptide sequence YQSYY 
with two different upstream sequences. Peptide concentration was fixed at 100 nM 
final concentration, and proteins were titrated from 0 to 13.3 μM (final concentration). A) 
Wild-type AtPEX5-C. B) AtPEX5-C D505H-D507T-N601A (AtPEX5-C*). MossHigh, the 
strongest (predicted) PTS1 sequence in Physcomitrella patens (P. patens); MossLow, 
the weakest (predicted) PTS1 sequence in P. patens; PTS1*a, peptide YQSYY with a 
weak upstream sequence; PTS1*f, peptide YQSYY with the strongest possible upstream 
sequence for peroxisomal targeting. A quadratic equation was used to fit the curves 
using OriginPro 9.1, assuming a one-to-one model of binding. 
It is apparent from Figure 67 that the fluorescence anisotropy results obtained were 
not as expected for lissamine-PTS1*a, lissamine-PTS1*f, or lissamine-MossLow, 
considering the PWM scores of the peptides tested. Lissamine-MossHigh did behave 
as expected, with a dissociation constant similar to lissamine-YQSKL; however, 
lissamine-MossLow exhibited an extremely low binding affinity for proteins tested, with 




exhibited a weaker binding affinity than expected as, with a PWM score of 0.54, it was 
predicted that the binding affinity of this peptide with wild-type AtPEX5-C would be 
stronger than the predicted import threshold (Maynard and Berg, 2007; Reumann et 
al., 2012; Skoulding et al., 2015): the dissociation constant of wild-type 
AtPEX5-C:lissamine-PTS1*f was predicted to be lower than that of wild-type 
AtPEX5-C:lissamine-YQSKV (1300 ± 100 nM) (Chapter 2, section 2.4). This could, 
however, be beneficial as the chances of peroxisomal import of PTS1*f with wild-type 
PEX5 could be much lower than predicted. As PTS1*f does not have as strong an 
affinity with wild-type AtPEX5-C as the PWM score predicts, it may have weak enough 
targeting efficiency to have no interference with the natural import system in vivo. 














Lissamine-MossHigh 0.7 1.4 1.39 
Lissamine-MossLow 58,000 4000 0.41 
Lissamine-PTS1*a 5900 700 -0.2 
Lissamine-PTS1*f 4300 1800 0.54 
D505H-
D507T-N601A 
Lissamine-MossHigh 150 30 N/D 
Lissamine-MossLow 22,000 1000 N/D 
Lissamine-PTS1*a 400 50 N/D 
Lissamine-PTS1*f 300 100 N/D 
Table 14|  Binding affinities of the 14-aa peptides MossHigh, MossLow, PTS1*a, 
and PTS1*f, as determined by fluorescence anisotropy. PWM scores, showing the 
predicted likelihood of the peptide sequence directing the peroxisomal import of a protein 
via the PTS1-mediated import pathway, are also shown for comparison. 
Following the testing of 14-aa peptides MossHigh, MossLow, PTS1*a, and PTS1*f by 
fluorescence anisotropy, it was decided that all peptide sequences (MossHigh, 




4.6 In vivo testing of PhypaPEX5-N–AtPEX5-C and 
PhypaPEX5-N–AtPEX5-C* with PTS1 and PTS1* 
Testing of the AtPEX5-C*:PTS1* pair in vivo was carried out by R. Paudyal 
(postdoctoral researcher in the A. Cuming laboratory, University of Leeds) and 
characterisation of results was enabled by S. Warriner. DNA of wild-type AtPEX5-C 
and AtPEX5-C* in separate pET-28b vectors was given to R. Paudyal for insertion of 
this (the C-terminus of the A. thaliana PEX5 receptor) downstream of the N-terminus 
of the P. patens PEX5 receptor. The resulting vector contained a hybrid receptor 
(PhypaPEX5-N–AtPEX5-C or PhypaPEX5-N–AtPEX5-C*). PTS1* peptide sequences 
were also sent to R. Paudyal so that primers could be designed for the insertion of 
each of these sequences just downstream of green fluorescent protein (GFP) (at the 
C-terminus) (Figure 68). R. Paudyal also inserted the MossHigh or MossLow 
sequences in the same way, just downstream of red fluorescent protein (RFP) (at the 
C-terminus) (Figure 68). Results in this section (4.6) are reported for completeness of 
the study. 
It was decided that the peroxisomal import of the PTS1* sequences would be tested 
alongside the MossHigh or MossLow sequences, to  simulate the real competition that 
the orthogonal system would be subject to in vivo. In order to achieve this, the gene 
coding for either the PhypaPEX5-N–AtPEX5-C  or the PhypaPEX5-N–AtPEX5-C* 
receptor was inserted in a vector which also carried the gene coding for RFP-
MossHigh or RFP-MossLow, under the control of a separate promoter (the receptor 
was under the control of an actin promoter, and RFP-MossHigh/MossLow was under 
the control of a double 35S promoter). The gene coding for either GFP-PTS1*a, GFP-
PTS1*b, GFP-PTS1*c, GFP-PTS1*d, GFP-PTS1*e, or GFP-PTS1*f was inserted into 
a separate vector (under the control of a double 35S promoter). Particle bombardment 
was then used to introduce the DNA into cells, 38–48 h prior to imaging. 
The set-up of the experiment, along with a cartoon of idealised results, is illustrated in 
Figure 68. The expectation, if the interaction had been designed correctly, was that 
peroxisomes would fluoresce red and the cytosol would fluoresce green in the wild-
type import system. In the mutated import system, the expectation was that 
peroxisomes would fluoresce green and the cytosol would fluoresce red, although 
some level of red peroxisomal fluorescence was expected due to the presence of 




targeted to the peroxisome fully, peroxisomes should appear to fluoresce yellow after 
merging the red and green channels after imaging. 
 
Figure 68|  The in vivo targeting concept. Particle bombardment can be used to 
introduce DNA into cells. Imaging is than carried out 38–48 h after particle 
bombardment. In the wild-type import system, we expect peroxisomes to fluoresce red 
and the cytosol to fluoresce green. In the mutated import system we expect peroxisomes 
to fluoresce green and the cytosol to fluoresce red. If both RFP-PTS1 
(MossHigh/MossLow) and GFP-PTS1* (PTS1*a-f) are imported, we expect to observe 
yellow-fluorescing peroxisomes as this shows co-localisation of the two fluorescent 
proteins. MossHigh and MossLow represent the potential strongest and weakest 
predicted PTS1 sequences in Physcomitrella patens (P. patens). PTS1, peroxisomal 
targeting signal 1; PTS1*, mutated peroxisomal targeting signal 1; RFP, red fluorescent 
protein; GFP, green fluorescent protein. 
Particle bombardment of the vectors, to induce transient expression within the moss 
cells, was carried out and images captured after 38–48 h. As an initial control 
experiment, the vector containing the hybrid PhypaPEX5-N–AtPEX5-C receptor and 
RFP-MossHigh was introduced into moss cells by bombardment, without the 
introduction of the GFP-PTS1*a-f vector. This was to test whether the hybrid receptor 
would import RFP, albeit against a background of endogenous levels of PhypaPEX5 
expression. In this experiment, we expected to see red fluorescing peroxisomes 
against a background of no other fluorescence. Results from this initial test are shown 





Figure 69|  Imaging of a P. patens cell, 38–48 h after particle bombardment with a 
vector containing the PhypaPEX5-N–AtPEX5-C receptor and RFP-MossHigh. Image 
courtesy of Rupesh Paudyal. 
Peroxisomes are apparent in Figure 69 by the presence of small bright ‘dots’ in the P. 
patens cell when imaging was carried out by R. Paudyal in the RFP channel. It is clear 
from Figure 69 that import of RFP-MossHigh into peroxisomes is functional under the 
experimental conditions used, so the study could continue. PTS1*c was not 
successfully inserted into the GFP vector by R. Paudyal, at the C-terminus of GFP (so 
this is not present in the following results). 
To test the import system with a more representative PTS1 sequence, a P. patens 
homologue of another example PTS1 sequence with a lower PWM score (1.01) than 
MossHigh (1.39) was determined from H. Ebeed’s work (GETIVVAGGMKSRL). This 
sequence was termed ‘MossMid’ and was sent to R. Paudyal for cloning into the 
RFP/receptor plasmid, at the C-terminus of RFP. MossMid was still a strong 
representative PTS1 sequence, as the average PWM score for a Physcomitrella 
patens PTS1 corresponding to a ‘major’ Arabidopsis thaliana PTS1 is 0.880 (median = 
0.890). (from H. Ebeed’s work). 
Following particle bombardment for the full experiment with a range of PTS1* 
sequences, 7,997 images were captured by R. Paudyal 38–48 h after bombardment 
and these were classified into one of 7 categories (-1 = unsure which cell to classify; 0 
= no fluorescence; 1 = cytosolic; 2 = >75% cytosolic; 3 = mixed; 4 = >75% 
peroxisomal; 5 = peroxisomal) independently by 7 people. In order to carry out a non-




were uploaded onto a server created by S. Warriner, to be presented in a random 
order (so that information about which receptor was being overexpressed in each cell 
was not known). When classification began, a random image from the total image set 
was presented for classification. Upon completing classification of the first image, the 
next image would be randomly selected from the image set and presented for 
classification. This continued until all images were classified. Images classified as 
either -1 or 0, in either the RFP or GFP channel, by more than four people were 
excluded from analysis, then the average score and standard error for each 
experiment was taken. Example images from the classification set are shown for 
PhypaPEX5-N–AtPEX5-C.RFP-MossHigh/MossLow + GFP-PTS1*a/f (Figure 70), 





Figure 70|  Cell (Physcomitrella patens) images captured by R. Paudyal, following 
particle bombardment with a vector containing either the PhypaPEX5-N–AtPEX5-C or 
PhypaPEX5-N–AtPEX5-C* receptor and RFP-MossHigh/MossLow, and a vector 
containing GFP-PTS1*a/f. With PhypaPEX5-N–AtPEX5-C, RFP-MossHigh is imported 
preferentially over even the strongest PTS1* sequence (GFP-PTS1*f). No import of either RFP-
MossLow or GFP-PTS1*a/f is seen with PhypaPEX5-N–AtPEX5-C. PhypaPEX5-N–AtPEX5-C* 
newly facilitates the import of GFP-PTS1*a/f; however, there is definite co-localisation of RFP-
MossHigh when PTS1*a is used as the PTS1* sequence. GFP-PTS1*f appears to out-compete 
much of the import of RFP-MossHigh, and so AtPEX5-C* seems to have a preference for 
importing GFP-PTS1*f over importing RFP-MossHigh. The RFP-MossLow negative control 
shows that PTS1* import can be fully achieved by PhypaPEX5-N–AtPEX5-C* when there is no 
competition from over-expressed PTS1 sequences. Images courtesy of Rupesh Paudyal. 
Average classification scores, for each image, are shown in the top right-hand corner of each 
image. All scale bars shown represent 10 μm. 
A definite change in import behaviour occurred as a result of three mutations in the 
AtPEX5-C portion of the receptor. Interestingly, RFP-MossLow was not imported into 
peroxisomes by either PhypaPEX5-N–AtPEX5-C or PhypaPEX5-N–AtPEX5-C*; 




import with either of the receptor proteins. The results of the analysis after 
classification of all images by all 7 people are shown in Figure 71. 
 
Figure 71|  Analysis following the classification of all cell (Physcomitrella patens) 
images captured by R. Paudyal, following particle bombardment with a vector 
containing either the PhypaPEX5-N–AtPEX5-C or PhypaPEX5-N–AtPEX5-C* 
receptor and RFP-MossHigh/RFP-MossMid/RFP-MossLow, and a vector containing 
GFP-PTS1*a/b/d/e/f. A higher import classification score means increased peroxisomal 
localisation of the fluorescent protein. 1 = fully cytosolic, 5 = fully peroxisomal. The 
switching of AtPEX5-C for AtPEX5-C* downstream of PhypaPEX5-N drastically 





The analysis of image classification shows that a change has occurred in the nature of 
the import of both RFP-MossHigh/RFP-MossMid and all GFP-PTS1* sequences 
tested, following mutation of just three residues in AtPEX5-C (two in TPR2 and one in 
TPR5). The import of GFP-PTS1*a/f was selective, as RFP-MossLow was not 
imported into the peroxisome upon overexpression of PhypaPEX5-N–AtPEX5-C*. The 
results of the in vivo testing have confirmed that it was possible to evolve the import of 
a protein containing a non-PTS1 sequence into the peroxisome, through mutation of 
three residues in the PTS1-binding domain of PEX5. When the hybrid receptor 
PhypaPEX5-N–AtPEX5-C* was overexpressed in the P. patens cell (as a result of 
particle bombardment), non-native PTS1 sequences at the C-terminus of GFP (GFP-
PTS1*a/b/d/e/f) mediated the import of GFP into the peroxisome. 
4.7 Summary 
The pull-down-LC-MS screen developed in this study was used to screen a small 
library of expressed and purified AtPEX5-C variants against a larger library of 
synthesised peptides. Some apparent binding of non-PTS1 sequences was occurring 
with three of the AtPEX5-C variants tested, and two mutations in the protein were 
combined in an attempt to enhance binding to specific non-PTS1 sequences. Binding 
was enhanced towards aromatic peptides for one of the AtPEX5-C variants with 
combined mutations. This appeared to be enhanced as a result of the combination of 
mutations, and this AtPEX5-C variant was taken forward for further analysis and 
optimisation. The final AtPEX5-C* protein was decided upon through a semi-rational 
approach, in which a further mutation was introduced into the previous best protein 
variant for binding to aromatic peptides. This additional mutation was applied at a 
residue in AtPEX5-C which had been found, through the pull-down-LC-MS screening 
in this study, not to be essential for peptide binding within the PTS1-binding site of 
AtPEX5-C. 
The resulting triple variant of AtPEX5-C (D505H-D507T-N601A) was termed 
AtPEX5-C* and this variant had a very similar affinity for lissamine-YQSKL (the 
representative PTS1 sequence in this study) and lissamine-YQSYY (the preliminary 
PTS1* sequence identified in the pull-down-LC-MS screen), by fluorescence 
anisotropy. This represented a change in selectivity from ~2454-fold in favour of 
lissamine-YQSKL over lissamine-YQSYY, in the case of wild-type AtPEX5-C, to ~1.1-
fold, in the case of AtPEX5-C*. The AtPEX5-C* protein was then tested with longer 




interaction with the preliminary PTS1* sequence YQSYY. These six sequences with 
additional upstream residues were termed PTS1*a-f and, when compared to wild-type 
AtPEX5-C, AtPEX5-C* was found in vitro to bind to lissamine-PTS1*a and lissamine-
PTS1*f with significantly higher affinities, and to lissamine-MossHigh, the predicted 
PTS1 sequence in P. patens with the highest PTS1 prediction score (PredPlantPTS1 
(Lingner et al., 2011; Reumann et al., 2012)), with a significantly lower binding affinity. 
Therefore, this protein was taken forward for in vivo testing by R. Paudyal (University 
of Leeds). 
R. Paudyal’s work included the construction of hybrid receptors (PhypaPEX5-N–
AtPEX5-C and PhypaPEX5-N–AtPEX5-C*) and the testing of import of RFP-
MossHigh, RFP-MossMid, RFP-MossLow and GFP-PTS1*a/b/d/e/f sequences when 
genes for the receptors and for the proteins for import were over-expressed following 
particle bombardment of their DNA at P. patens cells (Figure 68). The results from R. 
Paudyal’s in vivo experiments were very promising, as they showed that the 
AtPEX5-C* protein was able to import all PTS1* sequences tested, with decreasing 
levels of competition from RFP-MossHigh and RFP-MossMid when the PTS1* 
sequence had a stronger upstream sequence (a higher overall PWM score). The most 
optimal PTS1* sequence (PTS1*f) resulted in import of GFP while more weakly 
importing the strongest predicted PTS1 sequence from P. patens (RFP-MossHigh). 
From this point onwards, PTS1*f will be referred to as PTS1*. 
The sequence MossMid still directed the peroxisomal import of RFP by wild-type 
PEX5, yet was out-competed more readily by GFP-PTS1* when the triple variant of 
the receptor (PEX5*) was expressed in Physcomitrella patens. The sequence 
MossLow served as a specificity control for the receptors, and showed that PEX5* 
does not import sequences non-specifically. This work has demonstrated that it has 
been possible to swap the selectivity of the PEX5 receptor from preferentially 
importing RFP-MossHigh and RFP-MossMid to preferentially importing GFP-PTS1*, 
by mutation of three residues in the PTS1-binding site. 
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Chapter 5  
General Discussion and Future Perspectives 
 
The aim of this study was to evolve an interaction, involving a PEX5 variant, that would 
direct non-PTS1-containing proteins to the peroxisome whilst reducing or eliminating 
natural PTS1-cargo import. 
5.1 General discussion 
Through a semi-rational approach to the mutation of AtPEX5-C, alongside screening 
of protein variants against a library of chemically synthesised peptides, it was possible 
to isolate the variants D505H and N601A as binding to the peptide YQSYY, where 
wild-type AtPEX5-C did not. These two mutations were combined, resulting in a 
stronger interaction between YQSYY and the double variant D505H-N601A. A further 
mutation, D507T, was applied to the protein and this resulted in the triple variant 
D505H-D507T-N601A, which had a binding affinity for YQSYY ~25-fold stronger than 
wild-type AtPEX5-C did, and a binding affinity for YQSKL ~88-fold weaker than wild-
type AtPEX5-C did. The addition of enhancing residues upstream of YQSYY resulted 
in the PTS1* sequence create a new binding interaction between the mutated PEX5 
(AtPEX5-C*) and a novel targeting signal (PTS1*) (Figure 72). Pleasingly, in vivo the 
mutated PEX5 receptor (termed PEX5*) was able to direct proteins containing this 





Figure 72|  Summary of the research study. The C-terminal domain of Arabidopsis 
thaliana PEX5 was mutated and, following screening for binding to short peptide 
sequences, manipulated to bind to a non-PTS1 sequence as determined in vivo (in vivo 
work carried out by Dr Rupesh Paudyal). The thin blue bars on AtPEX5 = WxxxF/Y 
repeats; the pale red box on AtPEX5 = PEX7 binding site. 
A novel screen was developed, in which over 300 peptide sequences (per assay) 
could be tested for their binding to a purified protein. There was no need for a 
genotype-phenotype link in this assay, as binding peptides could be identified after pull 
down using high-resolution mass spectrometry. This method had benefits over colony 




assay, processing of screen results could be almost fully automated so hits were 
identified quickly, and a full peptide-binding profile of each protein variant was 
obtained. 
Despite the advantages of the screen developed, there were several factors that 
needed to be considered. As there were many peptide sequences being purified and 
tested in one mix in this assay, it was not possible to determine the exact 
concentration of each peptide in the library (as peptides were resuspended based on 
the average mass of the peptides in the library). The split-and-mix synthesis strategy 
eliminated bias at the initial synthesis stage but some peptides ionise more effectively, 
so could have been more abundant in the mass spectrum. This technique, therefore, 
presents a way to quickly assess protein binding of a range of peptides before 
performing more detailed binding assays. 
Using the pull-down-LC-MS screen, it was possible to confirm which residues in 
AtPEX5-C are necessary for PTS1 binding (Figure 73). When mutated to alanine, 
some residues knocked out binding with any peptide, indicating that these residues 
are crucial for the PTS1-binding site of PEX5 (Figure 73, coloured magenta). 
 
Figure 73|  Residues studied in this research. Magenta = crucial for peptide binding, 
as determined using the pull-down-LC-MS screen. AtPEX5-C model produced using I-
TASSER (Zhang, 2008; Roy et al., 2010; Yang et al., 2015; Yang and Zhang, 2015), and 





Most of the residues crucial for peptide binding, determined in this study through the 
use of the pull-down-LC-MS screen, were consistent with mutations in Saccharomyces 
cerevisiae PEX5 or Homo sapiens PEX5 which knocked out PTS1 binding or import 
(Klein et al., 2001; Dodt et al., 1995): AtPEX5 N537 is equivalent to ScPEX5 N393, 
AtPEX5 N628 is equivalent to HsPEX5S N489, and AtPEX5 R659 is equivalent to 
ScPEX5 R526 (section 1.4.2). The pull-down-LC-MS screen was therefore a fast and 
sensitive way to obtain a great deal of information on peptide sequences that bind to 
AtPEX5-C, and known binding sequences of wild-type AtPEX5-C (native PTS1 
sequences) were successfully pulled down using this method. 
A major deliverable of this research was a new targeting signal (PTS1*) unable to 
direct proteins to the peroxisome in the presence of wild-type PEX5 but, upon 
expression of PEX5*, enabled the direction of PTS1*-tagged proteins to the 
peroxisome. The overall aims of this study bear similarities to recently published 
research in Saccharomyces cerevisiae performed by DeLoache and colleagues 
(DeLoache et al., 2016). However, in the study performed by DeLoache and 
colleagues, their deliverable was an enhanced PTS1 (‘ePTS1’) that was imported 
preferentially into the peroxisome over an example PTS1 sequence used. This allowed 
the direction of a non-peroxisomal two-enzyme metabolic pathway into peroxisomes, 
where it was able to function (DeLoache et al., 2016); however, natural PTS1 
sequences were still able to import into peroxisomes normally, as the PEX5 receptor 
remained unchanged. In this study, the import of PTS1 sequences was greatly 
reduced upon expression of the receptor variant PEX5*. 
This work suggests that the PWM score (PredPlantPTS1 (Lingner et al., 2011; 
Reumann et al., 2012) could over-predict when there is a non-PTS1 at the C-terminus. 
The PWM score threshold for peroxisomal import has been defined as 0.15–0.412 
(Lingner et al., 2011; Reumann et al., 2012; Skoulding et al., 2015); however, the 
sequence PTS1* has a PWM score of 0.54 and shows no import in P. patens. This 
could be due to the length of the import experiments, as Reumann and colleagues 
carry out imaging up to 72 h after particle bombardment and, in this study, the 
maximum time after particle bombardment and before imaging was 48 h. 
5.2 Future perspectives 
It would be interesting to determine the association and dissociation rates for the 




AtPEX5-C:PTS1 interaction, using surface plasmon resonance (SPR). Work towards 
this goal had started during this study by coupling biotin to the peptide YQSKL with 
different linkers, to determine which biotinylated peptide exhibited a binding affinity 
most similar to unlabelled YQSKL (Appendix F). The most appropriate biotin label was 
identified as biotin-(PEG)2, so biotin-(PEG)2-YQSYY was also produced (Chapter 6 
(Experimental) section 6.18.21); therefore, biotin-(PEG)2-YQSKL or biotin-(PEG)2-
YQSYY  could be attached to a streptavidin-coated gold chip, to measure the SPR 
with wild-type AtPEX5-C or AtPEX5-C*. It would also be of interest to crystallise wild-
type AtPEX5-C:PTS1 and AtPEX5-C*:PTS1*, in order to compare shapes of the 
binding sites. A further N-terminally truncated construct of AtPEX5-C was created for 
this purpose, as crystallisation attempts with AtPEX5-C (AtPEX5(340-728)) had been 
unsuccessful. In AtPEX5(444-728), all of the predicted flexible portion of the protein 
had been removed, which should have resulted in a more compact protein. Initial 
crystallisation screens (Chapter 6 (Experimental) section 6.17) using this protein 
construct were unsuccessful; however, crystallisation of AtPEX5(444-728) could be 
possible by performing an increased number of crystallisation screens with more 
variation. 
The pull-down-LC-MS screen developed in this study could also be used to test PEX5 
proteins from different species and determine whether there are key differences in the 
PTS1 sequences that they bind to. For instance in parasitic trypanosomes, 
peroxisomes are crucial for cell survival and, therefore, so is PEX5. By identifying a 
PTS1 sequence that binds strongly to trypanosome PEX5 and not to human PEX5, it 
could be possible to selectively target trypanosome PEX5. 
One process in peroxisomal matrix protein import that is yet to be unravelled is cargo 
unloading into the matrix of the peroxisome. A recent study showed that the addition of 
a bulky C-terminal tag to mammalian PEX5 (designed to mimic a cargo protein unable 
to unload from PEX5) resulted in a monoubiquitinated, membrane-bound form of 
PEX5. It could be suggested that without a free C-terminus PEX5 is unable to 
participate in cargo unloading and, if export-driven import is the correct model 
(Chapter 1, section 1.3.5), it is therefore unable to be exported to the cytosol from the 
peroxisome membrane. There appears to be a conserved sequence, LxKEF, at the C-
terminus of PEX5 across plant species (Figure 74, insert), similar to the sequence 
identified at the N-terminus of mammalian PEX5, LVxEF, as being important for the 




terminal sequence could allow the cargo unloading process to occur, and could be a 
final point-of-contact for PEX5 to PEX14, before PEX5 begins the recycling process. 
 
Figure 74|  Proposed mechanism for cargo unloading. The conserved C-terminal 
sequence LxKEF in plant PEX5 could act as a final interacting motif for PEX5 with 
PEX14, after the WxxxF/Y repeats in PEX5 are interacting with PEX14. This final 
interacting step could allow for the release of PTS1-cargo into the peroxisomal matrix, as 
PEX5 is recycled to the cytosol in parallel. With a bulky C-terminal tag on PEX5, this 
could prevent the interaction of LxKEF with PEX14, preventing cargo release and 
therefore preventing PEX5 recycling after monoubiquitination (assuming export-driven 
import). Alignments were performed using BioEdit (sequence alignment editor). 
The orthogonal import system developed in this study could be used to test whether 
the C-terminus of PEX5 is involved in cargo unloading, as we now have a signal 
sequence (PTS1*) that shows no import with the native PEX5 receptor. Transient 
expression, therefore, could be used to test this theory (as background native PEX5 




of the LxKEF sequence, the cellular localisation of GFP-PTS1* would reveal the 
subsequent effect. 
The orthogonal system produced in this study could be fully realised by the creation of 
an inducible system, in which native PEX5 expression is knocked out alongside 
upregulation of PEX5* expression. A potential way to do this would be using Cre-Lox 
recombination, as illustrated in Figure 75. This would mean, when PEX5* is being 
produced, that no background of native PEX5 levels would interfere. 
 
Figure 75|  Cre-Lox recombination, for an inducible switch in expression between 
PhypaPEX5 and PhypaPEX5-N–AtPEX5-C*. One loxP site could be placed in an exon 
between the N- and C-terminal domain of PhypaPEX5, and the other could be placed in 
an exon just after the stop codon of PhypaPEX5. After the stop codon of PhypaPEX5, 
AtPEX5-C* could be inserted into the genome. Upon induction of Cre recombinase 
expression, the PhypaPEX5 C-terminal domain would be excised from the genome, 
leaving the PhypaPEX5-N–AtPEX5-C* protein to be expressed. 
A major concern of manipulating PTS1-protein import to by-pass the native pathway, 
upon switching PEX5 expression for PEX5*, is that cells depend on peroxisomal 
protein import, and therefore native PEX5, for their survival. Tanner and colleagues 
produced an artificial peroxisome by encapsulating two antioxidant enzymes within a 
polymer vesicle containing channel proteins for substrate-product exchange (Tanner et 




(ROS) detoxification,  so it could be possible to develop artificial peroxisomes for use 
in plant cell vitality while customising the role of pre-existing peroxisomes in the cell. 
As this proof-of-principle work was successful, it may be possible to work towards the 
development of peroxisomes as storage organelles. This would require a stable line of 
moss cells with inducible PEX5*, so that levels of wild-type will decline after a user-
specified switch of PEX5 expression for PEX5* expression. There also needs to be a 
way to keep the cell alive, which could possibly be achieved through the use of 
artificial peroxisomes (Tanner et al., 2013). To allow for the storage of as much protein 
as possible, a PEX11 knockout cell line could be used, which has been shown to 
contain ‘giant peroxisomes’ (Kamisugi et al., 2016). This could allow for the storage of 
therapeutic proteins, for example recombinant vaccines or monoclonal antibodies. 
Such a storage organelle could allow for longevity of unstable proteins within living 
cells until desired, at which time we envisage that stored proteins could be isolated 
from cell extract using the PEX5* receptor (Figure 76). 
 
Figure 76|  A use for a synthetic peroxisome. The gene of interest is inserted into the P. 
patens genome, and expression of natural PhypaPEX5 is switched for PhypaPEX5-N– 
AtPEX5-C*. Therapeutic protein is then stored inside peroxisomes until needed. 
Moss (Physcomitrella patens) was used as the host organism in this study as it is 
commonly used as a bioreactor in industrial applications (Decker and Reski, 2004) and 
the genome is fully sequenced (Rensing et al., 2008) so genes can be stably 
transformed into the genome for expression. It will be interesting to determine how 




altered, and if it will be possible to create a system where re-purposed peroxisomes 
carry out specified import and storage alongside maintenance of cell vitality by artificial 
peroxisomes. 
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Chapter 6  
Experimental 
 
6.1 Bacterial strains and plasmids 
XL10-Gold (Stratagene) 
Genotype: TetrΔ(mcrA)183 Δ(mcrCB-hsdSMR-mrr)173 endA1 supE44 thi-1 recA1 
gyrA96 relA1 lac Hte [F´ proAB lacIqZΔM15 Tn10 (Tetr) Amy Camr] 
BL21-Gold (DE3) (Agilent Technologies) 
Genotype: E. coli B F– ompT hsdS(rB– mB–) dcm+ Tetr gal λ(DE3) endA Hte 
The pET-28b (Kanr) plasmid, containing the His6-AtPEX5(340-728) gene, was a gift 
from T. Lanyon-Hogg (former student of University of Leeds). The His6-AtPEX5(340-
728) gene was originally cloned into pET-28b by S. Gunn (former student of University 
of Leeds). 
6.2 Kanamycin stock solution 
Kanamycin monophosphate (FormediumTM), made up in distilled water (50 mg/mL 
stock solution) and filter-sterilised. 
6.3 Bacterial media 
All bacterial media was made up in distilled water and autoclaved at 121°C for 20 
minutes. For ZY-AI, all components other than ZY were sterile-filtered and added after 
autoclaving of ZY. 
LB (Luria Bertani) media 





Tryptone (1% w/v), yeast extract (0.5% w/v), NaCl (1% w/v), agar (1.5% w/v) 
ZY media 
Tryptone (1% w/v), yeast extract (0.5% w/v), NaOH (1 mM) 
ZY-AI (autoinduction media) 
ZY media (928 mL/L), MgSO4 (1 mM), (NH4)2SO4 (25 mM), KH2PO4 (50 mM), 
Na2HPO4 (50 mM), glycerol (0.5% w/v), glucose (0.05% w/v), α-lactose (0.2% w/v) 
‘Selection media’ 
LB, LB-agar, or ZY with kanamycin stock solution added in a 1:1000 dilution; or ZY-AI 
with kanamycin stock solution added in a 1:500 dilution 
6.4 Restriction enzymes 
Restriction enzymes were obtained from New England Biolabs (NEB) and conditions 
for restriction digests were determined using the NEB online ‘Double Digest Finder’. 
6.5 Site-directed mutagenesis 
A QuikChange Lightning Site-Directed Mutagenesis Kit (Agilent Technologies) was 
used according to manufacturer’s instructions. Transformation of each DpnI-treated 
mutagenesis reaction into XL10-Gold cells was performed, followed by DNA 
purification and confirmation of mutagenesis by sequencing (Beckman Genomics). 
6.6 Ligation-independent cloning (for the production of 
AtPEX5(444-728)) 
Ligation-independent cloning (LIC) was used for the deletion of a large portion of the 
N-terminus of AtPEX5(340-728) in order to generate the truncated variant 
AtPEX5(444-728). Primers were designed with a 16-bp overlap according to a 
methodology article about LIC, or ‘FastCloning’ (Li et al., 2011). An 18-cycle PCR 
amplification was performed using Q5 polymerase, followed by a 1 h DpnI digestion of 





Cells were divided into 45 µL aliquots in pre-chilled 14 mL BD Falcon tubes. If using 
XL10-Gold cells, 2 µL 2-mercaptoethanol was added to each aliquot of cells and 
incubated for 10 minutes on ice with occasional swirling. 1 µL purified DNA or 2 µL 
mutagenesis reaction was added and incubated with the cells for 30 minutes. Heat 
shock at 42°C was performed for the length of time specified in Table 15. Cells were 
then incubated on ice for 2 min, and 450 µL of pre-heated LB media (42°C) was added 
to each aliquot of cells. Transformations were incubated at 37°C for 1 h with shaking 
and cells were plated onto both LB-agar plates containing 50 µg/mL kanamycin and 
LB-agar plates with no antibiotic as a positive control. Plates were incubated at 37°C 
overnight. 
Cell strain 
Length of heat shock 
(seconds) 
XL10-Gold 30 
BL21-Gold (DE3) 20 
Table 15|  Required length of heat shock for competent cells used. 
6.8 Plasmid DNA extractions 
Plasmid DNA was extracted from cells using a QIAprep Spin Miniprep Kit (QIAGEN) 
according to manufacturer instructions. DNA was eluted from the spin column using 
50 µL nuclease-free water. 
6.9 Protease inhibition 
Protease inhibitors (COmplete EDTA-free, Roche) were used at a final concentration 
of 1 tablet per 50 mL buffer. Protease inhibitors were included in buffers used for cell 




6.10  Expression and purification of His6-AtPEX5(340-728) 
and variants 
6.10.1 Solutions 
Lysis buffer (wash buffer 1) 
NaH2PO4 (50 mM), NaCl (300 mM), 2-mercaptoethanol (10 mM), glycerol (15% v/v), 
pH 8.0 with ~50 mL 1M NaOH 
Elution buffer 
NaH2PO4 (50 mM), NaCl (300 mM), 2-mercaptoethanol (10 mM), glycerol (15% v/v), 
imidazole (200 mM), pH 8.0 
Wash buffer 2 
97.5% lysis buffer, 2.5% elution buffer to achieve a final imidazole concentration of 
5 mM 
Phosphate-buffered saline (PBS) 
NaCl (8 g/L), KCl (0.2 g/L), Na2HPO4 (1.44 g/L), KH2PO4 (0.24 g/L), pH 7.4 
Cobalt-agarose resin 
HisPur™ Cobalt Resin (Fisher Scientific), 500 µL settled cobalt-agarose resin used per 
500 mL original autoinduction culture 
6.10.2 Autoinduction of His6-AtPEX5(340-728) and variants 
The pET-28b.His6-AtPEX5(340-728) DNA, of either wild-type PEX5 or each of the site-
directed variants, was transformed into BL21-Gold (DE3) cells (section 6.7) for efficient 
protein expression. Overnight growth of single colonies in 5 mL selection media (LB) at 
37°C was performed, followed by 8 h cultures of 20 µL of overnight culture in 1 mL 
selection media (LB) at 37°C. Flasks containing 500 mL ZY-AI with kanamycin (1:500) 
were inoculated with day culture (1:2000) and incubated at 28°C for 18 h. Cells were 
then pelleted by centrifugation at 4,500 x g (20 min, 4°C) and pellets were stored at -




6.10.3 Cell disruption of BL21-Gold (DE3) E .coli cells 
Cell pellets from 500 mL autoinduced cell culture were transferred to 150 mL universal 
containers. Pellets were thawed on ice and resuspended in 20 mL chilled lysis buffer 
(containing protease inhibitors) per 500 mL original autoinduction culture. Cells were 
homogenised, transferred to the inlet of a TS Series Benchtop Cell Disruptor (Constant 
Systems Ltd.) and broken by applying 20 kpsi. Cells were chased through with 20 mL 
chilled lysis buffer containing protease inhibitors and the 40 mL lysed cell slurry was 
passed through the cell disruptor a second time. 
6.10.4 Purification of His6-AtPEX5(340-728) and variants 
Induced, lysed cells were centrifuged at 25,000 x g (30 min) and supernatant was 
loaded onto 500 μL settled Co-NTA resin (Thermo Fisher) per 40 mL supernatant. This 
was incubated at 4°C for 2 h with constant agitation. The resin was pelleted by 
centrifugation at 2,000 x g (2 min) and supernatant was decanted, leaving 
approximately 4 mL on the resin. Lysis buffer (section 6.1.9) was used for resin 
washing (2 x 7.5 mL (per 500 µL resin) followed by centrifugation at 2,000 x g (2 min) 
and decanting of supernatant). The resin was then washed in the same way (2 
washes) with wash buffer 2. Elution buffer was then added at 5 mL per 500 µL resin, 
resin was incubated at 4°C for 30 min, and resin was pelleted by centrifugation at 
2,000 x g (2 minutes). Eluted His6-AtPEX5(340-728) protein was then concentrated 
and buffer-exchanged into an appropriate buffer (containing protease inhibitors) 
(section 6.10.6). 
6.10.5 Gel filtration of His6-AtPEX5(340-728) 
Gel filtration was performed on an ÄKTA prime, on which an S75 column (GE 
Healthcare Life Sciences) was first washed with 600mL sterile de-gassed distilled 
water (3 mL/min) and equilibration was performed using 300mL lysis buffer, or low salt 
buffer for crystallisation screens (section 6.17.1) (3 mL/min). Protein was loaded onto 
the S75 column by syringe and flow rate was slowed to 1 mL/min for 45 minutes. Flow 
rate was then further slowed to 0.2 mL/min and 2mL fractions were collected over a 
period of approximately 2 h. Fractions were analysed by denaturing SDS-PAGE and 
the fractions containing purest looking protein were confirmed. These fractions were 




6.10.6 Concentration and buffer exchange of  
His6-AtPEX5(340-728) 
Concentrators (Millipore, 30 kDa cut-off) were equilibrated with 5 mL distilled water 
(centrifugation at 4,500 x g, 6 minutes), followed by 5 mL of the appropriate buffer (the 
current buffer of the protein). Protein solution was loaded onto a concentrator and 
concentrated to 1 mL. 4 mL of the desired buffer for the protein (containing protease 
inhibitors) was then added and concentrators centrifuged for 15 min (x 2). Protein 
solutions were then topped up with 2 x 4 mL desired buffer (with 2 x 15 min 
centrifugation after each top-up). Finally, protein solutions were concentrated to 1 mL 
and stored at 4°C for a maximum of one month. 
6.10.7 Protein concentration determination 
Protein concentration was determined by the Beer-Lambert law using the absorbance 
at 280 nm, measured using a Kontron Uvikon 930 spectrophotometer. Extinction 
coefficients were calculated using ExPASy ProtParam. 
6.11  SDS-PAGE 
Samples were prepared by the addition of 2 x SDS-PAGE loading buffer (1:1) and 
samples were boiled for denaturation in a PTC-100® Thermal Cycler (MJ Research) at 
100°C for 5 min. SDS-PAGE gels were made up of 60–70% resolving gel and 30–40% 
stacking gel. Gels were prepared in a BIO-RAD gel casting system. Prepared samples 
were loaded into wells and gels were run at 30 mA if running one gel (60 mA if running 
more than one) in SDS running buffer. Gels were transferred into Quick Blue stain 
(20 mL per gel), left to stain for 30 min, transferred to distilled water for 30 min and 
then imaged using an InGenius gel imager (Syngene). 
Stacking gel for SDS-PAGE (2 gels) 
30% acrylamide (625 µL/5 mL), 1 M Tris·HCl (625 µL/5 mL, pH 6.9), SDS (10% 
solution) (50 µL/5 mL), distilled water (3.65 mL/5 mL), ammonium persulfate (25% 




Resolving gel for SDS-PAGE (2 gels) 
30% acrylamide (7.5 mL/15 mL), 1.5 M Tris·HCl (3.75 mL/15 mL, pH 8.8), SDS (10% 
solution) (150 µL/15 mL), distilled water (3.5 mL/15 mL), Ammonium persulfate (25% 
solution) (100 µL/15 mL), TEMED (10 µL/15 mL) 
2 x SDS-PAGE loading buffer 
Tris·HCl (50 mM, pH 6.8), DTT (100 mM), SDS (2% w/v), bromophenol blue 
(0.1% w/v), glycerol (10% v/v) 
SDS-PAGE running buffer (10x) 
Tris base (30.2 g/L), glycine (144 g/L), SDS (10 g/L). Used at a 1 x working solution 
Quick Blue - Coomassie stain 
20 mL Quick Blue (Triple Red) was used per gel 
Blue Prestained Protein Standard (Broad Range (11-190 kDa), P7706S, NEB) 
5 µL used in the first lane of each SDS-PAGE gel 
6.12  Blotting 
6.12.1 Antibodies 
Primary 
 Anti-polyhistidine from mouse (Sigma) used at a 1:3,000 dilution 
 Anti-AtPEX5(340-728) raised in rabbit (Genosphere) used at a 1:10,000 
dilution 
Secondary 
 Anti-mouse IgG from rabbit conjugated to horse radish peroxidase (Sigma) 
used at a 1:20,000 dilution 
 Anti-rabbit IgG from goat conjugated to horse radish peroxidase (Sigma) used 
at a 1:5,000 dilution 
HRP-conjugates 
 HRP-YQSKL used at a final concentration of 350 nM 




 HRP-YQSKV used at a final concentration of 350 nM 
 HRP-YQSEV used at a final concentration of 350 nM 
6.12.2 Western blotting 
After running an SDS-PAGE gel (section 6.11), the gel was placed in transfer buffer in 
preparation for transfer using a Mini Trans-Blot® Electrophoretic Transfer Cell (BIO-
RAD) and a transfer stack was assembled according to manufacturer instructions. 
Transfer of proteins from the gel to the nitrocellulose membrane was performed for 1 h 
at 100V. The nitrocellulose membrane was then placed in blocking buffer for 1 h at 
room temperature (if using 5% skimmed milk powder in blocking buffer) or at 4°C 
overnight (if using 3% BSA in blocking buffer). Blocking buffer was removed and the 
membrane was incubated for 1 h at room temperature in primary antibody solution. 
The membrane was washed with PBS-T (3 x 10 min washes), followed by a 45 min 
incubation with secondary antibody solution at room temperature. If using HRP-SKL or 
PEX14(1-154)-HRP conjugates, these were diluted in blocking buffer at an appropriate 
dilution and membranes were incubated with these solutions for 1 h immediately after 
the blocking step. The membrane was washed with PBS-T (3 x 10 min washes) 
followed by a wash with PBS (10 min). Membranes were then visualised with 
increasing levels of exposure on a GeneGnome5 system (Syngene) after incubation 
(1 min) with ECL Prime Western blotting detection reagent (VWR International). 
PBS-T 
PBS, Tween-20 (0.05% v/v) 
Blocking buffer 
5% skimmed dried milk powder or 3% BSA in PBS-T 
Antibody solution 
Blocking buffer (10 mL per membrane) with antibody at the appropriate dilution 
Transfer buffer 




6.12.3 Dot blotting 
An appropriate amount of the protein to be analysed was dotted onto nitrocellulose 
membrane. Blocking of the membrane was performed as for western blotting, as were 
all downstream steps of the procedure. 
6.12.4 Colony blotting 
Saturation primers were used in a mutagenesis reaction (section 6.5), and 
mutagenesis reactions were transformed directly into an expression cell line (BL21-
Gold (DE3)). Colonies were picked using cocktail sticks and were used to inoculate 
separate wells of 96-deep-well plates, each containing 1.5 mL selection media (LB 
with kanamycin (50 mg/L)). Cells were grown for 20 h at 24°C in a microplate 
incubator shaker, and were then transferred into 384-well plates, with each well 
containing 70 μL selection media, using the ‘re-arraying’ function of a Genetix QPix 
colony picker. Following the growing of cells for 20 h at 24°C in a microplate incubator 
shaker, cells were stamped onto nitrocellulose membrane using the ‘gridding’ function 
of a Genetix QPix colony picker. Remaining cells in the 96-deep-well plates were 
centrifuged at 2,000 x g for 10 min, supernatant was removed, and cells were stored at 
-80°C for retrospective identification by DNA purification and sequencing. 
Nitrocellulose membranes were transferred (colony side up) to LB-agar-kanamycin 
plates, without introducing air bubbles. Plates were incubated (inverted) for 14 h at 
30°C, and nitrocellulose membranes were then transferred onto fresh LB-agar plates 
containing 50 mg/L kanamycin and 250 μM IPTG. Plates were incubated (inverted) for 
4 h at 37°C to induce protein expression. Cell lysis and blotting steps were performed 
as per the QIA expressionist (The QIAexpressionist, 2001), with the exception of the 
blocking step, which was carried out overnight (without agitation) at 4°C. Blotting was 
carried out using HRP-peptide conjugates (HRP-YQSKL/EL/KV/EV) at a final 
concentration of 350 nM. Nitrocellulose membranes were then visualised, with 30 
seconds exposure time, on a GeneGnome5 system (Syngene) after incubation (1 min) 
with ECL Prime Western blotting detection reagent (VWR International). 
SDS solution 





NaOH (0.5 M), NaCl (1.5 M) 
Neutralisation solution 
NaOH (1.5 M), Tris base (0.5 M), pH 7.5 
2 x SSC 
NaCl (8.76 g per 500 mL), trisodium citrate·2H2O (5.02 g per 500 mL) 
TBS 
Tris base (10 mM), NaCl (150 mM), pH 7.5 
TBS-T 
Tris base (20 mM), NaCl (500 mM), Tween-20 (0.05% v/v), pH 7.5 
Blocking solution 
5% skimmed dried milk powder in TBS-T 
6.13  Peptide synthesis 
General Information 
Solvents were purchased from Fluka, Sigma-Aldrich, or Fisher Scientific. All Fmoc-
protected amino acids, pre-loaded 2-chlorotrityl resin (0.6–0.9 mmol/g), HCTU (2-(6-
Chloro-1H-benzotriazole-1-yl)-1,1,3,3-tetramethylaminium hexafluorophosphate), 
Oxyma Pure® (ethyl (hydroxyimino)cyanoacetate) and N-Biotinyl-NH-PEG2-COOH 
were purchased from Novabiochem. EDC (N-(3-Dimethylaminopropyl)-N’-
ethylcarbodiimide hydrochloride) was purchased from Sigma-Alrich. Dansyl chloride 
was purchased from Sigma-Aldrich and will be referred to as dansyl from this point 
onwards. 7-Methoxycoumarin-4-acetic acid was purchased from Novabiochem and will 
be referred to as coumarin from this point onwards. LissamineTM Rhodamine B sulfonyl 
chloride (mixed isomers) was purchased from Thermo Fisher Molecular Probes and 
will be referred to as lissamine from this point onwards. 
N-terminal Fmoc-protected amino acids and pre-loaded 2-chlorotrityl resins with the 




His(Trt), Ile, Lys(Boc), Leu, Met, Asn(Trt), Pro, Gln(Trt), Arg(Pbf), Ser(tBu), Thr(tBu), 
Val, Trp(Boc), Tyr(tBu). Manual Fmoc solid phase peptide synthesis was performed 
using reservoir tubes with a polyethylene frit (Grace Discovery Sciences) and a 
vacuum tank attached to a water aspirator. Automated Fmoc solid phase peptide 
synthesis was performed using a CEM Liberty® automated microwave assisted peptide 
synthesiser, with double coupling (20°C, 60 min) used for each amino acid addition. 
6.13.1 General procedure for Fmoc-protected amino acid 
coupling (manual SPPS) 
DMF (2 mL) was added to pre-loaded 2-chlorotrityl chloride resin (1 eq.) and the resin 
left to swell for 1h. DMF was drained from the reaction vessel. A solution of Fmoc-
protected amino acid (5 eq.) in 1 mL DMF, HCTU (5 eq.) in 1 mL DMF, and DIPEA 
(10 eq.) were added and the reaction mixture agitated for 1h at RT. The solution was 
filtered from the resin by vacuum filtration and resin was washed with DMF (3 x 2 mL x 
2 min), 20% piperidine in DMF (5 x 2 mL x 2 min), and DMF (5 x 2 mL x 2 min). This 
coupling process was repeated three additional times, resulting in a pentamer. Resin 
was then washed with DMF (3 x 2 mL x 2 min), DCM (3 x 2 mL x 2 min) and MeOH (3 
x 2 mL x 2 min) before drying of the resin in vacuo. The crude resin-bound peptide 
was then stored at -20°C, and then weighed out for use as required. Either direct 
cleavage and purification of peptides was performed (section 6.13.9), or N-terminal 
coupling of a fluorescent label (sections 6.13.4, 6.13.5, and 6.13.6) or a biotin moiety 
(sections 6.13.7 and 6.13.8) was carried out. 
6.13.2 Procedure for Fmoc-protected amino acid coupling 
(automated SPPS) 
Automated Fmoc SPPS was performed on a 0.1 mmol scale using a CEM Liberty® 
automated microwave assisted peptide synthesiser. Pre-loaded 2-chlorotrityl resin was 
swelled in DMF for at least 1h prior to synthesis, and all amino acid coupling steps 
were performed using double coupling with no microwave. Following peptide 
synthesis, resin was washed with DMF (3 x 2 mL x 2 min), DCM (3 x 2 mL x 2 min) 
and MeOH (3 x 2 mL x 2 min) before drying of the resin in vacuo. The crude resin-




6.13.3 Split-and-pool amino acid coupling 
Peptide sub-libraries were synthesised by first adding 30 mg of each required 
preloaded 2-chlorotrityl chloride resin into a reaction vessel. The pooled resin was 
swelled in DMF (5 mL) for 1 h, and then the reaction vessel was drained. DMF washes 
were performed (3 x 2 mL x 2 min), followed by washes with 20% piperidine in DMF (5 
x 2 mL x 2 min) and DMF (5 x 2 mL x 2 min). Resin was washed with DCM (3 x 2 mL x 
2 min) and dried in vacuo before splitting equally between reservoir tubes for coupling 
of each of the amino acids at position -2. To each aliquot of resin, a different Fmoc-
protected amino acid (5 eq.) in DMF (1 mL) was added, along with HCTU (5 eq.) in 
DMF (1 mL) and DIPEA (10 eq.). The reaction was agitated for 1 h (at RT). All aliquots 
of resin were pooled for the deprotection (20% piperidine in DMF) and wash (DMF) 
steps, and all subsequent amino acids were coupled using standard protocol (see 
section 6.13.1). 
6.13.4 N-terminal lissamine coupling 
Lissamine couplings were performed under an inert atmosphere in foil-covered round-
bottom flasks. LissamineTM Rhodamine B sulfonyl chloride (mixed isomers) (3 eq.) in 
DMF (1 mL) was added to peptide-bound resin (1 e.q.) at 0°C. Dry DIPEA (10 eq.) was 
added and the solution was stirred overnight. The solution was filtered from the resin, 
which was then washed with DMF (3 x 2 mL x 2 min), DCM (3 x 2 mL x 2 min) and 
MeOH (3 x 2 mL x 2 min) before drying of the resin in vacuo. Cleavage of peptides 
from resin was performed (see section 6.13.9), and peptides were purified by mass-
directed preparatory HPLC (gradient elution 5–95% MeOH in H2O). Solvent was 
removed in vacuo using a Büchi rotary evaporator and peptides were lyophilised to 
give a dark pink solid (yield = 15–20%). Before use in fluorescence anisotropy, 
peptides were resuspended in sterile H2O to produce a 500μM solution. 
6.13.5 N-terminal coumarin coupling 
Peptide-bound resin (1 eq.) was swelled in DMF (2 mL) for 1 h. DMF was drained from 
the reaction vessel. 7-Methoxycoumarin-4-acetic acid (4 eq.) in DMF (1 mL) was 
added to EDC (4.4 eq.) and Oxyma Pure® (8 eq.) in DMF (1 mL), and the solution was 
well-mixed then incubated at RT for 10 min. The coumarin mixture was then added to 
the peptide-bound resin (1 eq.) and agitated for 4 h. The solution was filtered from the 
resin, which was then washed with DMF (3 x 2 mL), DCM (3 x 2 mL) and MeOH (3 x 




protocol (Pennington, 1994). Cleavage of peptides from resin was performed (see 
section 6.13.9), and peptides were purified by mass-directed preparatory HPLC 
(gradient elution 5–95% MeOH in H2O). Solvent was removed in vacuo and peptides 
were lyophilised to give a pale yellow solid (yield = 15–25%). 
6.13.6 N-terminal dansyl coupling 
Peptide-bound resin (1 eq.) was swelled in DMF (2 mL) for 1 h. DMF was drained from 
the reaction vessel. DIPEA (6 eq.) was added to dansyl chloride (5 eq.) in DMF (2 mL), 
and the solution was well-mixed and then incubated at RT for 10 min. The dansyl 
mixture was then added to the peptide-bound resin (1 eq.) and stirred overnight. The 
solution was filtered from the resin which was then washed with DMF (3 x 2 mL), DCM 
(3 x 2 mL) and MeOH (3 x 2 mL) before drying of the resin in vacuo. Cleavage of 
peptides from resin was performed (see section 6.13.9), and peptides were purified by 
mass-directed preparatory HPLC (gradient elution 5–95% MeOH in H2O). Solvent was 
removed in vacuo and peptides were lyophilised to give a yellow solid (yield = 86–
93%). 
6.13.7 N-terminal (+)-biotin coupling 
Peptide-bound resin (1 eq.) was swelled in DMF (2 mL) for 1 h. DMF was drained from 
the reaction vessel. (+)-Biotin (6 eq.) was dissolved in DMF:DMSO (1:1) and HCTU 
(6 eq.) was added to the biotin solution. DIPEA (10 eq.) was then added to the biotin + 
HCTU solution, and the resulting activated biotin solution was added to the peptide-
bound resin (1 eq.) and stirred overnight. The solution was filtered from the resin which 
was then washed with DMF:DMSO (1:1) (2 x 2 mL), DMF (2 x 2 mL), DCM (3 x 2 mL) 
and MeOH (3 x 2 mL) before drying of the resin in vacuo. Cleavage of peptides from 
resin was performed (see section 6.13.9), and peptides were purified by mass-directed 
preparatory HPLC (gradient elution 5–95% MeOH in H2O). Solvent was removed in 
vacuo and peptides were lyophilised to give a white solid (yield = 38%). 
6.13.8 N-terminal biotin-(PEG)2 coupling 
Peptide-bound resin (1 eq.) was swelled in DMF (2 mL) for 1 h. DMF was drained from 
the reaction vessel. N-Biotinyl-NH-PEG2-COOH·DIPEA (2 eq.) and HCTU (2 eq.) were 
added to the peptide-bound resin (1 eq.) and stirred for 3 h. The solution was filtered 
from the resin which was then washed with DMF (3 x 2 mL), DCM (3 x 2 mL) and 




was performed (see section 6.13.9), and peptides were purified by mass-directed 
preparatory HPLC (gradient elution 5–95% MeOH in H2O). Solvent was removed in 
vacuo and peptides were lyophilised to give a white solid (yield = 35–40%). 
6.13.9 Cleavage of peptides from the solid resin support 
A cleavage cocktail of TFA, H2O, and TIPS (95:2.5:2.5) was added to dried resin 
(500 µL per 25 mg resin) and agitated for 1h at RT. The cleavage mixture was filtered 
drop-wise into cold diethyl ether (1:100) and precipitated peptide was collected by 
centrifugation. Three diethyl ether washes were performed, all diethyl ether collected 
and water extraction carried out. Diethyl ether-precipitated peptide was left open to air 
overnight to allow for evaporation of diethyl ether and was then resuspended in sterile 
H2O and pooled with the aqueous fraction. Preparative HPLC was performed if further 
purification was required. After HPLC, peptides were lyophilised and resuspended in 
sterile water to the desired concentration.  
6.14  Fluorescence anisotropy 
6.14.1 Solutions 
FA buffer 
HEPES (20 mM), NaCl (150 mM), pH 7.5 
Plate blocking buffer 
Gelatin from porcine skin, type A (Sigma) (0.32 mg/mL) in FA buffer 
6.14.2 Fluorescently labelled peptide solutions 
After N-terminal lissamine coupling, peptides were purified by HPLC, then lyophilised 
and re-dissolved to produce a 500 μM solution. Lissamine-labelled peptides were used 
at a final concentration of 100 nM for protein titration assays, and a final concentration 
of 30 nM for peptide competition assays. 
6.14.3 Protein solutions 
After concentration and buffer exchange of proteins into FA buffer, dilution to an 




6.14.4 General assay information 
Fluorescence anisotropy studies used an EnVisionTM 2103 multilabel plate reader 
(Perkin Elmer) All required wells of a Black OptiplateTM-384 F (PerkinElmer) 384-well 
plate was blocked with 80 μL plate blocking buffer per well, sealed with self-adhesive 
plate seals (Fasson®) and stored at 4°C at least 14 hours prior to use. 
6.14.5 Protein titration 
To determine binding affinity of a protein to a lissamine-labelled peptide, a dilution 
series of AtPEX5-C (wild-type or variant) (0.3 nM–10 µM) was measured with 100 nM 
(final concentration) lissamine-peptide (final volume 40 µL). 
Plate blocking buffer (60 μL) was removed from each well, after the ≥14 h blocking 
incubation. Protein solution (40 μL) was added to wells of rows A–F in column 1, this 
was agitated by pipetting, and 40 μL was removed and added to wells in column 2. 
This process was repeated until the protein was diluted along all 24 columns of the 
plate (leaving column 24 with no protein solution). FA buffer was added to rows A–C of 
the plate (20 μL per well) to act as the blanks, and peptide solution (20 μL per well) (at 
200 nM) was added to rows D–F, to test binding of the peptide to the protein. 
6.14.6 Peptide competition assay 
To determine the inhibition constant for peptides competing with lissamine-YQSKL for 
the binding site of AtPEX5-C, a number of stock solutions were prepared for each 
competing peptide. Final concentration of competing peptide in the assay ranged from 
0 to 1 mM. Final lissamine-YQSKL concentration was 30 nM and final protein 
concentration was 200 nM in each well. 
Only columns 1–14 were used in these assays. Plate blocking buffer (70 μL) was 
removed from each well, after the ≥14 h blocking incubation. Stock solutions of 
competing peptides were prepared (14 solutions, from 0–4 mM) and 10 μL of each 
was added into separate wells of columns 1–14 (rows A–F). 10 μL of lissamine-
YQSKL (stock concentration 120 nM) was added into each well of columns 1–14 (rows 
D–F), and 10 μL of FA buffer was added into each well of columns 1–14 (rows A–C) to 
act as the blanks. 10 μL protein solution (stock concentration 800 nM) was then added 




6.14.7 Reading of fluorescence anisotropy plates 
Plates were agitated with linear shaking (900 rpm) using a EnvisionTM 2103 multilabel 
plate reader (PerkinElmer) for 15 minutes, and values obtained by reading using a 
BODIPY TMR dichroic mirror (555 nm) and the following filters: 
Excitation: BODIPY TMR FP 531 (Wavelength 531 nm, bandwidth 25 nm) 
Emission 1: BODIPY TMR FP P-pol 595 (Wavelength 595 nm, bandwidth 60 nm) 
Emission 2: BODIPY TMR FP S-pol 595 (Wavelength 595 nm, bandwidth 60 nm) 
Plates were read at a measurement height of 7.4 mm with a g-factor of 1.16. Each well 
received 30 flashes per measurement. Anisotropy values were obtained by applying 
the following formula to the blank corrected P-values and S-values: 
Anisotropy (r) = 1000*(S-G*P)/(S + 2*G*P) 
Amount of peptide bound was then calculated using anisotropy values, and formulas 
previously published (Skoulding et al., 2015). The mean values and standard 
deviations for each triplicate were plotted using OriginPro 9.1, with protein 
concentration plotted along the x axis (logarithmic scale). 
6.15  Pull-down-LC-MS screening 
6.15.1 Pull-down of binding peptides by Co-NTA purification of 
AtPEX5-C protein 
Purified protein (final concentration: 12.5 µM) was added to a library of peptides (final 
concentration: 500 nM each peptide in the library (concentration calculated based on 
the average molecular weight of the peptides in the sub-library)) in a 500 µL reaction 
mixture in lysis buffer (wash buffer 1 (section 6.10.1)), and this was incubated at 4°C 
for 1 h with agitation. This protein-peptide mixture was added to Co-NTA resin (100 µL 
settled resin per 500 µL reaction) and was incubated at 4°C for 1 h with agitation. 
Supernatant was removed and 500 µL wash buffer was added to the resin (4 x 500 µL 
washes) followed by wash buffer containing 5 mM imidazole (3 x 500 µL washes). 
Elution of the protein was performed by incubating the resin with wash buffer 
containing 6 M urea (300 µL) at 4°C for 30 min with agitation. Eluate was collected in 




6.15.2 Mass spectrometry for identification of binding peptides 
Electrospray ionisation LC-MS was performed using a Bruker MaXis Impact time of 
flight mass spectrometer in the positive ion mode. Column guard used: Waters Acquity 
UPLC Peptide CSH C18 column 130 angstrom, 1.7 μm stationary phase Vanguard 
precolumn (column dimensions 2.1 mm x 5 mm). Analytical column used: Waters 
Acquity UPLC Peptide CSH C18 column 130 angstrom, 1.7 μm stationary phase 
(column dimensions 2.1 mm x 100 mm). A Dionex Ultimate 3000 HPLC was used, with 
solvents: A) water + 0.1% formic acid; B) acetonitrile + 0.1% formic acid. Timetable 
(flowrate 0.7 mL/min, linear gradients between points): -1.3 min = 99:1 A:B (pre-
equilibration); 0 min = inject; 0.3 min = 99:1 A:B; 1.5 min = 80:20 A:B; 2.5 min = 78:22 
A:B; 4.5 min = 70:30 A:B; 5.5 min = 60:40 A:B; 6 min = 5:95 A:B; 7.5 min = 1:99 A:B. 
Calibration of the mass spectrometry instrument was performed using sodium formate, 
injected at the end of each run. 
6.15.3 Data processing 
Following ‘elution’ of peptides upon unfolding of the protein after peptide pull-down, 
LC-MS was performed and extracted ion chromatograms (EICs) were added for the 
mass of each peptide in the full library of dansyl-labeled peptides. An Excel sheet was 
exported containing the area-under-EIC for each EIC added, along with corresponding 
potential peptide sequence (based on mass) and retention time from the LC column. 
The retention times and potential peptide sequences were compared to a master 
sequence-retention time list, and the ‘best match’ peptide sequence was found using 
this information. Overall drift times (up to ±5 seconds) were applied to the entire list of 
retention times in the exported data set in order to find the lowest average difference 
between the sequence-retention time master list and the raw data (Figure 77). There 
were 45 pairs of peptides with identical masses and retention times, so these could not 
be distinguished from one another; however, the peak (if present) could be assigned 
as belonging to the pair. One of each of these pairs was included in the sequence-
retention time master list (shaded in pale blue) and the other, for each pair, can be 
found in the table entitled ‘Peptides with identical exact mass and retention times to 45 
peptides in the retention time-sequence list’. If a peptide from one of these pairs was 
found in a data set after pull-down-LC-MS, the corresponding peptide in the pair was 
automatically added to the output matrix, as we could not be certain which peptide had 





Figure 77|  Data processing pipeline after the capture of peptides using purified 
protein associated with cobalt resin, and ‘elution’ of peptides by unfolding of the 
protein with 6 M urea. LC-MS, liquid chromatography-mass spectrometry; EIC, 
extracted ion chromatogram; Seq-ReT, sequence and retention time; ReT-mass, 
retention time and mass. 
6.16  Circular dichroism 
6.16.1 Buffer exchange of His6-AtPEX5(340-728) 
Buffer exchange was performed as previously described (section 6.10.6). The protein 
was buffer-exchanged into 10 mM sodium phosphate before circular dichroism (CD) 
measurements. 
6.16.2 Measurement of circular dichroism 
CD was measured by loading 250 μL protein (at 0.2 mg/mL in 10 mM sodium 
phosphate, pH 7.5) into a 0.1 mm pathlength cuvette. CD measurements were taken 
in 1 nm increments from 180 nm to 260 nm at 21°C. HT voltage was also measured to 





6.17  Crystallisation screens 
6.17.1 Gel filtration, concentration and buffer exchange of His6-
AtPEX5(340-728) 
This was performed as previously described (sections 6.10.5 and 6.10.6) after protein 
purification. The buffer used for setting up crystal screens was a low salt buffer, to try 
to reduce the chance of salt crystals forming. 
Low salt buffer 
NaCl (50 mM), HEPES (5 mM), pH 7.5, filtered and de-gassed 
6.17.2 Setting up of crystal screens 
Five 96-well plate screens were prepared: Hampton 1 and 2, Index 1 and 2, Wizard 1, 
2, 3 and 4, and SaltRx 1 and 2. 80 μL of each screen was placed into wells of separate 
96-well plates. A Douglas Crystallisation Robot was used to load 1 μL His6-
AtPEX5(340-728) onto each platform with 1 μL of screen. 1 μL low salt buffer was also 
loaded onto a platform alongside the protein, along with 1 μL of screen solution. After 
all screens were prepared, lines of the Douglas robot were washed with 70% ethanol, 
and screen plates were covered with clear adhesive seal. Plates were analysed by 
light microscopy to record any immediate amorphous precipitate, and plates were then 
stored at 18°C. Plates were analysed by light microscopy after 7, 9, 11, 13, 15 and 18 




6.18  Synthetic peptide analytical data 
6.18.1 H2N-YQSKL-CO2H 
 
Ascentis Peptide (ES-C18, 100 x 2.1 mm, 2.7 µm particle size); Flow rate 0.5 mL  
min-1; Gradient elution t = 0 min, MeCN:H2O with 0.1 % TFA, 5:95; t = 10.0 min, 95:5;  
t = 10.5 min, 5:95; t = 12.0 min, 5:95; Rt 2.0 min, m/z (ES) found [M+H]+ 638.3512; 
C29H48N7O9 requires 638.3508. 
 















Ascentis Express (C18, 50 x 2.1 mm, 2.7 µm particle size); Flow rate 0.5 mL min-1; 
Gradient elution t = 0 min, MeCN:H2O with 0.1 % TFA, 5:95; t = 5.0 min, 95:5; Rt 
1.9 min, m/z (ES) found [M+H]+ 1178.4906; C56H76N9O15S2 requires 1178.4903. 
 


















Ascentis Express (C18, 50 x 2.1 mm, 2.7 µm particle size); Flow rate 0.5 mL min-1; 
Gradient elution t = 0 min, MeCN:H2O with 0.1 % TFA, 5:95; t = 5.0 min, 95:5; Rt 
2.0 min, m/z (ES) found [M+H]+ 1179.4397; C55H71N8O17S2 requires 1179.4379. 
 

















Ascentis Peptide (ES-C18, 100 x 2.1 mm, 2.7 µm particle size); Flow rate 0.5 mL  
min-1; Gradient elution t = 0 min, MeCN:H2O with 0.1 % TFA, 5:95; t = 10.0 min, 95:5;  
t = 10.5 min, 5:95; t = 12.0 min, 5:95; Rt 5.5 min, m/z (ES) found [M+H]+ 1164.4752; 
C55H74N9O15S2 requires 1164.4746. 
 



















Ascentis Express (C18, 50 x 2.1 mm, 2.7 µm particle size); Flow rate 0.5 mL min-1; 
Gradient elution t = 0 min, MeCN:H2O with 0.1 % TFA, 5:95; t = 5.0 min, 95:5; Rt 
1.9 min, m/z (ES) found [M+H]+ 1165.4216; C54H69N8O17S2 requires 1165.4223. 
 

















Ascentis Express (C18, 50 x 2.1 mm, 2.7 µm particle size); Flow rate 0.5 mL min-1; 
Gradient elution t = 0 min, MeCN:H2O with 0.1 % TFA, 5:95; t = 5.0 min, 95:5; t = 
5.4 min, 95:5; Rt 1.4 min, m/z (ES) found [M+H]+ 912.4229; C38H62N11O13S requires 
912.4244. 
 

















Ascentis Express (C18, 50 x 2.1 mm, 2.7 µm particle size); Flow rate 0.5 mL min-1; 
Gradient elution t = 0 min, MeCN:H2O with 0.1 % TFA, 5:95; t = 5.0 min, 95:5; t = 
5.4 min, 95:5; Rt 1.6 min, m/z (ES) found [M+H]+ 913.3700; C37H57N10O15S requires 
913.3720. 
 














Ascentis Express (C18, 50 x 2.1 mm, 2.7 µm particle size); Flow rate 0.5 mL min-1; 
Gradient elution t = 0 min, MeCN:H2O with 0.1 % TFA, 5:95; t = 5.0 min, 95:5; t = 
5.4 min, 95:5; Rt 1.2 min, m/z (ES) found [M+H]+ 898.4088; C37H60N11O13S requires 
898.4087. 
 
















Ascentis Express (C18, 50 x 2.1 mm, 2.7 µm particle size); Flow rate 0.5 mL min-1; 
Gradient elution t = 0 min, MeCN:H2O with 0.1 % TFA, 5:95; t = 5.0 min, 95:5; t = 
5.4 min, 95:5; Rt 1.4 min, m/z (ES) found [M+H]+ 899.3538; C36H55N10O15S requires 
899.3564. 
 
















Ascentis Peptide (ES-C18, 100 x 2.1 mm, 2.7 µm particle size); Flow rate 0.5 mL  
min-1; Gradient elution t = 0 min, MeCN:H2O with 0.1 % TFA, 5:95; t = 10.0 min, 95:5;  
t = 10.5 min, 5:95; t = 12.0 min, 5:95; Rt 3.0 min, m/z (ES) found [M+H]+ 854.3925; 
C41H56N7O13 requires 854.3937. 
 


















Ascentis Peptide (ES-C18, 100 x 2.1 mm, 2.7 µm particle size); Flow rate 0.5 mL  
min-1; Gradient elution t = 0 min, MeCN:H2O with 0.1 % TFA, 5:95; t = 10.0 min, 95:5;  
t = 10.5 min, 5:95; t = 12.0 min, 5:95; Rt 2.6 min, m/z (ES) found [M+H]+ 871.4023; 
C41H59N8O11S requires 871.4019. 
 


















Ascentis Express (C18, 50 x 2.1 mm, 2.7 µm particle size); Flow rate 0.5 mL min-1; 
Gradient elution t = 0 min, MeCN:H2O with 0.1 % TFA, 5:95; t = 5.0 min, 95:5; Rt 2.0 
and 2.1 min (mixed isomers of Lissamine Rhodamine B sulfonyl chloride used), m/z 
(ES) found [M+H]+ 1247.4433; C62H71N8O16S2 requires 1247.4424. 
 



















Ascentis Express (C18, 50 x 2.1 mm, 2.7 µm particle size); Flow rate 0.5 mL min-1; 
Gradient elution t = 0 min, MeCN:H2O with 0.1 % TFA, 5:95; t = 5.0 min, 95:5; Rt 1.9 
and 2.0 min (mixed isomers of Lissamine Rhodamine B sulfonyl chloride used), m/z 
(ES) found [M+H]+ 1263.4381; C62H71N8O17S2 requires 1264.4373. 
 




















Ascentis Peptide (ES-C18, 100 x 2.1 mm, 2.7 µm particle size); Flow rate 0.5 mL  
min-1; Gradient elution t = 0 min, MeCN:H2O with 0.1 % TFA, 5:95; t = 10.0 min, 95:5;  
t = 10.5 min, 5:95; t = 12.0 min, 5:95; Rt 3.6 min, m/z (ES) found [M+2H]2+ 1108.5170; 
C100H148N23O30S2 requires 1108.5181. 
 


















Ascentis Peptide (ES-C18, 100 x 2.1 mm, 2.7 µm particle size); Flow rate 0.5 mL  
min-1; Gradient elution t = 0 min, MeCN:H2O with 0.1 % TFA, 5:95; t = 10.0 min, 95:5;  
t = 10.5 min, 5:95; t = 12.0 min, 5:95; Rt 5.5 min, m/z (ES) found [M+2H]2+ 983.4400; 







Ascentis Peptide (ES-C18, 100 x 2.1 mm, 2.7 µm particle size); Flow rate 0.5 mL  
min-1; Gradient elution t = 0 min, MeCN:H2O with 0.1 % TFA, 5:95; t = 10.0 min, 95:5;  
t = 10.5 min, 5:95; t = 12.0 min, 5:95; Rt 3.8 min, m/z (ES) found [M+2H]2+ 1136.9460; 
C106H131N22O31S2 requires 1136.9475. 
 

















Ascentis Peptide (ES-C18, 100 x 2.1 mm, 2.7 µm particle size); Flow rate 0.5 mL  
min-1; Gradient elution t = 0 min, MeCN:H2O with 0.1 % TFA, 5:95; t = 10.0 min, 95:5;  
t = 10.5 min, 5:95; t = 12.0 min, 5:95; Rt 3.9 min, m/z (ES) found [M+2H]2+ 1241.9890; 
C121H145N22O32S2 requires 1241.9908. 
 


















Ascentis Peptide (ES-C18, 100 x 2.1 mm, 2.7 µm particle size); Flow rate 0.5 mL  
min-1; Gradient elution t = 0 min, MeCN:H2O with 0.1 % TFA, 5:95; t = 10.0 min, 95:5;  
t = 10.5 min, 5:95; t = 12.0 min, 5:95; Rt 2.5 min, m/z (ES) found [M+H]+ 1035.4936; 
C45H71N12O14S requires 1035.4928. 
 















Ascentis Express (C18, 50 x 2.1 mm, 2.7 µm particle size); Flow rate 0.5 mL min-1; 
Gradient elution t = 0 min, MeCN:H2O with 0.1 % TFA, 5:95; t = 5.0 min, 95:5; Rt 
1.5 min, m/z (ES) found [M+H]+ 1180.6291; C54H90N11O16S requires 1180.6243. 
 















Ascentis Peptide (ES-C18, 100 x 2.1 mm, 2.7 µm particle size); Flow rate 0.5 mL  
min-1; Gradient elution t = 0 min, MeCN:H2O with 0.1 % TFA, 5:95; t = 10.0 min, 95:5;  
t = 10.5 min, 5:95; t = 12.0 min, 5:95; Rt 4.6 min, m/z (ES) found [M+H]+ 1167.5609; 
C52H83N10O18S requires 1167.5602. 
 















Ascentis Express (C18, 50 x 2.1 mm, 2.7 µm particle size); Flow rate 0.5 mL min-1; 
Gradient elution t = 0 min, MeCN:H2O with 0.1 % TFA, 5:95; t = 5.0 min, 95:5; Rt 
1.6 min, m/z (ES) found [M+H]+ 1265.5779; C60H85N10O18S requires 1265.5759. 
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Appendix A  
Recombinant protein constructs 
 
A.1 His6-AtPEX5(340-728) 
























Highlighted in green: start codons 
Highlighted in cyan: His6 tag 
Highlighted in red: stop codon 







Highlighted in cyan: His6 tag 





A.2.1 His6-AtPEX5(444-728) plasmid map 
 














Highlighted in green: start codon 
Highlighted in cyan: His6 tag 















Appendix B  
Primers for AtPEX5(340-728) mutants and AtPEX5(444-728) 
 
B.1 AtPEX5(340-728) D505A primers 
Forward (5’-3’): CACACGCAGAGAACGCTGATGATCAACAGGC 
Reverse (5’-3’): GCCTGTTGATCATCAGCGTTCTCTGCGTGTG 
B.2 AtPEX5(340-728) D505H and AtPEX5(340-728) D505H(-N601A) 
primers 
Forward (5’-3’): CACACACGCAGAGAACCATGATGATCAACAGGC 
Reverse (5’-3’): GCCTGTTGATCATCATGGTTCTCTGCGTGTGTG 
B.3 AtPEX5(340-728) D505K primers 
Forward (5’-3’): GGTCACACACGCAGAGAACAAGGATGATCAACAGGCAATAG 
Reverse (5’-3’): CTATTGCCTGTTGATCATCCTTGTTCTCTGCGTGTGTGACC 
B.4 AtPEX5(340-728) D507A primers 
Forward (5’-3’): CGCAGAGAACGATGATGCTCAACAGGCAATAGCTG 
Reverse (5’-3’): CAGCTATTGCCTGTTGAGCATCATCGTTCTCTGCG 
B.5 AtPEX5(340-728) D507K primers 
Forward (5’-3’): CACGCAGAGAACGATGATAAACAACAGGCAATAGCTGC 




B.6 AtPEX5(340-728) V533A primers 
Forward (5’-3’): CTTCTTGCGCTTGGTGCGAGTCATACCAACGAG 
Reverse (5’-3’): CTCGTTGGTATGACTCGCACCAAGCGCAAGAAG 
B.7 AtPEX5(340-728) V533W primers 
Forward (5’-3’): GGTGCTTCTTGCGCTTGGTTGGAGTCATACCAACGAGTTAG 
Reverse (5’-3’): CTAACTCGTTGGTATGACTCCAACCAAGCGCAAGAAGCACC 
B.8 AtPEX5(340-728) T536A primers 
Forward (5’-3’): CTTGGTGTGAGTCATGCCAACGAGTTAGAGC 
Reverse (5’-3’): GCTCTAACTCGTTGGCATGACTCACACCAAG 
B.9 AtPEX5(340-728) T536N primers 
Forward (5’-3’): CGCTTGGTGTGAGTCATAACAACGAGTTAGAGCAAGC 
Reverse (5’-3’): GCTTGCTCTAACTCGTTGTTATGACTCACACCAAGCG 
B.10 AtPEX5(340-728) T536W primers 
Forward (5’-3’): CTTGCGCTTGGTGTGAGTCATTGGAACGAGTTAGAGCAAGCAAC 
Reverse (5’-3’): GTTGCTTGCTCTAACTCGTTCCAATGACTCACACCAAGCGCAAG 
B.11 AtPEX5(340-728) N537A primers 
Forward (5’-3’): CTTGGTGTGAGTCATACCGCCGAGTTAGAGCAAGCAAC 
Reverse (5’-3’): GTTGCTTGCTCTAACTCGGCGGTATGACTCACACCAAG 
B.12 AtPEX5(340-728) N537Q primers 
Forward (5’-3’): CGCTTGGTGTGAGTCATACCCAGGAGTTAGAGCAAGCAACTGC 




B.13 AtPEX5(340-728) N537T primers 
Forward (5’-3’): CTTGGTGTGAGTCATACCACCGAGTTAGAGCAAGCAAC 
Reverse (5’-3’): GTTGCTTGCTCTAACTCGGTGGTATGACTCACACCAAG 
B.14 AtPEX5(340-728) E538A primers 
Forward (5’-3’): GTGAGTCATACCAACGCGTTAGAGCAAGCAACTG 
Reverse (5’-3’): CAGTTGCTTGCTCTAACGCGTTGGTATGACTCAC 
B.15 AtPEX5(340-728) N601A primers 
Forward (5’-3’): GTTGGGCGTGCTCTACGCTCTGTCGAGAGAGTTC 
Reverse (5’-3’): GAACTCTCTCGACAGAGCGTAGAGCACGCCCAAC 
B.16 AtPEX5(340-728) N601Q primers 
Forward (5’-3’): GTTGGGCGTGCTCTACCAGCTGTCGAGAGAGTTC 
Reverse (5’-3’): GAACTCTCTCGACAGCTGGTAGAGCACGCCCAAC 
B.17 AtPEX5(340-728) F613A primers 
Forward (5’-3’): GATAGAGCAATCACATCCGCCCAAACAGCATTACAAC 
Reverse (5’-3’): GTTGTAATGCTGTTTGGGCGGATGTGATTGCTCTATC 
B.18 AtPEX5(340-728) N628A primers 
Forward (5’-3’): CGATTATTCTCTGTGGGCTAAGCTAGGTGCAACGC 
Reverse (5’-3’): GCGTTGCACCTAGCTTAGCCCACAGAGAATAATCG 
B.19 AtPEX5(340-728) A632G primers 
Forward (5’-3’): GGAATAAGCTAGGTGGAACGCAAGCCAACAG 




B.20 AtPEX5(340-728) N636A primers 
Forward (5’-3’): CTAGGTGCAACGCAAGCCGCCAGTGTCCAGAGTGCTGATG 
Reverse (5’-3’): CATCAGCACTCTGGACACTGGCGGCTTGCGTTGCACCTAG 
B.21 AtPEX5(340-728) Y647F primers 
Forward (5’-3’): GCTGATGCCATATCTGCTTTTCAACAGGCTCTAG 
Reverse (5’-3’): CTAGAGCCTGTTGAAAAGCAGATATGGCATCAGC 





B.23 AtPEX5(340-728) N663A primers 
Forward (5’-3’): GTTCGTGCTTGGGCAGCCATGGGAATCAGTTAC 
Reverse (5’-3’): GTAACTGATTCCCATGGCTGCCCAAGCACGAAC 
B.24 AtPEX5(340-728) S667A primers 
Forward (5’-3’): GGCAAACATGGGAATCGCTTACGCAAACCAGGGG 
Reverse (5’-3’): CCCCTGGTTTGCGTAAGCGATTCCCATGTTTGCC 
B.25 AtPEX5(340-728) D505K-D507K primers 
Forward (5’-3’): GGTCACACACGCAGAGAACAAAGATAAACAACAGGCAATAGCTGC 
Reverse (5’-3’): GCAGCTATTGCCTGTTGTTTATCTTTGTTCTCTGCGTGTGTGACC 
B.26 AtPEX5(340-728) D505F(-N601A) primers 
Forward (5’-3’): GGTCACACACGCAGAGAACTTTGATGATCAACAGGCAATAGCTGC 




B.27 AtPEX5(340-728) D505F-D507F(-N601A) primers 
Forward (5’-3’): GGTCACACACGCAGAGAACTTTGATTTTCAACAGGCAATAGCTGC 
Reverse (5’-3’): GCAGCTATTGCCTGTTGAAAATCAAAGTTCTCTGCGTGTGTGACC 
B.28 AtPEX5(340-728) D505H/D507H(-N601A) primers 
Forward (5’-3’): GGTCACACACGCAGAGAACCATGATCATCAACAGGCAATAGCTGC 
Reverse (5’-3’): GCAGCTATTGCCTGTTGATGATCATGGTTCTCTGCGTGTGTGACC 
B.29 AtPEX5(340-728) D505H-D507T(-N601A) primers 
Forward (5’-3’): CACGCAGAGAACCATGATACTCAACAGGCAATAGCTGC 
Reverse (5’-3’): GCAGCTATTGCCTGTTGAGTATCATGGTTCTCTGCGTG 
B.30 AtPEX5(340-728) D505H-D507V(-N601A) primers 
Forward (5’-3’): CGCAGAGAACCATGATGTTCAACAGGCAATAGCTG 
Reverse (5’-3’): CAGCTATTGCCTGTTGAACATCATGGTTCTCTGCG 
B.31 AtPEX5(340-728) D505x/D507x primers 
Forward (5’-3’): GGTCACACACGCAGAGAACVRNGATVRNCAACAGGCAATAGCTGC 
Reverse (5’-3’): GCAGCTATTGCCTGTTGNYBATCNYBGTTCTCTGCGTGTGTGACC 





B.33 AtPEX5(340-728) N601x primers 
Forward (5’-3’): GTGTTGGGCGTGCTCTACNNKCTGTCGAGAGAGTTCGATAG 




B.34 AtPEX5(444-728) primers 
Forward (5’-3’): CCTGGTGGTCTACGTCTTCTCTGACATGAATCC 





Appendix C  
Mass Spectrometry of AtPEX5-C Protein Variants 
 
Liquid chromatography-mass spectrometry of AtPEX5-C and variants was carried out 
using a Bruker maXis impact Q-TOF mass spectrometer and proteins eluted between 
3 and 3.5 minutes. In some of the spectra, the mass + approximately 76 g/mol, and the 
mass + approximately (2*76 g/mol) is observed. These peaks correspond to the mass 
of the protein + one or two molecules of 2-mercaptoethanol. AtPEX5 C has two 
surface-exposed cysteine residues (not near the PTS1-binding site), available to react 
and form disulfide bonds with 2-mercaptoethanol, and TCEP was used to reduce 
these disulfide bonds with varying degrees of success. 
C.1 Wild-type AtPEX5(340-728): MS trace 
 
Figure C-1|  Mass spectrum and deconvoluted mass data (inset) for wild-type 




C.2 AtPEX5(340-728) D505A: MS trace 
 
Figure C-2|  Mass spectrum and deconvoluted mass data (inset) for AtPEX5-C 
D505A. Expected mass: 45,536.3 Da. Observed mass: 45,536.5 Da. 
C.3 AtPEX5(340-728) D505H: MS trace 
 
Figure C-3|  Mass spectrum and deconvoluted mass data (inset) for AtPEX5-C 




C.4 AtPEX5(340-728) D505K: MS trace 
 
Figure C-4|  Mass spectrum and deconvoluted mass data (inset) for AtPEX5-C 
D505K. Expected mass: 45,593.4 Da. Observed mass: 45,593.2 Da. 
C.5 AtPEX5(340-728) D507A: MS trace 
 
Figure C-5|  Mass spectrum and deconvoluted mass data (inset) for AtPEX5-C 




C.6 AtPEX5(340-728) D507K: MS trace 
 
Figure C-6|  Mass spectrum and deconvoluted mass data (inset) for AtPEX5-C 
D507K. Expected mass: 45,593.4 Da. Observed mass: 45,590.8 Da. 
C.7 AtPEX5(340-728) V533A: MS trace 
 
Figure C-7|  Mass spectrum and deconvoluted mass data (inset) for AtPEX5-C 




C.8 AtPEX5(340-728) V533W: MS trace 
 
Figure C-8|  Mass spectrum and deconvoluted mass data (inset) for AtPEX5-C 
V533W. Expected mass: 45,667.4 Da. Observed mass: 45,667.4 Da. 
C.9 AtPEX5(340-728) T536A: MS trace 
 
Figure C-9|  Mass spectrum and deconvoluted mass data (inset) for AtPEX5-C 




C.10 AtPEX5(340-728) T536N: MS trace 
 
Figure C-10|  Mass spectrum and deconvoluted mass data (inset) for AtPEX5-C 
T536N. Expected mass: 45,593.3 Da. Observed mass: 45,594.2 Da. 
C.11 AtPEX5(340-728) T536W: MS trace 
 
Figure C-11|  Mass spectrum and deconvoluted mass data (inset) for AtPEX5-C 




C.12 AtPEX5(340-728) N537A: MS trace 
 
Figure C-12|  Mass spectrum and deconvoluted mass data (inset) for AtPEX5-C 
N537A. Expected mass: 45,537.3 Da. Observed mass: 45,537.0 Da. 
C.13 AtPEX5(340-728) N537Q: MS trace 
 
Figure C-13|  Mass spectrum and deconvoluted mass data (inset) for AtPEX5-C 




C.14 AtPEX5(340-728) N537T: MS trace 
 
Figure C-14|  Mass spectrum and deconvoluted mass data (inset) for AtPEX5-C 
N537T. Expected mass: 45,567.3 Da. Observed mass: 45,571.1 Da. 
C.15 AtPEX5(340-728) E538A: MS trace 
 
Figure C-15|  Mass spectrum and deconvoluted mass data (inset) for AtPEX5-C 




C.16 AtPEX5(340-728) N601A: MS trace 
 
Figure C-16|  Mass spectrum and deconvoluted mass data (inset) for AtPEX5-C 
N601A. Expected mass: 45,537.3 Da. Observed mass: 45,536.0 Da. 
C.17 AtPEX5(340-728) N601Q: MS trace 
 
Figure C-17|  Mass spectrum and deconvoluted mass data (inset) for AtPEX5-C 




C.18 AtPEX5(340-728) F613A: MS trace 
 
Figure C-18|  Mass spectrum and deconvoluted mass data (inset) for AtPEX5-C 
F613A. Expected mass: 45,504.2 Da. Observed mass: 45,501.7 Da. 
C.19 AtPEX5(340-728) N628A: MS trace 
 
Figure C-19|  Mass spectrum and deconvoluted mass data (inset) for AtPEX5-C 




C.20 AtPEX5(340-728) A632G: MS trace 
 
Figure C-20|  Mass spectrum and deconvoluted mass data (inset) for AtPEX5-C 
A632G. Expected mass: 45,566.3 Da. Observed mass: 45,563.2 Da. 
C.21 AtPEX5(340-728) N636A: MS trace 
 
Figure C-21|  Mass spectrum and deconvoluted mass data (inset) for AtPEX5-C 




C.22 AtPEX5(340-728) Y647F: MS trace 
 
Figure C-22|  Mass spectrum and deconvoluted mass data (inset) for AtPEX5-C 
Y647F. Expected mass: 45,564.3 Da. Observed mass: 45,563.1 Da. 
C.23 AtPEX5(340-728) R659A: MS trace 
 
Figure C-23|  Mass spectrum and deconvoluted mass data (inset) for AtPEX5-C 




C.24 AtPEX5(340-728) N663A: MS trace 
 
Figure C-24|  Mass spectrum and deconvoluted mass data (inset) for AtPEX5-C 
N663A. Expected mass: 45,537.3 Da. Observed mass: 45,538.9 Da. 
C.25 AtPEX5(340-728) S667A: MS trace 
 
Figure C-25|  Mass spectrum and deconvoluted mass data (inset) for AtPEX5-C 




C.26 AtPEX5(340-728) D505K-D507K: MS trace 
 
Figure C-26|  Mass spectrum and deconvoluted mass data (inset) for AtPEX5-C 
D505K-D507K. Expected mass: 45,606.5 Da. Observed mass: 45,604.9 Da. 
C.27 AtPEX5(340-728) D505H-T536W: MS trace 
 
Figure C-27|  Mass spectrum and deconvoluted mass data (inset) for AtPEX5-C 




C.28 AtPEX5(340-728) D505F-N601A: MS trace 
 
Figure C-28|  Mass spectrum and deconvoluted mass data (inset) for AtPEX5-C 
D505F-N601A. Expected mass: 45,569.4 Da. Observed mass: 45,571.4 Da. 
C.29 AtPEX5(340-728) D505H-N601A: MS trace 
 
Figure C-29|  Mass spectrum and deconvoluted mass data (inset) for AtPEX5-C 




C.30 AtPEX5(340-728) D505F-D507F-N601A: MS trace 
 
Figure C-30|  Mass spectrum and deconvoluted mass data (inset) for AtPEX5-C 
D505F-D507F-N601A. Expected mass: 45,601.5 Da. Observed mass: 45,599.5 Da. 
C.31 AtPEX5(340-728) D505H-D507H-N601A: MS trace 
 
Figure C-31|  Mass spectrum and deconvoluted mass data (inset) for AtPEX5-C 




C.32 AtPEX5(340-728) D505H-D507T-N601A: MS trace 
 
Figure C-32|  Mass spectrum and deconvoluted mass data (inset) for AtPEX5-C 
D505H-D507T-N601A. Expected mass: 45,545.3 Da. Observed mass: 45,545.1 Da. 
C.33 AtPEX5(340-728) D505H-D507V-N601A: MS trace 
 
Figure C-33|  Mass spectrum and deconvoluted mass data (inset) for AtPEX5-C 




C.34 AtPEX5(340-728) D505H-N601A-N636A: MS trace 
 
Figure C-34|  Mass spectrum and deconvoluted mass data (inset) for AtPEX5-C 
D505H-N601A-N636A. Expected mass: 45,516.3 Da. Observed mass: 45,515.3 Da. 
C.35 AtPEX5(340-728) D505H-D507T-E538A-N601A: MS trace 
 
Figure C-35|  Mass spectrum and deconvoluted mass data (inset) for AtPEX5-C 





C.36 Wild-type AtPEX5(444-728): MS trace 
 
Figure C-36|  Mass spectrum and deconvoluted mass data (inset) for truncated 





Appendix D  
Pull-down-LC-MS data analysis 
 
D.1 Peptide characterisation tables – example data and 
processing 
D.1.1 Retention time-sequence list 
Peptide sequence Retention time (s) 
Dansyl-YQSAA 225.78 
Dansyl-YQSAD 218.814 













Dansyl-YQSAV  272.168 
Dansyl-YQSAW 348.428 
Dansyl-YQSAY  267.664 






Dansyl-YQSDI  295.383 
Dansyl-YQSDK 148.802 




















Dansyl-YQSEL  307.298 




Dansyl-YQSES  201.61 
Dansyl-YQSET  218.799 
Dansyl-YQSEV  262.445 













Dansyl-YQSFS  313.8 
Dansyl-YQSFT 330.036 











Dansyl-YQSGI  294.387 
Dansyl-YQSGK 145.56 





















Dansyl-YQSHS  150.547 
Dansyl-YQSHT 153.272 

















































Dansyl-YQSLS  294.857 




Dansyl-YQSNA  202.635 
Dansyl-YQSND 197.918 
Dansyl-YQSNF  305.602 
Dansyl-YQSNH  151.046 
Dansyl-YQSNI  276.195 







Dansyl-YQSNV  242.548 




























Dansyl-YQSQS  191.886 
Dansyl-YQSQT  205.834 
Dansyl-YQSQV  244.244 
Dansyl-YQSQW 325.246 













































Dansyl-YQSTW  341.2 
















































D.1.2 Peptides with identical exact mass and retention times to 45 
peptides in the retention time-sequence list 


















































D.1.3 Example data processing 
The following example data shown are for D505F-D507F-N601A. 
Name Chromatogram ReT (s) Area 
Cmpd 1 XYQSHK & XYQSKH 128.78 5622.347 
Cmpd 2 XYQSRH & XYQSHR 130.275 8791.736 
Cmpd 3 XYQSHH 132.021 3972.709 
Cmpd 4 
XYQSNW & XYQSHY & XYQSWN & 
XYQSYH 
171.415 1427.574 
Cmpd 5 XYQSDV & XYQSVD 182.386 604.4569 
Cmpd 6 XYQSRE & XYQSER 220.038 554.2702 




Cmpd 8 XYQSHW & XYQSWH 231.757 2027.002 
Cmpd 9 XYQSGG 282.869 364.8235 
Cmpd 10 XYQSNG & XYQSGN 318.277 347.5375 
Cmpd 11 XYQSIF & XYQSLF & XYQSFI & XYQSFL 389.335 1146.977 
Cmpd 12 
XYQSIW & XYQSLW & XYQSWI & 
XYQSWL 
390.083 912.2089 
Cmpd 13 XYQSVV 402.8 1350.508 
Cmpd 14 XYQSRH & XYQSHR 406.29 2993.248 
 
A drift  time of -1 seconds was applied to the retention times as this produced the 
lowest average difference between the retention time master list and the raw data. 
Rows with a light red fill show the peptides which were too far outside the retention 
time identifier for the peptide sequences shown. 
Highlighted in yellow are the peptide sequences that were identified as having a 
retention time closest to that in the master list. Cells where two peptide sequences are 
highlighted in yellow show that these two peptide sequences have identical retention 
times so I have plotted both peptide sequences in the final plot. A plot with an altered 





Figure D-1|  Pull-down-LC-MS screen result for AtPEX5-C D505F-D507F-N601A. 
Shading represents the area-under-EIC (extracted ion chromatogram) for each of the 
peptides after pull-down-LC-MS. A smaller scale bar than screen results in Appendix E 




D.2 Code for adding EICs for each peptide sequence after mass 
spectrometry, and exporting data 
'********************************** 
'All code in this section (D.2) was written by Stuart Warriner 
'********************************** 
 
Dim Chrom, f , i,rstart, rstop 
rstart = 100 ' retention time window start 
rstop = 480 ' retention time window stop for peak picking 
rstart = rstart/60 







For Each Chrom in Analysis.Chromatograms 






Sub ReadData  
Dim sequenceformula, listhandler, f  
Set listhandler = New clsCreateFormulaList  
listhandler.FileInfo "D:\targetlists\peptideLibrary_Dan_full.csv",1,2   
For Each f In listhandler.ForumlaList_Dict.Keys  
AddEIC f, listhandler.ForumlaList_Dict.Item(f)  
Next  
Set listhandler = Nothing  
End Sub  
  
'Sub AddEIC(formula,text)  
'End Sub  
  
  
Sub AddEIC(formula, text)  
Dim EIC  
 Set EIC = CreateObject("DataAnalysis.EICChromatogramDefinition")   
EIC.MSFilter.Type = daMSFilterAllMS   
EIC.Polarity = daPositive   
EIC.WidthLeft = 0.008  
EIC.WidthRight = 0.008  
EIC.Formula = formula  
EIC.Adducts = "M+H"   
EIC.Charges = MaxCharge(text) 
Analysis.Chromatograms.AddChromatogram EIC   
Analysis.Chromatograms(Analysis.Chromatograms.Count).Name_ = text 
End Sub  
  
   
Function MaxCharge(sequence)  
Dim seq, arr, count, seq_startlength  
arr = Split(sequence, " & ")  
seq=arr(0)  
seq_startlength = Len(seq)  
seq = Replace(seq,"H","")  




seq = Replace(seq,"R","")  
count = seq_startlength - Len(seq)  
If count >1 Then  
MaxCharge = "1-2"  
Else  





Class clsCreateFormulaList  
Private filepath, fso, sequence_data, formula_col, sequence_col  
  
Sub Class_Initialize  
    Set fso = createobject("scripting.filesystemobject")  
    Set sequence_data = createobject("Scripting.Dictionary")    
    sequence_data.CompareMode = vbTextCompare  
End Sub  
  
Sub Class_Terminate  
    Set fso  = Nothing  
    Set sequence_data = Nothing  
End Sub  
  
   
 Public Property Get ForumlaList_Dict  
  Set  ForumlaList_Dict = sequence_data  
 End Property  
   
   
 Public Sub FileInfo (setfilepath, sequencecolumn, formulacolumn)  
 filepath = setfilepath  
 formula_col = formulacolumn - 1 ' array numbering  
 sequence_col= sequencecolumn - 1  
PopulateLists  
 End Sub  
   
 Private Sub PopulateLists  
 Dim i, j, imnputfile, fields  
 Set inputfile = fso.OpentextFile(filepath,1)  
 inputfile.ReadLine  
 Do While Not(inputfile.AtEndofStream)  
  fields = Split(inputfile.ReadLine,",")  
If sequence_data.Exists(fields(formula_col)) Then  
 sequence_data.Item(fields(formula_col)) = 
sequence_data.Item(fields(formula_col)) & " & " & fields(sequence_col)  
 Else  
 sequence_data.Add fields(formula_col), fields(sequence_col)  
 End If  
 'sgBox(fields(sequence_col))  
  
 Loop  
  
   
 End Sub  
      

















filepath = "D:\Laura_Reports\Reports\" & strip(Analysis.Name) & ".pdf" 
Analysis.PrintToPDF "Leeds_Laura", filepath 




Dim cmpd, fso, filepath, outfile, line 
Set fso = createobject("scripting.filesystemobject") 
filepath = "D:\Laura_Reports\Lists\" & strip(Analysis.Name) & ".csv" 
Set outfile = fso.CreatetextFile(filepath,True) 
line = "Name, Chromatogram,RT,Area" 
outfile.WriteLine(line) 
For each cmpd In Analysis.Compounds 
line = stripRT(cmpd.Name) & "," & cmpd.Chromatogram & "," & 




Set outfile = Nothing 






newstr = Split(str,",") 






newstr = Left(str,Len(str)-2) 







'This code was used to add EICs for tandem MS data 
'********************************** 
 
Dim Chrom, f , i,rstart, rstop, AAS 
rstart = 100 ' retention time window start 
rstop = 480 ' retention time window stop for peak picking 
rstart = rstart/60 











For Each Chrom in Analysis.Chromatograms 






Sub ReadData  
Dim sequenceformula, listhandler, seq, p,t 
Set listhandler = New clsCreateFormulaList  
listhandler.FileInfo "D:\targetlists\peptideLibrary_Dan_1_1.csv",1,2   
For Each seq In listhandler.ForumlaList_Dict.Keys  
p = GetMass(listhandler.ForumlaList_Dict.Item(seq)) 
t = GetTarget(seq) 
AddEIC p, t,seq 
Next  
Set listhandler = Nothing  
End Sub  
  
'Sub AddEIC(formula,text)  




Function GetMass(fm)  
dim SF    
set SF = CreateObject("DataAnalysis.SumFormula")   
SF.Formula = fm  
SF.Add("H2")  
GetMass = SF.MonoIsotopicMass(+2)   
End Function 
  
Sub AddEIC(prec, target, text)   
Dim EIC   
Set EIC = CreateObject("DataAnalysis.EICChromatogramDefinition")    
EIC.MSFilter.Type = daMSFilterMSMS    
EIC.MSFilter.FragmentationPath = prec  
EIC.Polarity = daPositive    
EIC.WidthLeft = 0.008   
EIC.WidthRight = 0.008   
EIC.Range = target 
'MsgBox (prec & " " & target & " " & text)  
'EIC.Adducts = "M+H"    
'EIC.Charges = MaxCharge(text)  
Analysis.Chromatograms.AddChromatogram EIC    
Analysis.Chromatograms(Analysis.Chromatograms.Count).Name_ = text  
End Sub  
  
    
Function MaxCharge(sequence)  
Dim seq, arr, count, seq_startlength  
arr = Split(sequence, " & ")  
seq=arr(0)  
seq_startlength = Len(seq)  
seq = Replace(seq,"H","")  
seq = Replace(seq,"K","")  
seq = Replace(seq,"R","")  
count = seq_startlength - Len(seq)  
If count >1 Then  












dim aa, mass 
Set AAS = createobject("Scripting.Dictionary") 
AAS.CompareMode = vbTextCompare 






For i = 0 to Ubound(aa) 






txt = Right(seq,1) 




Class clsCreateFormulaList   
Private filepath, fso, sequence_data, formula_col, sequence_col   
   
Sub Class_Initialize   
    Set fso = createobject("scripting.filesystemobject")   
    Set sequence_data = createobject("Scripting.Dictionary")     
    sequence_data.CompareMode = vbTextCompare   
End Sub   
   
Sub Class_Terminate   
    Set fso  = Nothing   
    Set sequence_data = Nothing   
End Sub   
   
    
 Public Property Get ForumlaList_Dict   
  Set  ForumlaList_Dict = sequence_data   
 End Property   
    
    
 Public Sub FileInfo (setfilepath, sequencecolumn, formulacolumn)   
 filepath = setfilepath   
 formula_col = formulacolumn - 1 ' array numbering   
 sequence_col= sequencecolumn - 1   
PopulateLists   
 End Sub   
    
 Private Sub PopulateLists   
 Dim i, j, imnputfile, fields   
 Set inputfile = fso.OpentextFile(filepath,1)   
 inputfile.ReadLine   
 Do While Not(inputfile.AtEndofStream)   
  fields = Split(inputfile.ReadLine,",")   




 sequence_data.Add fields(sequence_col),fields(formula_col)  
 End If 
 'sgBox(fields(sequence_col))   
  Loop   
   
    
 End Sub   
       





D.3 Code for data-processing macros 
D.3.1 Generation of ‘drifted’ retention times and matching of these to the 
retention times of peptides in the ‘seq-RT’ master list 
'********************************** 
' Drive the 'Master' Sub, iterating through a drift in retention time 
from -5 to +5 seconds 




Dim i As Integer 







' Add a drift time error on to each of the retention times in the 
exported '.csv' file and print these 'drifted' retention times onto 
the worksheet 
' Written by Stuart Warriner 
'********************************** 
 
Sub Master(x As Integer) 
 
Dim RtList As Dictionary 
Dim PeakChroms As Dictionary 
Dim PeakAreas As Dictionary 
Dim PeakRT As Dictionary 
Dim PeakBestFit As Dictionary 
Dim PeakBestOff As Dictionary 
Dim DataSheet As Worksheet 
Dim j, k, l 
Set RtList = New Scripting.Dictionary 
RtList.CompareMode = TextCompare 
Set PeakChroms = New Scripting.Dictionary 
PeakChroms.CompareMode = TextCompare 
Set PeakAreas = New Scripting.Dictionary 
PeakAreas.CompareMode = TextCompare 
Set PeakRT = New Scripting.Dictionary 
PeakRT.CompareMode = TextCompare 
Set PeakBestFit = New Scripting.Dictionary 





Set DataSheet = Worksheets(44) ' This is the Worksheet number that 
this particular '.csv' file was copied and pasted into 
drift = -5 + x ' Add -5 to 0, then 1, then ..., then 10 (this is the 
line being driven by the 'drive' Sub) 
 For j = 2 To 280 
  If Not RtList.Exists(Worksheets(1).Cells(j, 1).Value) Then 
RtList.Add Trim(Worksheets(1).Cells(j, 1).Value), 
Worksheets(1).Cells(j, 2).Value 
  End If 
 Next 
 
 For j = 2 To LastRow(DataSheet) 
PeakChroms.Add DataSheet.Cells(j, 1), DataSheet.Cells(j, 2) ' A 
'dictionary' is created, containing compound name (e.g. cmpd1) 
against peptide sequence name (e.g. XYQSKL) 
PeakAreas.Add DataSheet.Cells(j, 1), DataSheet.Cells(j, 4) ' A 
dictionary is created, containing compound name against EIC area 
for each peak 
PeakRT.Add DataSheet.Cells(j, 1), DataSheet.Cells(j, 3) ' A 
dictionary is created, containing compound name against 




 For k = 0 To PeakChroms.Count - 1 
 l = PeakChroms.Keys(k) 
 Chrom = Split(PeakChroms.Items(k), "&") 
 best = 5 
 bestSeq = "" 
  For j = 0 To UBound(Chrom) 
  off = PeakRT.Items(k) - RtList.Item(Trim(Chrom(j))) 
  off = off + drift 
   If Abs(off) < Abs(best) Then 
   best = off 
bestSeq = Trim(Chrom(j)) ' For each peak, look for 
the peptide sequence name (within the possible 
peptides defined in 'Chromatogram' column) that has 
the closest matching retention time (in the seq-RT 
master list) for each 'drift' time applied to the 
retention time of the peak 
   End If 
  Next 
 PeakBestFit.Add l, bestSeq 
 PeakBestOff.Add l, best 
  If Abs(best) < 5 Then 
  DataSheet.Cells(2 + k, 6 + 2 * x).Value = bestSeq 
DataSheet.Cells(2 + k, 7 + 2 * x).Value = best ' Print 
each best matching peptide sequence name, next to the 
drift that would have to be applied to the peak in order 
to have an exact retention time match 












' Calculate which row in the worksheet was the last row, to then allow 
assessment of the entire dataset 
' Written by Stuart Warriner 
'********************************** 
 
Function LastRow(s As Worksheet) 
 
LastRow = s.Range("A2000").End(xlUp).Row 
 
End Function 
D.3.2 Average and count of peptide sequences found when each ‘drift’ 
time was applied to retention times 
'********************************** 
' Calculate the average of each of the errors on the 'drifted' 
retention times and to count the number of peptides found when each 
'drift' time was applied 





Dim PeakAssign As Worksheet 
Dim PeakAssignbook 
Dim RTdiff1 As Dictionary 
Dim RTdiff2 As Dictionary 
Dim RTdiff3 As Dictionary 
Dim RTdiff4 As Dictionary 
Dim RTdiff5 As Dictionary 
Dim RTdiff6 As Dictionary 
Dim RTdiff7 As Dictionary 
Dim RTdiff8 As Dictionary 
Dim RTdiff9 As Dictionary 
Dim RTdiff10 As Dictionary 




Set RTdiff1 = New Scripting.Dictionary 
Set RTdiff2 = New Scripting.Dictionary 
Set RTdiff3 = New Scripting.Dictionary 
Set RTdiff4 = New Scripting.Dictionary 
Set RTdiff5 = New Scripting.Dictionary 
Set RTdiff6 = New Scripting.Dictionary 
Set RTdiff7 = New Scripting.Dictionary 
Set RTdiff8 = New Scripting.Dictionary 
Set RTdiff9 = New Scripting.Dictionary 
Set RTdiff10 = New Scripting.Dictionary 
Set RTdiff11 = New Scripting.Dictionary 
 
 
Set PeakAssign = Worksheets(44) 










  If Not IsEmpty(.Cells(h, 6)) Then 
RTdiff1.Add PeakAssign.Cells(h, 6), PeakAssign.Cells(h, 7) 
' A 'dictionary' will be created, containing assigned 
peptide sequence against retention time drift (if that 
sequence were the correctly assigned peptide) 
  End If 
 
  If Not IsEmpty(.Cells(h, 8)) Then 
RTdiff2.Add PeakAssign.Cells(h, 8), PeakAssign.Cells(h, 9) 
' Separate dictionaries are created for each 'drifted' 
column in the Worksheet, in the same way as the note above 
  End If 
 
  If Not IsEmpty(.Cells(h, 10)) Then 
  RTdiff3.Add PeakAssign.Cells(h, 10),PeakAssign.Cells(h,11) 
  End If 
 
  If Not IsEmpty(.Cells(h, 12)) Then 
  RTdiff4.Add PeakAssign.Cells(h, 12),PeakAssign.Cells(h,13) 
  End If 
 
  If Not IsEmpty(.Cells(h, 14)) Then 
  RTdiff5.Add PeakAssign.Cells(h, 14),PeakAssign.Cells(h,15) 
  End If 
 
  If Not IsEmpty(.Cells(h, 16)) Then 
  RTdiff6.Add PeakAssign.Cells(h, 16),PeakAssign.Cells(h,17) 
  End If 
 
  If Not IsEmpty(.Cells(h, 18)) Then 
  RTdiff7.Add PeakAssign.Cells(h, 18),PeakAssign.Cells(h,19) 
  End If 
 
  If Not IsEmpty(.Cells(h, 20)) Then 
  RTdiff8.Add PeakAssign.Cells(h, 20),PeakAssign.Cells(h,21) 
  End If 
 
  If Not IsEmpty(.Cells(h, 22)) Then 
  RTdiff9.Add PeakAssign.Cells(h, 22),PeakAssign.Cells(h,23) 
  End If 
 
  If Not IsEmpty(.Cells(h, 24)) Then 
  RTdiff10.Add PeakAssign.Cells(h,24),PeakAssign.Cells(h,25) 
  End If 
 
  If Not IsEmpty(.Cells(h, 26)) Then 
  RTdiff11.Add PeakAssign.Cells(h,26),PeakAssign.Cells(h,27) 




.Cells(265, 6).Value = 
Application.WorksheetFunction.Average(RTdiff1.Items) 
.Cells(265, 8).Value = 
Application.WorksheetFunction.Average(RTdiff2.Items) 
.Cells(265, 10).Value = 
Application.WorksheetFunction.Average(RTdiff3.Items) 
.Cells(265, 12).Value = 
Application.WorksheetFunction.Average(RTdiff4.Items) 





.Cells(265, 16).Value = 
Application.WorksheetFunction.Average(RTdiff6.Items) 
.Cells(265, 18).Value = 
Application.WorksheetFunction.Average(RTdiff7.Items) 
.Cells(265, 20).Value = 
Application.WorksheetFunction.Average(RTdiff8.Items) 
.Cells(265, 22).Value = 
Application.WorksheetFunction.Average(RTdiff9.Items) 
.Cells(265, 24).Value = 
Application.WorksheetFunction.Average(RTdiff10.Items) 
.Cells(265, 26).Value = 
Application.WorksheetFunction.Average(RTdiff11.Items) ' The average of 
retention time drift in each column is calculated and the result 
placed in row 265, columns 6 (F), 8 (H), 10 (J)... to 26 (Z) 
 
.Cells(266, 6).Value = RTdiff1.Count 
.Cells(266, 8).Value = RTdiff2.Count 
.Cells(266, 10).Value = RTdiff3.Count 
.Cells(266, 12).Value = RTdiff4.Count 
.Cells(266, 14).Value = RTdiff5.Count 
.Cells(266, 16).Value = RTdiff6.Count 
.Cells(266, 18).Value = RTdiff7.Count 
.Cells(266, 20).Value = RTdiff8.Count 
.Cells(266, 22).Value = RTdiff9.Count 
.Cells(266, 24).Value = RTdiff10.Count 
.Cells(266, 26).Value = RTdiff11.Count ' The count of retention time 
drift in each column is calculated and the result placed in row 266, 





D.3.3 Sorting of peptides by hydrophobicity 
'********************************** 
' Select the column with the highest count and lowest average, and 
copy the data from this column into another Worksheet 









Dim Averages As Dictionary   
Dim BestCol As Dictionary   
 
Dim i, j, k, l, m 
 
Dim target As Variant 
Dim seqs As Variant 
Dim out, outarr 
 
Set BestCol = New Scripting.Dictionary 
Set Averages = New Scripting.Dictionary 
 
 




Set PeakAssignbook = 
Workbooks("DataProcess1.xlsm").Worksheets("Sheet44") ' The data are 
being read from Worksheet 44. This number was changed for the 
processing of each screen, as the '.csv' data from each screen was 
copied and pasted into a separate Worksheet in the same Workbook 
Set Output = Workbooks("DataProcess2.xlsm").Worksheets("Sheet1") ' The 
'target file' for the data is 'DataProcess2', which contains all amino 
acid sequences ordered by hydrophobicity, plus a column named 'area' 
for the data to be transferred to, plus a column with areas from the 





For i = 6 To 26 ' This will start with column 6 (F) and apply 
the code up until column 26 (Z) 
     
If Not IsEmpty(.Cells(266, i)) Then ' If there is a value 
in row 266 and column i (this will contain the peptide-RT 
'count' if the overall column contains the peptide 
sequence names) 
If .Cells(266, i).Value <> 
Application.WorksheetFunction.Max(Range("F266:Z266")
) Then 
   .Cells(266, i).ClearContents     
.Cells(265, i).ClearContents ' Delete the contents 
of rows 265 and 266 (containing average and count) 
if the count is not the maximum across the range 
   End If 




 For i = 6 To 26 ' This will look through the same columns again 
 
  If Not IsEmpty(.Cells(266, i)) Then 
If Not IsEmpty(.Cells(265, i)) Then ' If there are 
values in rows 265 and 266 (which there will be if 
the count is the maximum)... 
Averages.Add Abs(Worksheets(44).Cells(264, i)), 
Abs(Worksheets(44).Cells(265, i)) ' A 'dictionary' 
is created containing identifier numbers (in row 
264) against the averages of retention time drift 
for all columns where count was the highest 
   End If 




 For i = 6 To 26 ' This will look through the same columns again 
  For j = 2 To LastRow(PeakAssign) 
 
   If Not IsEmpty(.Cells(266, i)) Then 
If Abs(.Cells(265, i).Value) = 
Application.WorksheetFunction.Min(Averages.Ite
ms) Then ' If the average of retention times 
is the lowest absolute number in the 
dictionary createed above... 
     If Not IsEmpty(.Cells(j, i)) Then 
If Not 
BestCol.Exists(Worksheets(44).Cell






Trim(Worksheets(44).Cells(j, 4)) ' 
Another dictionary is created 
which takes the peptide names in 
the 'best row' (highest count, 
lowest average) against the EIC 
areas for each of those peptides 
      End If 
     End If 
    End If 
   End If 






' From this point onwards, this part of the code was written by Stuart 
Warriner and modified by Laura Cross 
'********************************** 
 
 For k = 2 To 325 
 
 target = Output.Cells(k, 1).Value 
 out = "" 
 
  For l = 0 To BestCol.Count - 1 
seqs = BestCol.Keys(l) ' Keys from the dictionary 
containing data from the best row (the peptide names of 
this dictionary) are named 'seqs' 
 
If InStr(1, seqs, target, vbTextCompare) > 0 Then ' 
If the peptide name from the 'best row' dictionary 
is found in the target file (containing all peptide 
sequences sorted by hydrophobicity) (which it will 
be)... 
 
    If out <> "" Then 
    out = out & "_" 
    End If 
out = out & BestCol.Items(l) ' Record the 




   End If 
  Next 
 outarr = Split(out, "_") 
  For m = 0 To UBound(outarr) 
Output.Cells(k, m + 3).Value = outarr(m) ' Transfer the 
EIC areas next to their corresponding peptide sequence in 
the list of peptides ordered by hydrophobicity 







' Calculate which row in the worksheet was the last row, to then allow 




' Written by Stuart Warriner 
'********************************** 
 
Function LastRow(s As Worksheet) 
 
LastRow = s.Range("A2000").End(xlUp).Row 
 
End Function 
D.3.4 Adding EIC areas for pair set 2 (of the 45 pairs of peptides without 
unique RT-mass identifiers) when a peptide of pair set 1 was 
identified in the screen 
'********************************** 
' Add EIC areas for the 45 peptides not in the master seq-RT list (of 
the pairs without unique RT-mass identifiers) if the corresponding 
peptide in the pair was identified 







Dim i, h, j, k 
 
Dim target1 As Variant 
Dim target2 As Variant 
Dim seqs1 As Variant 






Set IdentifyCmpd = Workbooks("DataProcess2.xlsm").Worksheets("Sheet1") 




t1arr = IdentifyCmpd.Range("A2:A325").Value ' Create a target array 
containing all peptide 'names', e.g. XYQSKL 
t2arr = IdentifyCmpd.Range("B2:B325").Value ' Create another target 
array containing the same peptide 'names', e.g. XYQSKL 
s1arr = SameRTs.Range("A2:A46").Value ' Create an array of peptide 
names in the master 'seq-RT' list which belong to the 45 pairs of 
peptides without a unique RT-mass identifier (set 1 of the pairs) 
s2arr = SameRTs.Range("B2:B46").Value ' Create an array of the peptide 
names which do not appear in the master 'seq-RT' list and which belong 
to the 43 pairs of peptides without a unique RT-mass identifier (set 2 
of the pairs) 
area = IdentifyCmpd.Range("C2:C325").Value ' Name the range containing 
EIC areas of peptides identified in the screen 
 
Application.ScreenUpdating = False 
Application.Calculation = xlCalculationManual 
 
 For i = 1 To UBound(t1arr) 
 target1 = t1arr(i, 1) 
 




  target2 = t2arr(h, 1) 
 
   For j = 1 To UBound(s1arr) 
   seqs1 = s1arr(j, 1) 
   seqs2 = s2arr(j, 1) 
 
If (InStr(1, seqs1, target1, vbTextCompare) > 
0 And area(i, 1) > 0) Then ' If set 1 of the 
43 pairs of peptides are found (which they 
will be), do something if there is a value in 
the 'EIC area' column 
If InStr(1, seqs2, target2, 
vbTextCompare) > 0 Then   
    
IdentifyCmpd.Cells(h + 1, 3) = 
IdentifyCmpd.Cells(i + 1, 3) ' If set 2 
of the 45 pairs of peptides are found 
(which they will be), take the EIC area 
next to set 1 and place it next to set 2 
of each pair 
     End If 
 
    End If 
     
   Next 
  Next 
 Next 
 
Application.ScreenUpdating = True 
Application.Calculation = xlCalculationAutomatic 
 
End Sub 
D.3.5 Blank correcting of data 
'********************************** 
' Subtract EIC areas from the 'blank' screen (run using the same 
protocol as a screen but without protein in the initial incubation) 
' Also replace any empty cells (where no EIC area was detected) with 
the value 0 (for use of the data in OriginPro 9.1) 






Dim i, j 
 




    For i = 2 To 325 
.Cells(i, 5).Value = .Cells(i, 3).Value - .Cells(i, 4).Value ' 
Minus EIC area for peptide in blank screen (already pasted into 
Worksheet) from EIC area of peptide in current screen 
    Next 
     
 For j = 2 To 325 
If .Cells(j, 5).Value < 0 Then ' Place the value "0" in 




  .Cells(j, 5).Value = "0" 
  End If 
 Next 




D.3.6 Splitting -1 and -2 amino acids into separate columns 
'********************************** 
' Split the two C-terminal amino acids into separate columns 


















Range("E1").Value = "Position -1" 






 For q = 2 To 325 
  While Not IsEmpty(.Cells(q, 2).Value) 
.Cells(q, 5).Value = Mid((.Cells(q, 2).Value), 6, 1) ' 
Take the C-terminal amino acid one-letter code and place 
this in column E 
  q = q + 1 
  Wend 
 Next 
 
 For q = 2 To 325 
  While Not IsEmpty(.Cells(q, 2).Value) 
.Cells(q, 6).Value = Mid((.Cells(q, 2).Value), 5, 1) ' 
Take the '-2' amino acid one-letter code and place this in 
column F 
  q = q + 1 









D.3.7 Converting amino acids to numbers 
'********************************** 
' Replace the two C-terminal amino acid one-letter codes with numbers 
for plotting a matrix of the data in OriginPro 9.1 






Dim a, b 
 




 For a = 2 To 325 
 
  If .Cells(a, 5).Text = "F" Then 
  .Cells(a, 5).Value = "1" 
  End If 
   
  If .Cells(a, 5).Text = "I" Then 
  .Cells(a, 5).Value = "2" 
  End If 
   
  If .Cells(a, 5).Text = "W" Then 
  .Cells(a, 5).Value = "3" 
  End If 
   
  If .Cells(a, 5).Text = "L" Then 
  .Cells(a, 5).Value = "4" 
  End If 
   
  If .Cells(a, 5).Text = "V" Then 
  .Cells(a, 5).Value = "5" 
  End If 
   
  If .Cells(a, 5).Text = "Y" Then 
  .Cells(a, 5).Value = "6" 
  End If 
   
  If .Cells(a, 5).Text = "A" Then 
  .Cells(a, 5).Value = "7" 
  End If 
   
  If .Cells(a, 5).Text = "T" Then 
  .Cells(a, 5).Value = "8" 
  End If 
   
  If .Cells(a, 5).Text = "H" Then 
  .Cells(a, 5).Value = "9" 
  End If 
   
  If .Cells(a, 5).Text = "G" Then 
  .Cells(a, 5).Value = "10" 
  End If 
   
  If .Cells(a, 5).Text = "S" Then 
  .Cells(a, 5).Value = "11" 
  End If 




  If .Cells(a, 5).Text = "Q" Then 
  .Cells(a, 5).Value = "12" 
  End If 
   
  If .Cells(a, 5).Text = "R" Then 
  .Cells(a, 5).Value = "13" 
  End If 
   
  If .Cells(a, 5).Text = "K" Then 
  .Cells(a, 5).Value = "14" 
  End If 
   
  If .Cells(a, 5).Text = "N" Then 
  .Cells(a, 5).Value = "15" 
  End If 
   
  If .Cells(a, 5).Text = "E" Then 
  .Cells(a, 5).Value = "16" 
  End If 
   
  If .Cells(a, 5).Text = "P" Then 
  .Cells(a, 5).Value = "17" 
  End If 
   
  If .Cells(a, 5).Text = "D" Then 
  .Cells(a, 5).Value = "18" 




 For b = 2 To 325 
 
  If .Cells(b, 6).Text = "D" Then 
  .Cells(b, 6).Value = "1" 
  End If 
   
  If .Cells(b, 6).Text = "P" Then 
  .Cells(b, 6).Value = "2" 
  End If 
   
  If .Cells(b, 6).Text = "E" Then 
  .Cells(b, 6).Value = "3" 
  End If 
   
  If .Cells(b, 6).Text = "N" Then 
  .Cells(b, 6).Value = "4" 
  End If 
   
  If .Cells(b, 6).Text = "K" Then 
  .Cells(b, 6).Value = "5" 
  End If 
   
  If .Cells(b, 6).Text = "R" Then 
  .Cells(b, 6).Value = "6" 
  End If 
   
  If .Cells(b, 6).Text = "Q" Then 
  .Cells(b, 6).Value = "7" 
  End If 
   
  If .Cells(b, 6).Text = "S" Then 




  End If 
   
  If .Cells(b, 6).Text = "G" Then 
  .Cells(b, 6).Value = "9" 
  End If 
   
  If .Cells(b, 6).Text = "H" Then 
  .Cells(b, 6).Value = "10" 
  End If 
   
  If .Cells(b, 6).Text = "T" Then 
  .Cells(b, 6).Value = "11" 
  End If 
   
  If .Cells(b, 6).Text = "A" Then 
  .Cells(b, 6).Value = "12" 
  End If 
   
  If .Cells(b, 6).Text = "Y" Then 
  .Cells(b, 6).Value = "13" 
  End If 
   
  If .Cells(b, 6).Text = "V" Then 
  .Cells(b, 6).Value = "14" 
  End If 
   
  If .Cells(b, 6).Text = "L" Then 
  .Cells(b, 6).Value = "15" 
  End If 
   
  If .Cells(b, 6).Text = "W" Then 
  .Cells(b, 6).Value = "16" 
  End If 
   
  If .Cells(b, 6).Text = "I" Then 
  .Cells(b, 6).Value = "17" 
  End If 
   
  If .Cells(b, 6).Text = "F" Then 
  .Cells(b, 6).Value = "18" 










D.3.8 Reset of worksheet for processing of the next dataset 
'********************************** 
' Reset the 'DataProcess2' Worksheet for processing of the next 
dataset 






Dim a, b 
 











 For a = 2 To 325 
    .Cells(a, 3).ClearContents 
 Next 
 
 For b = 2 To 325 









Appendix E  
Pull-down-LC-MS results for all AtPEX5-C variants 
 
E.1 Wild-type AtPEX5(340-728): pull-down-LC-MS heat map 
 
Figure E-1|  Pull-down-LC-MS screen result for wild-type AtPEX5-C. Shading 





E.2 AtPEX5(340-728) D505A: pull-down-LC-MS heat map 
 
Figure E-2|  Pull-down-LC-MS screen result for AtPEX5-C D505A. Shading 
represents the area-under-EIC (extracted ion chromatogram) for each of the peptides 
after pull-down-LC-MS. 
E.3 AtPEX5(340-728) D505H: pull-down-LC-MS heat map 
 
Figure E-3|  Pull-down-LC-MS screen result for AtPEX5-C D505H. Shading 





E.4 AtPEX5(340-728) D505K: pull-down-LC-MS heat map 
 
Figure E-4|  Pull-down-LC-MS screen result for AtPEX5-C D505K. Shading 
represents the area-under-EIC (extracted ion chromatogram) for each of the peptides 
after pull-down-LC-MS. 
E.5 AtPEX5(340-728) D507A: pull-down-LC-MS heat map 
 
Figure E-5|  Pull-down-LC-MS screen result for AtPEX5-C D507A. Shading 





E.6 AtPEX5(340-728) D507K: pull-down-LC-MS heat map 
 
Figure E-6|  Pull-down-LC-MS screen result for AtPEX5-C D507K. Shading 
represents the area-under-EIC (extracted ion chromatogram) for each of the peptides 
after pull-down-LC-MS. 
E.7 AtPEX5(340-728) V533A: pull-down-LC-MS heat map 
 
Figure E-7|  Pull-down-LC-MS screen result for AtPEX5-C V533A. Shading 





E.8 AtPEX5(340-728) V533W: pull-down-LC-MS heat map 
 
Figure E-8|  Pull-down-LC-MS screen result for AtPEX5-C V533W. Shading 
represents the area-under-EIC (extracted ion chromatogram) for each of the peptides 
after pull-down-LC-MS. 
E.9 AtPEX5(340-728) T536A: pull-down-LC-MS heat map 
 
Figure E-9|  Pull-down-LC-MS screen result for AtPEX5-C T536A. Shading 





E.10 AtPEX5(340-728) T536N: pull-down-LC-MS heat map 
 
Figure E-10|  Pull-down-LC-MS screen result for AtPEX5-C T536N. Shading 
represents the area-under-EIC (extracted ion chromatogram) for each of the peptides 
after pull-down-LC-MS. 
E.11 AtPEX5(340-728) T536W: pull-down-LC-MS heat map 
 
Figure E-11|  Pull-down-LC-MS screen result for AtPEX5-C T536W. Shading 





E.12 AtPEX5(340-728) N537A: pull-down-LC-MS heat map 
 
Figure E-12|  Pull-down-LC-MS screen result for AtPEX5-C N537A. Shading 
represents the area-under-EIC (extracted ion chromatogram) for each of the peptides 
after pull-down-LC-MS. 
E.13 AtPEX5(340-728) N537Q: pull-down-LC-MS heat map 
 
Figure E-13|  Pull-down-LC-MS screen result for AtPEX5-C N537Q. Shading 





E.14 AtPEX5(340-728) N537T: pull-down-LC-MS heat map 
 
Figure E-14|  Pull-down-LC-MS screen result for AtPEX5-C N537T. Shading 
represents the area-under-EIC (extracted ion chromatogram) for each of the peptides 
after pull-down-LC-MS. 
E.15 AtPEX5(340-728) E538A: pull-down-LC-MS heat map 
 
Figure E-15|  Pull-down-LC-MS screen result for AtPEX5-C E538A. Shading 





E.16 AtPEX5(340-728) N601A: pull-down-LC-MS heat map 
 
Figure E-16|  Pull-down-LC-MS screen result for AtPEX5-C N601A. Shading 
represents the area-under-EIC (extracted ion chromatogram) for each of the peptides 
after pull-down-LC-MS. 
E.17 AtPEX5(340-728) N601Q: pull-down-LC-MS heat map 
 
Figure E-17|  Pull-down-LC-MS screen result for AtPEX5-C N601Q. Shading 





E.18 AtPEX5(340-728) F613A: pull-down-LC-MS heat map 
 
Figure E-18|  Pull-down-LC-MS screen result for AtPEX5-C F613A. Shading 
represents the area-under-EIC (extracted ion chromatogram) for each of the peptides 
after pull-down-LC-MS. 
E.19 AtPEX5(340-728) N628A: pull-down-LC-MS heat map 
 
Figure E-19|  Pull-down-LC-MS screen result for AtPEX5-C N628A. Shading 





E.20 AtPEX5(340-728) A632G: pull-down-LC-MS heat map 
 
Figure E-20|  Pull-down-LC-MS screen result for AtPEX5-C A632G. Shading 
represents the area-under-EIC (extracted ion chromatogram) for each of the peptides 
after pull-down-LC-MS. 
E.21 AtPEX5(340-728) N636A: pull-down-LC-MS heat map 
 
Figure E-21|  Pull-down-LC-MS screen result for AtPEX5-C N636A. Shading 





E.22 AtPEX5(340-728) Y647F: pull-down-LC-MS heat map 
 
Figure E-22|  Pull-down-LC-MS screen result for AtPEX5-C Y647F. Shading 
represents the area-under-EIC (extracted ion chromatogram) for each of the peptides 
after pull-down-LC-MS. 
E.23 AtPEX5(340-728) R659A: pull-down-LC-MS heat map 
 
Figure E-23|  Pull-down-LC-MS screen result for AtPEX5-C R659A. Shading 





E.24 AtPEX5(340-728) N663A: pull-down-LC-MS heat map 
 
Figure E-24|  Pull-down-LC-MS screen result for AtPEX5-C N663A. Shading 
represents the area-under-EIC (extracted ion chromatogram) for each of the peptides 
after pull-down-LC-MS. 
E.25 AtPEX5(340-728) S667A: pull-down-LC-MS heat map 
 
Figure E-25|  Pull-down-LC-MS screen result for AtPEX5-C S667A. Shading 





E.26 AtPEX5(340-728) D505K-D507K: pull-down-LC-MS heat map 
 
Figure E-26|  Pull-down-LC-MS screen result for AtPEX5-C D505K-D507K. Shading 
represents the area-under-EIC (extracted ion chromatogram) for each of the peptides 
after pull-down-LC-MS. 
E.27 AtPEX5(340-728) D505H-T536W: pull-down-LC-MS heat map 
 
Figure E-27|  Pull-down-LC-MS screen result for AtPEX5-C D505H-T536W. Shading 





E.28 AtPEX5(340-728) D505F-N601A: pull-down-LC-MS heat map 
 
Figure E-28|  Pull-down-LC-MS screen result for AtPEX5-C D505F-N601A. Shading 
represents the area-under-EIC (extracted ion chromatogram) for each of the peptides 
after pull-down-LC-MS. 
E.29 AtPEX5(340-728) D505H-N601A: pull-down-LC-MS heat map 
 
Figure E-29|  Pull-down-LC-MS screen result for AtPEX5-C D505H-N601A. Shading 





E.30 AtPEX5(340-728) D505F-D507F-N601A: pull-down-LC-MS heat 
map 
 
Figure E-30|  Pull-down-LC-MS screen result for AtPEX5-C D505F-D507F-N601A. 
Shading represents the area-under-EIC (extracted ion chromatogram) for each of the 
peptides after pull-down-LC-MS. 
E.31 AtPEX5(340-728) D505H-D507H-N601A: pull-down-LC-MS heat 
map 
 
Figure E-31|  Pull-down-LC-MS screen result for AtPEX5-C D505H-D507H-N601A. 
Shading represents the area-under-EIC (extracted ion chromatogram) for each of the 




E.32 AtPEX5(340-728) D505H-D507T-N601A: pull-down-LC-MS heat 
map 
 
Figure E-32|  Pull-down-LC-MS screen result for AtPEX5-C D505H-D507T-N601A. 
Shading represents the area-under-EIC (extracted ion chromatogram) for each of the 
peptides after pull-down-LC-MS. 
E.33 AtPEX5(340-728) D505H-D507V-N601A: pull-down-LC-MS heat 
map 
 
Figure E-33|  Pull-down-LC-MS screen result for AtPEX5-C D505H-D507V-N601A. 
Shading represents the area-under-EIC (extracted ion chromatogram) for each of the 




E.34 AtPEX5(340-728) D505H-N601A-N636A: pull-down-LC-MS heat 
map 
 
Figure E-34|  Pull-down-LC-MS screen result for AtPEX5-C D505H-N601A-N636A. 
Shading represents the area-under-EIC (extracted ion chromatogram) for each of the 
peptides after pull-down-LC-MS. 
E.35 AtPEX5(340-728) D505H-D507T-E538A-N601A: pull-down-LC-
MS heat map 
 
Figure E-35|  Pull-down-LC-MS screen result for AtPEX5-C D505H-D507T-E538A-
N601A. Shading represents the area-under-EIC (extracted ion chromatogram) for each 




E.36 Wild-type AtPEX5(444-728) : pull-down-LC-MS heat map 
 
Figure E-36|  Pull-down-LC-MS screen result for wild-type truncated AtPEX5-C. 
Shading represents the area-under-EIC (extracted ion chromatogram) for each of the 





Appendix F  
Additional data (generated by H. Ebeed and L. Cross) 
 





14 C-terminal sequences from P. patens homologues to  












































































14 C-terminal sequences from P. patens homologues to  









14 C-terminal sequences from P. patens homologues to  













F.2 L. Cross additional data, testing binding of AtPEX5-C with 
biotinylated peptides 
 
Figure F-1|  Fluorescence anisotropy competition assays using a fixed 
concentration of lissamine-YQSKL (30 nM final concentration), and of AtPEX5 C 
(200 nM final concentration), and competitor peptide (ranging from 0-1 mM final 
concentration).  Biotin-(PEG)2-YQSKL appears to out-compete lissamine-YQSKL much 
more effectively than biotin-GGGYQSKL. Ki of unlabelled YQSKL = 22 ± 12 nM. Ki of 
biotin-GGGYQSKL = 230 ± 140 nM. Ki of biotin-(PEG)2-YQSKL = 26 ± 15 nM. Data were 
fitted to a one-site competition model using OriginPro 9.1. 
 
